You are on page 1of 66

European Heart Journal (2017) 00, 1–66 ESC GUIDELINES


2017 ESC Guidelines for the management of
acute myocardial infarction in patients
presenting with ST-segment elevation
The Task Force for the management of acute myocardial infarction
in patients presenting with ST-segment elevation of the European
Society of Cardiology (ESC)

Authors/Task Force Members: Borja Ibanez* (Chairperson) (Spain), Stefan James*
(Chairperson) (Sweden), Stefan Agewall (Norway), Manuel J. Antunes (Portugal),
Chiara Bucciarelli-Ducci (UK), Héctor Bueno (Spain), Alida L. P. Caforio (Italy),
Filippo Crea (Italy), John A. Goudevenos (Greece), Sigrun Halvorsen (Norway),
Gerhard Hindricks (Germany), Adnan Kastrati (Germany), Mattie J. Lenzen
(The Netherlands), Eva Prescott (Denmark), Marco Roffi (Switzerland),
Marco Valgimigli (Switzerland), Christoph Varenhorst (Sweden), Pascal Vranckx
(Belgium), Petr Widimsk y (Czech Republic)
Document Reviewers: Jean-Philippe Collet (CPG Review Coordinator) (France),
Steen Dalby Kristensen (CPG Review Coordinator) (Denmark), Victor Aboyans (France),

* Corresponding authors. The two chairmen contributed equally to the document: Borja Ibanez, Director Clinical Research, Centro Nacional de Investigaciones
Cardiovasculares Carlos III (CNIC), Melchor Fernandez Almagro 3, 28029 Madrid, Spain; Department of Cardiology, IIS-Fundacion Jiménez Dıaz University Hospital, Madrid,
Spain; and CIBERCV, Spain. Tel: þ34 91 453.12.00 (ext: 4302), Fax: þ34 91 453.12.45, E-mail: or Stefan James, Professor of Cardiology,
Department of Medical Sciences, Scientific Director UCR, Uppsala University and Sr. Interventional Cardiologist, Department of Cardiology Uppsala University Hospital UCR
Uppsala Clinical Research Center Dag Hammarskjölds v€ag 14B SE-752 37 Uppsala, Sweden. Tel: þ46 705 944 404, Email:
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix.
ESC entities having participated in the development of this document:
Associations: Acute Cardiovascular Care Association (ACCA), European Association of Preventive Cardiology (EAPC), European Association of Cardiovascular Imaging
(EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Cardiovascular Nursing and Allied Professions (CCNAP), Council for Cardiology Practice (CCP).
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Coronary Pathophysiology and Microcirculation, Myocardial and Pericardial Diseases, Thrombosis.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of
the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence avail-
able at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other offi-
cial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health
professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of pre-
ventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the
patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or
guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical
and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of

C The European Society of Cardiology 2017. All rights reserved. For permissions please email:
2 ESC Guidelines

Andreas Baumbach (UK), Raffaele Bugiardini (Italy), Ioan Mircea Coman (Romania), Victoria Delgado
(The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Anthony H. Gershlick (UK),
Stephan Gielen (Germany), Veli-Pekka Harjola (Finland), Hugo A. Katus (Germany), Juhani Knuuti
(Finland), Philippe Kolh (Belgium), Christophe Leclercq (France), Gregory Y. H. Lip (UK), Joao Morais
(Portugal), Aleksandar N. Neskovic (Serbia), Franz-Josef Neumann (Germany), Alexander Niessner
(Austria), Massimo Francesco Piepoli (Italy), Dimitrios J. Richter (France), Evgeny Shlyakhto (Russian
Federation), Iain A. Simpson (UK), Ph. Gabriel Steg (France), Christian Juhl Terkelsen (Denmark),
Kristian Thygesen (Denmark), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain),
Uwe Zeymer (Germany).

The disclosure forms of all experts involved in the development of these guidelines are available on the
ESC website

Keywords Guidelines • Acute coronary syndromes • Acute myocardial infarction • Antithrombotic therapy •
Antithrombotics • Emergency medical system • Evidence • Fibrinolysis • Ischaemic heart disease • Primary
percutaneous coronary intervention • Quality indicators • MINOCA • Reperfusion therapy • Risk
assessment • Secondary prevention • ST-segment elevation.

Table of Contents .. 5.4 Coronary artery bypass graft surgery. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
.. 6. Management during hospitalization and at discharge . . . . . . . . . . . . . . . . 24
Abbreviations and acronyms. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 .. 6.1 Coronary care unit/intensive cardiac care unit . . . . . . . . . . . . . . . . . . 24
1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 .. 6.2 Monitoring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 .. 6.3 Ambulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.1 Definition of acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . 6 .. 6.4 Length of stay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.2 Epidemiology of ST-segment elevation myocardial infarction . . . . . 6 .. 6.5 Special patient subsets. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3. What is new in the 2017 version? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 .. 6.5.1 Patients taking oral anticoagulation. . . . . . . . . . . . . . . . . . . . . . . . . 25
4. Emergency care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 .. 6.5.2 Elderly patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.1 Initial diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
.. 6.5.3 Renal dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.2 Relief of pain, breathlessness, and anxiety. . . . . . . . . . . . . . . . . . . . . . . . 9 .. 6.5.4 Non-reperfused patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.3 Cardiac arrest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
.. 6.5.5 Patients with diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4.4 Pre-hospital logistics of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 .. 6.6. Risk assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.4.1 Delays. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
.. 6.6.1 Clinical risk assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.4.2 Emergency medical system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 .. 6.6.2 Non-invasive imaging in management and risk
4.4.3 Organization of ST-segment elevation myocardial
.. stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
infarction treatment in networks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 .. 7. Long-term therapies for ST-segment elevation myocardial
5. Reperfusion therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 .. infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.1 Selection of reperfusion strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 .. 7.1 Lifestyle interventions and risk factor control . . . . . . . . . . . . . . . . . . . 29
5.2 Primary percutaneous coronary intervention and .. 7.1.1 Smoking cessation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
adjunctive therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 .. 7.1.2 Diet, alcohol, and weight control. . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.2.1 Procedural aspects of primary percutaneous .. 7.1.3 Exercise-based cardiac rehabilitation . . . . . . . . . . . . . . . . . . . . . . . 30
coronary intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 .. 7.1.4 Resumption of activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.2.2 Periprocedural pharmacotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . 18 .. 7.1.5 Blood pressure control. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.3 Fibrinolysis and pharmacoinvasive strategy . . . . . . . . . . . . . . . . . . . . . 20 .. 7.1.6 Adherence to treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.3.1 Benefit and indication of fibrinolysis . . . . . . . . . . . . . . . . . . . . . . . . 20 .. 7.2 Antithrombotic therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.3.2 Pre-hospital fibrinolysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 .. 7.2.1 Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.3.3 Angiography and percutaneous coronary intervention .. 7.2.2 Duration of dual antiplatelet therapy and antithrombotic
after fibrinolysis (pharmacoinvasive strategy) . . . . . . . . . . . . . . . . . . . . 21 .. combination therapies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
5.3.4 Comparison of fibrinolytic agents . . . . . . . . . . . . . . . . . . . . . . . . . . 22 .. 7.3 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
5.3.5 Adjunctive antiplatelet and anticoagulant therapies . . . . . . . . . 22
.. 7.3.1 Early intravenous beta-blocker administration . . . . . . . . . . . . . . 32
5.3.6 Hazards of fibrinolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 .. 7.3.2 Mid- and long-term beta-blocker treatment . . . . . . . . . . . . . . . . 32
5.3.7 Contraindications to fibrinolytic therapy . . . . . . . . . . . . . . . . . . . 23
.. 7.4 Lipid-lowering therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
ESC Guidelines 3

7.5 Nitrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 .. ATLAS ACS Anti-Xa Therapy to Lower cardiovascular
7.6 Calcium antagonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 .. 2–TIMI 51 events in Addition to Standard therapy
7.7 Angiotensin-converting enzyme inhibitors and angiotensin II .. in subjects with Acute Coronary
receptor blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 .. Syndrome–Thrombolysis In Myocardial
7.8 Mineralocorticoid/aldosterone receptor antagonists . . . . . . . . . . . . 33 ..
.. Infarction 51
8. Complications following ST-segment elevation myocardial .. ATOLL Acute myocardial infarction Treated with
infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 ..
.. primary angioplasty and inTravenous
8.1 Myocardial dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 .. enOxaparin or unfractionated heparin to
8.1.1 Left ventricular dysfunction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 ..
.. Lower ischaemic and bleeding events at short-
8.1.2 Right ventricular involvement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 .. and Long-term follow-up
8.2 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 ..
.. AV atrioventricular
8.2.1 Clinical presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 .. b.i.d. bis in die (twice a day)
8.2.2 Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
.. BMI body mass index
8.3 Management of arrhythmias and conduction disturbances .. BMS bare-metal stent
in the acute phase. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
.. BNP B-type natriuretic peptide
8.3.1 Supraventricular arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 .. CABG coronary artery bypass graft surgery
8.3.2 Ventricular arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
.. CAD coronary artery disease
8.3.3 Sinus bradycardia and atrioventricular block . . . . . . . . . . . . . . . . 41 .. CAPITAL AMI Combined Angioplasty and Pharmacological
8.4 Mechanical complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
.. Intervention versus Thrombolytics ALone in
8.4.1 Free wall rupture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 .. Acute Myocardial Infarction
8.4.2 Ventricular septal rupture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 .. CCNAP Council on Cardiovascular Nursing and Allied
8.4.3 Papillary muscle rupture. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 .. Professions
8.5 Pericarditis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 .. CCP Council for Cardiology Practice;
8.5.1 Early and late (Dressler syndrome) infarct-associated .. CCU coronary care unit
pericarditis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 .. CHA2DS2-VASc Cardiac failure, Hypertension, Age 75
8.5.2 Pericardial effusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 .. (Doubled), Diabetes, Stroke (Doubled) –
9. Myocardial infarction with non-obstructive coronary arteries . . . . . . . 42 .. VAScular disease, Age 65–74 and Sex category
10. Assessment of quality of care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 ..
.. (Female)
11. Gaps in the evidence and areas for future research . . . . . . . . . . . . . . . . 44 .. CI confidence interval
12. Key messages. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 ..
.. CKD chronic kidney disease
13. Evidenced-based ‘to do and not to do’ messages .. CMR cardiac magnetic resonance
from the Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 ..
.. CPG Committee for Practice Guidelines
14. Web addenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 .. CRISP AMI Counterpulsation to Reduce Infarct Size Pre-
15. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 ..
.. PCI-Acute Myocardial Infarction
16. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 .. CT computed tomography
.. COMFORTABLE- Effect of biolimus-eluting stents with
.. AMI biodegradable polymer vs. bare-metal
.. stents on cardiovascular events among
Abbreviations and acronyms .. patients with acute myocardial infarction
.. trial;
ACE angiotensin-converting enzyme .. Compare-Acute Comparison Between FFR Guided
ACCA Acute Cardiovascular Care Association ... Revascularization Versus Conventional
ACS acute coronary syndrome .. Strategy in Acute STEMI Patients With
AF atrial fibrillation .. Multivessel disease trial
ALBATROSS Aldosterone Lethal effects Blockade in Acute .. CURRENT- The Clopidogrel and aspirin Optimal Dose
myocardial infarction Treated with or without .. OASIS 7 usage to reduce recurrent events–Seventh
Reperfusion to improve Outcome and Survival .. organization to assess strategies in ischaemic
at Six months follow-up .. syndromes
AMI acute myocardial infarction .. CvLPRIT Complete Versus Lesion-Only Primary PCI
ARB angiotensin II receptor blocker
.. Trial
ASSENT 3 ASsessment of the Safety and Efficacy of a New .. DANAMI DANish Study of Optimal Acute Treatment of
Thrombolytic 3
.. Patients with ST-segment Elevation Myocardial
ATLANTIC Administration of Ticagrelor in the Cath Lab or .. Infarction
in the Ambulance for New ST Elevation
.. DANAMI 3- DANAMI 3 – Deferred versus conventional
Myocardial Infarction to Open the Coronary .. DEFER stent implantation in patients with ST-segment
. elevation myocardial infarction
4 ESC Guidelines

DANAMI-3– DANAMI 3 – Complete revascularisation ... LV left ventricle/ventricular
PRIMULTI versus treatment of the culprit lesion only in
.. LVAD Left ventricular assist device
patients with ST-segment elevation myocardial .. LVEF left ventricular ejection fraction
infarction and multivessel disease
.. MACE major adverse cardiac event
DAPT dual antiplatelet therapy .. MATRIX Minimizing Adverse Haemorrhagic Events by
DES drug-eluting stent
.. TRansradial Access Site and Systemic
EACVI European Association of Cardiovascular .. Implementation of angioX
Imaging .. METOCARD- Effect of Metoprolol in Cardioprotection
EAPC European Association of Preventive Cardiology .. CNIC During an Acute Myocardial Infarction
EAPCI European Association of Percutaneous .. MI myocardial infarction
Cardiovascular Interventions .. MINOCA myocardial infarction with non-obstructive
EARLY-BAMI Early Intravenous Beta-Blockers in Patients .. coronary arteries
With ST-Segment Elevation Myocardial .. MRA mineralocorticoid receptor antagonist
Infarction Before Primary Percutaneous .. MVO microvascular obstruction
Coronary Intervention .. NORSTENT Norwegian Coronary Stent
ECG electrocardiogram .. NSTEMI non-ST-segment elevation myocardial
ECLS extracorporeal life support .. infarction
ECMO extracorporeal membrane oxygenation .. NT-proBNP N-terminal pro B-type natriuretic peptide
eGFR estimated glomerular filtration rate .. OASIS-6 Organization for the Assessment of Strategies
EHRA European Heart Rhythm Association .. for Ischemic Syndromes
EMS emergency medical system .. o.d. omni die (once a day)
EPHESUS Eplerenone Post-AMI Heart failure Efficacy and .. PAMI-II Second Primary Angioplasty in Myocardial
SUrvival Study ... Infarction
ESC European Society of Cardiology
.. PaO2 partial pressure of oxygen
EXAMINATION Everolimus-Eluting Stents Versus Bare-Metal .. PCI percutaneous coronary intervention
Stents in ST-Segment Elevation Myocardial
.. PCSK9 proprotein convertase subtilisin/kexin type 9
Infarction .. PEGASUS- Prevention of Cardiovascular Events in Patients
ExTRACT– Enoxaparin and Thrombolysis Reperfusion for
.. TIMI 54 with Prior Heart Attack Using Ticagrelor
TIMI 25 Acute myocardial infarction .. Compared to Placebo on a Background of
Treatment–Thrombolysis In Myocardial .. Aspirin–Thrombolysis in Myocardial Infarction 54
Infarction .. PET positron emission tomography
FFR fractional flow reserve .. PIONEER Open-Label, Randomized, Controlled,
FMC first medical contact .. AF-PCI Multicenter Study Exploring Two Treatment
FOCUS Fixed-Dose Combination Drug for Secondary .. Strategies of Rivaroxaban and a Dose-Adjusted
Cardiovascular Prevention .. Oral Vitamin K Antagonist Treatment Strategy
FOURIER Further Cardiovascular Outcomes Research .. in Subjects with Atrial Fibrillation who
with PCSK9 Inhibition in Subjects with Elevated .. Undergo Percutaneous Coronary Intervention
Risk trial. .. p.o. per os (orally)
GP glycoprotein .. PPI proton pump inhibitor
GRACE Global Registry of Acute Coronary Events .. PRAMI Preventive Angioplasty in Acute Myocardial
GRACIA Grupo de Analisis de la Cardiopatıa Isquémica .. Infarction
Aguda .. PRODIGY PROlonging Dual Antiplatelet Treatment After
HDL-C high-density lipoprotein cholesterol .. Grading stent-induced Intimal hyperplasia
HFA Heart Failure Association .. studY
HR hazard ratio
.. RBBB right bundle branch block
IABP intra-aortic balloon pump .. REMINDER A Double-Blind, Randomized, Placebo-
ICCU intensive cardiac care unit
.. Controlled Trial Evaluating The Safety And
ICD implantable cardioverter defibrillator .. Efficacy Of Early Treatment With Eplerenone
IMPROVE-IT Improved Reduction of Outcomes: Vytorin
.. In Patients With Acute Myocardial Infarction
Efficacy International Trial .. RIFLE- Radial Versus Femoral Randomized
IRA infarct-related artery
.. STEACS Investigation in ST-Elevation Acute Coronary
IU international units .. Syndrome
i.v. intravenous .. RIVAL Radial Versus Femoral Access for Coronary
LBBB left bundle branch block .. intervention
LDL-C low-density lipoprotein cholesterol .. RV right ventricle/ventricular
LGE late gadolinium enhancement .. SaO2 arterial oxygen saturation
ESC Guidelines 5

SBP systolic blood pressure .. established in order to make all decisions transparent to the user.
s.c. subcutaneous
.. The recommendations for formulating and issuing ESC Guidelines
SGLT2 sodium-glucose co-transporter-2 .. can be found on the ESC website (
SPECT single-photon emission computed tomography
.. Guidelines/Clinical-Practice-Guidelines/Guidelines-development/
STEMI ST-segment elevation myocardial infarction .. Writing-ESC-Guidelines). ESC Guidelines represent the official posi-
STREAM STrategic Reperfusion Early After Myocardial
.. tion of the ESC on a given topic and are regularly updated.
infarction .. Members of this Task Force were selected by the ESC, including
TIMI Thrombolysis In Myocardial Infarction
.. representation from its relevant ESC sub-specialty groups, in order
TNK-tPA Tenecteplase tissue plasminogen activator .. to represent professionals involved with the medical care of patients
.. with this pathology. Selected experts in the field undertook a com-
TOTAL Trial of Routine Aspiration Thrombectomy ..
with PCI versus PCI Alone in Patients with .. prehensive review of the published evidence for management of a
.. given condition according to ESC Committee for Practice Guidelines
tPA tissue plasminogen activator .. (CPG) policy. A critical evaluation of diagnostic and therapeutic pro-
.. cedures was performed, including assessment of the risk–benefit
UFH unfractionated heparin ..
VALIANT VALsartan In Acute myocardial iNfarcTion .. ratio. The level of evidence and the strength of the recommendation
.. of particular management options were weighed and graded accord-
VF ventricular fibrillation ..
VT ventricular tachycardia .. ing to predefined scales, as outlined in Tables 1 and 2.
.. The experts of the writing and reviewing panels provided declara-
24/7 24 h a day, seven days a week ..
.. tion of interest forms for all relationships that might be perceived as
.. real or potential sources of conflicts of interest. These forms were
.. compiled into one file and can be found on the ESC website (http://
1. Preamble .. Any changes in declarations of interest
Guidelines summarize and evaluate available evidence with the aim of .. that arise during the writing period were notified to the ESC and
assisting health professionals in selecting the best management strat- .. updated. The Task Force received its entire financial support from
egies for an individual patient with a given condition. Guidelines and .. the ESC without any involvement from the healthcare industry.
their recommendations should facilitate decision making of health .. The ESC CPG supervises and coordinates the preparation of new
professionals in their daily practice. However, the final decisions con- .. ESC Guidelines. The Committee is also responsible for the endorse-
cerning an individual patient must be made by the responsible health .. ment process of these Guidelines. The ESC Guidelines undergo
professional(s) in consultation with the patient and caregiver as .. extensive review by the CPG and external experts. After appropriate
appropriate. .. revisions the Guidelines are approved by all the experts involved in
A great number of guidelines have been issued in recent years by .. the Task Force. The finalized document is approved by the CPG for
the European Society of Cardiology (ESC), as well as by other soci- .. publication in the European Heart Journal. The Guidelines were
eties and organisations. Because of the impact on clinical practice,
.. developed after careful consideration of the scientific and medical
quality criteria for the development of guidelines have been . knowledge and the evidence available at the time of their dating.

Table 1 Classes of recommendations
6 ESC Guidelines

Table 2 Levels of evidence
.. strategy. The levels of evidence and the strengths of recommenda-
.. tion of particular treatment options were weighed and graded
.. according to pre-defined scales, as outlined in Tables 1 and 2. Despite
.. recommendations with a level of evidence being based on expert
.. opinion, this Task Force decided to add references to guide the
.. reader regarding data that were taken into consideration for these
.. decisions in some cases.
.. 2.1 Definition of acute myocardial
.. infarction
.. The term acute myocardial infarction (AMI) should be used when
.. there is evidence of myocardial injury (defined as an elevation of car-
.. diac troponin values with at least one value above the 99th percentile
.. upper reference limit) with necrosis in a clinical setting consistent
The task of developing ESC Guidelines also includes the creation .. with myocardial ischaemia.8 For the sake of immediate treatment
of educational tools and implementation programmes for the recom- .. strategies such as reperfusion therapy, it is usual practice to designate
mendations including condensed pocket guideline versions, summary .. patients with persistent chest discomfort or other symptoms sugges-
slides, booklets with essential messages, summary cards for non- .. tive of ischaemia and ST-segment elevation in at least two contiguous
specialists and an electronic version for digital applications (smart- .. leads as STEMI. In contrast, patients without ST-segment elevation at
phones, etc.). These versions are abridged and thus, if needed, one .. presentation are usually designated as having a non-ST-segment ele-
should always refer to the full text version, which is freely available .. vation myocardial infarction (MI) (NSTEMI) and separate guidelines
via the ESC website and hosted on the EHJ website. The National .. have recently been developed for these.2 Some patients with MI
Societies of the ESC are encouraged to endorse, translate and imple- .. develop Q-waves (Q-wave MI), but many do not (non-Q-wave MI).
ment all ESC Guidelines. Implementation programmes are needed .. In addition to these categories, MI is classified into various types,
because it has been shown that the outcome of disease may be .. based on pathological, clinical, and prognostic differences, along with
favourably influenced by the thorough application of clinical
.. different treatment strategies (see the Third Universal Definition of
recommendations. .. MI document,8 which will be updated in 2018). Despite the fact that
Surveys and registries are needed to verify that real-life daily prac-
.. the majority of STEMI patients are classified as a type 1 MI (with evi-
tice is in keeping with what is recommended in the guidelines, thus .. dence of a coronary thrombus), some STEMIs fall into other MI
completing the loop between clinical research, writing of guidelines,
.. types.8 MI, even presenting as STEMI, also occurs in the absence of
disseminating them and implementing them into clinical practice. .. obstructive coronary artery disease (CAD) on angiography.9–12 This
Health professionals are encouraged to take the ESC Guidelines
.. type of MI is termed ‘myocardial infarction with non-obstructive cor-
fully into account when exercising their clinical judgment, as well as in .. onary arteries’ (MINOCA) and is discussed in Chapter 9 of this
the determination and the implementation of preventive, diagnostic .. document.
or therapeutic medical strategies. However, the ESC Guidelines do ..
not override in any way whatsoever the individual responsibility of .. 2.2 Epidemiology of ST-segment
health professionals to make appropriate and accurate decisions in ..
.. elevation myocardial infarction
consideration of each patient’s health condition and in consultation .. Worldwide, ischaemic heart disease is the single most common cause
with that patient or the patient’s caregiver where appropriate and/or ..
.. of death and its frequency is increasing. However, in Europe, there
necessary. It is also the health professional’s responsibility to verify ..
.. has been an overall trend for a reduction in ischaemic heart disease
the rules and regulations applicable to drugs and devices at the time .. mortality over the past three decades.13 Ischaemic heart disease now
of prescription. ..
.. accounts for almost 1.8 million annual deaths, or 20% of all deaths in
.. Europe, although with large variations between countries.14
2. Introduction .. The relative incidences of STEMI and NSTEMI are decreasing and
.. increasing, respectively.15,16 Probably the most comprehensive
Updates on the management of patients presenting with ST-segment .. European STEMI registry is found in Sweden, where the incidence
elevation myocardial infarction (STEMI) should be based on sound .. rate of STEMI was 58 per 100 000 per year in 2015.17 In other
evidence, derived from well-conducted clinical trials whenever possi- .. European countries, the incidence rate ranged from 43 to 144 per
ble, or motivated expert opinion when needed. It must be recognized .. 100 000 per year.18 Similarly, the reported adjusted incidence rates
that, even when excellent clinical trials have been undertaken, the .. from the USA decreased from 133 per 100 000 in 1999 to 50 per
results are open to interpretation and treatments may need to be .. 100 000 in 2008, whereas the incidence of NSTEMI remained con-
adapted to take account of clinical circumstances and resources. .. stant or increased slightly.19 There is a consistent pattern for STEMI
The present Task Force has made an important effort to be as .. to be relatively more common in younger than in older people, and
aligned as possible with the other ESC Guidelines1–6 and consensus .. more common in men than in women.17,20
documents, including the simultaneously published update on dual
.. The mortality in STEMI patients is influenced by many factors,
antiplatelet therapy (DAPT),7 for consistency in the ESC Guidelines . among them advanced age, Killip class, time delay to treatment,
ESC Guidelines 7

presence of emergency medical system (EMS)-based STEMI net- .. symptoms, up to 30% in some registries,27 and tend to present later
works, treatment strategy, history of MI, diabetes mellitus, renal fail- .. than men.28,29 It is therefore important to maintain a high degree of
ure, number of diseased coronary arteries, and left ventricular .. awareness for MI in women with potential symptoms of ischaemia.
ejection fraction (LVEF). Several recent studies have highlighted a fall
.. Women also have a higher risk of bleeding complications with PCI.
in acute and long-term mortality following STEMI in parallel with .. There is an ongoing debate regarding whether outcomes are poorer in
greater use of reperfusion therapy, primary percutaneous coronary
.. women, with several studies indicating that a poorer outcome is
intervention (PCI), modern antithrombotic therapy, and secondary .. related to older age and more comorbidities among women suffering
prevention.14,21,22 Nevertheless, mortality remains substantial; the in-
.. MI.26,30,31 Some studies have indicated that women tend to undergo
hospital mortality of unselected patients with STEMI in the national .. fewer interventions than men and receive reperfusion therapy less fre-
registries of the ESC countries varies between 4 and 12%,23 while
.. quently.26,32,33 These guidelines aim to highlight the fact that women
reported 1-year mortality among STEMI patients in angiography .. and men receive equal benefit from a reperfusion strategy and STEMI-
registries is approximately 10%.24,25 .. related therapy, and that both genders must be managed in a similar
Although ischaemic heart disease develops on average 7–10 years .. fashion.
later in women compared with men, MI remains a leading cause of ..
death in women. Acute coronary syndrome (ACS) occurs three to ..
four times more often in men than in women below the age of .. 3. What is new in the 2017
60 years, but after the age of 75, women represent the majority of ..
.. version?
patients.26 Women tend to present more often with atypical ..



Figure 1 What is new in 2017 STEMI Guidelines. BMS = bare metal stent; DES = drug eluting stent; IRA = infarct related artery; i.v. = intravenous;
LDL = low-density lipoprotein; PCI = percutaneous coronary intervention; SaO2 = arterial oxygen saturation; STEMI = ST-elevation myocardial
infarction; TNK-tPA = Tenecteplase tissue plasminogen activator. For explanation of trial names, see list of.
Only for experienced radial operators.
Before hospital discharge (either immediate or staged).
Routine thrombus aspiration (bailout in certain cases may be considered).
In 2012 early discharge was considered after 72h, in 2017 early discharge is 48–72h.
If symptoms or haemodynamic instability IRA should be opened regardless time from symptoms onset.
In left and mid panels, below each recommendation, the most representative trial (acronym and reference) driving the indication is
8 ESC Guidelines

4. Emergency care .. The presence of a Q-wave on the ECG should not necessarily change
.. the reperfusion strategy decision.
4.1 Initial diagnosis
Management—including diagnosis and treatment—of STEMI starts Recommendations for initial diagnosis
from the point of first medical contact (FMC, defined in Table 4). It is
recommended that a regional reperfusion strategy should be estab- Recommendations Classa Levelb
lished to maximize efficiency.
A working diagnosis of STEMI (called the ‘STEMI diagnosis’ ECG monitoring
throughout this document) must first be made. This is usually based 12-lead ECG recording and interpretation is
on symptoms consistent with myocardial ischaemia (i.e. persistent indicated as soon as possible at the point of
chest pain) and signs [i.e. 12-lead electrocardiogram (ECG)]. FMC, with a maximum target delay of
Important clues are a history of CAD and radiation of pain to the 10 min.36,38
neck, lower jaw, or left arm. Some patients present with less-typical
symptoms such as shortness of breath, nausea/vomiting, fatigue, pal- ECG monitoring with defibrillator capacity
pitations, or syncope.34 A reduction in chest pain after nitroglycerin is indicated as soon as possible in all patients I B
(glyceryl trinitrate) administration can be misleading and is not rec- with suspected STEMI.44,45
ommended as a diagnostic manoeuvre.35 In cases of symptom relief The use of additional posterior chest wall
after nitroglycerin administration, another 12-lead ECG must be leads (V7 –V9) in patients with high suspicion
obtained. A complete normalization of the ST-segment elevation IIa B
of posterior MI (circumflex occlusion)
after nitroglycerin administration, along with complete relief of symp- should be considered. 8,46–49

toms, is suggestive of coronary spasm, with or without associated MI.
In these cases, an early coronary angiography (within 24 h) is recom- The use of additional right precordial leads
mended. In cases of recurrent episodes of ST-segment elevation or (V3R and V4R) in patients with inferior MI
chest pain, immediate angiography is required. should be considered to identify concomi-
It is recommended to initiate ECG monitoring as soon as possible tant RV infarction.8,43
in all patients with suspected STEMI in order to detect life- Blood sampling
threatening arrhythmias and allow prompt defibrillation if indicated.
When a STEMI is suspected, a 12-lead ECG must be acquired and Routine blood sampling for serum markers
interpreted as soon as possible at the time of FMC to facilitate early is indicated as soon as possible in the acute
STEMI diagnosis and triage.36–40 phase but should not delay reperfusion
In patients with a clinical suspicion of myocardial ischaemia and ST- treatment.
segment elevation, reperfusion therapy needs to be initiated as soon
as possible.41 If the ECG is equivocal or does not show evidence to ECG = electrocardiogram; FMC = first medical contact; MI = myocardial infarc-
tion; RV = right ventricle; STEMI = ST-segment elevation myocardial infarction.
support the clinical suspicion of MI, ECGs should be repeated and, a
Class of recommendation.
when possible compared with previous recordings. If interpretation b
Level of evidence.
of pre-hospital ECG is not possible on-site, field transmission of the
ECG is recommended.42
ECG criteria are based on changes of electrical currents of the The ECG diagnosis may be more difficult in some cases, which
heart (measured in millivolts). Standard calibration of the ECG is nevertheless deserve prompt management and triage. Among these:
10mm/mV. Therefore 0.1 mV equals to 1 mm square on the vertical Bundle branch block. In the presence of LBBB, the ECG diagno-
axis. For simplicity, in this document ECG deviations are expressed in sis of AMI is difficult but often possible if marked ST-segment abnor-
mm following the standard calibration. malities are present. Somewhat complex algorithms have been offered
In the proper clinical context, ST-segment elevation (measured at to assist the diagnosis,50,51 but they do not provide diagnostic cer-
the J-point) is considered suggestive of ongoing coronary artery acute tainty.52 The presence of concordant ST-segment elevation (i.e. in
occlusion in the following cases: at least two contiguous leads with leads with positive QRS deflections) appears to be one of the best indi-
ST-segment elevation  2.5 mm in men < 40 years, 2 mm in men cators of ongoing MI with an occluded infarct artery.53 Patients with a 
40 years, or  1.5 mm in women in leads V2 –V3 and/or  1 mm in clinical suspicion of ongoing myocardial ischaemia and LBBB should be
the other leads [in the absence of left ventricular (LV) hypertrophy managed in a way similar to STEMI patients, regardless of whether the
or left bundle branch block LBBB)].8 In patients with inferior MI, it is LBBB is previously known. It is important to remark that the presence
recommended to record right precordial leads (V3R and V4R) seek- of a (presumed) new LBBB does not predict an MI per se.54
ing ST-segment elevation, to identify concomitant right ventricular Patients with MI and right bundle branch block (RBBB) have a
(RV) infarction.8,43 Likewise, ST-segment depression in leads V1 –V3 poor prognosis.55 It may be difficult to detect transmural ischaemia in
suggests myocardial ischaemia, especially when the terminal T-wave patients with chest pain and RBBB.55 Therefore, a primary PCI strat-
is positive (ST-segment elevation equivalent), and confirmation by egy (emergent coronary angiography and PCI if indicated) should be
concomitant ST-segment elevation  0.5 mm recorded in leads considered when persistent ischaemic symptoms occur in the pres-
V7 –V9 should be considered as a means to identify posterior MI.8 ence of RBBB.
ESC Guidelines 9

Ventricular pacing. Pacemaker rhythm may also prevent .. (1 mm in men, 40 years old)] is recommended to detect ST-
interpretation of ST-segment changes and may require urgent angiog- .. segment elevation consistent with inferior and basal MI.
raphy to confirm diagnosis and initiate therapy. Reprogramming the .. Left main coronary obstruction. The presence of ST depres-
pacemaker—allowing an evaluation of ECG changes during intrinsic .. sion  1 mm in six or more surface leads (inferolateral ST depres-
heart rhythm—may be considered in patients who are not depend- .. sion), coupled with ST-segment elevation in aVR and/or V1, suggests
ent on ventricular pacing, without delaying invasive investigation.56,57
.. multivessel ischemia or left main coronary artery obstruction, partic-
Non-diagnostic ECG. Some patients with an acute coronary .. ularly if the patient presents with haemodynamic compromise.60
occlusion may have an initial ECG without ST-segment elevation,
.. Blood sampling for serum markers is routinely carried out in the
sometimes because they are seen very early after symptom onset (in .. acute phase. This is indicated, but should not delay the reperfusion
which case, one should look for hyper-acute T-waves, which may pre-
.. strategy/treatment.
cede ST-segment elevation). It is important to repeat the ECG or .. If in doubt regarding the possibility of acute evolving MI, emergency
monitor for dynamic ST-segment changes. In addition, there is a con-
.. imaging aids the provision of timely reperfusion therapy to these
cern that some patients with acute occlusion of a coronary artery and .. patients. Recommendations for the use of echocardiography for ini-
ongoing MI, such as those with an occluded circumflex coronary .. tial diagnosis are described in section 6.6.2. If echocardiography is not
artery,58,59 acute occlusion of a vein graft, or left main disease, may .. available or if doubts persist after echo, a primary PCI strategy is indi-
present without ST-segment elevation and be denied reperfusion ther- .. cated (including immediate transfer to a PCI centre if the patient is
apy, resulting in a larger infarction and worse outcomes. Extending the .. being treated in a non-PCI centre).
standard 12-lead ECG with V7–V9 leads may identify some of these .. In the STEMI emergency setting, there is no role for routine com-
patients. In any case, suspicion of ongoing myocardial ischaemia is an .. puted tomography (CT). Use of CT should be confined to selected
indication for a primary PCI strategy even in patients without diagnos- .. cases where acute aortic dissection or pulmonary embolism is sus-
tic ST-segment elevation.8,38,46–49 Table 3 lists the atypical ECG pre- .. pected, but CT is not recommended if STEMI diagnosis is likely.
sentations that should prompt a primary PCI strategy in patients with .. Some non-AMI conditions can present with symptoms and ECG
ongoing symptoms consistent with myocardial ischaemia. .. findings similar to STEMI. An emergency coronary angiography is
Isolated posterior MI. In AMI of the inferior and basal portion .. therefore indicated in these cases (Chapter 9 expands on this topic).
of the heart, often corresponding to the left circumflex territory, iso- ..
lated ST-segment depression  0.5 mm in leads V1 –V3 represents .. 4.2 Relief of pain, breathlessness, and
the dominant finding. These should be managed as a STEMI. The use .. anxiety
of additional posterior chest wall leads [elevation V7 –V9  0.5 mm .. Relief of pain is of paramount importance, not only for comfort rea-
.. sons but because the pain is associated with sympathetic activation,
.. which causes vasoconstriction and increases the workload of the
Table 3 Atypical electrocardiographic presentations ..
that should prompt a primary percutaneous coronary .. heart. Titrated intravenous (i.v.) opioids (e.g. morphine) are the anal-
intervention strategy in patients with ongoing symp- .. gesics most commonly used in this context. However, morphine use
toms consistent with myocardial ischaemia
.. is associated with a slower uptake, delayed onset of action, and
.. diminished effects of oral antiplatelet agents (i.e. clopidogrel, ticagre-
.. lor, and prasugrel), which may lead to early treatment failure in sus-
.. ceptible individuals.61–63

Relief of hypoxaemia and symptoms

Recommendations Classa Levelb


Oxygen is indicated in patients with hypo-
xaemia (SaO2 < 90% or PaO2 < 60 mmHg).

Routine oxygen is not recommended in
patients with SaO2  90%.64–66


Titrated i.v. opioids should be considered to
relieve pain.

A mild tranquillizer (usually a benzodiaze-
pine) should be considered in very anxious IIa C

ECG = electrocardiogram; LBBB = left bundle branch block; RBBB = right bundle
branch block; RV = right ventricular; STEMI = ST-segment elevation myocardial i.v. = intravenous; PaO2 = partial pressure of oxygen; SaO2 = arterial oxygen
infarction. saturation.
Class of recommendation.
Level of evidence.
10 ESC Guidelines

Oxygen is indicated in hypoxic patients with arterial oxygen satu- .. catheterization laboratory. Close attention to anticoagulation needs
ration (SaO2) < 90%. There is some evidence suggesting that hyper- .. to be paid in patients reaching low temperatures.84
oxia may be harmful in patients with uncomplicated MI, presumably .. Prevention and improved treatment of out-of-hospital cardiac
due to increased myocardial injury.64–67 Thus, routine oxygen is not .. arrest is crucial to reduce the mortality related to CAD. For a more
recommended when SaO2 is  90%. .. detailed discussion of these issues, refer to the recent European
Anxiety is a natural response to the pain and the circumstances .. Resuscitation Council Guidelines for resuscitation.74
surrounding an MI. Reassurance of patients and those closely associ-
ated with them is of great importance. Cardiac arrest
A mild tranquillizer (usually a benzodiazepine) should be consid-
ered in anxious patients.
Recommendations Classa Levelb

4.3 Cardiac arrest A primary PCI strategy is recommended in
Many deaths occur very early after STEMI onset due to ventricular patients with resuscitated cardiac arrest and I B
fibrillation (VF).68 As this arrhythmia frequently occurs at an early an ECG consistent with STEMI.69–71,85
stage, these deaths usually happen out of hospital. It is indicated that
Targeted temperature managementc is indi-
all medical and paramedical personnel caring for patients with sus-
cated early after resuscitation of cardiac
pected MI have access to defibrillation equipment and are trained in I B
arrest patients who remain
cardiac life support, and that, at the point of FMC, ECG monitoring
must be implemented immediately for all patients with suspected MI.
Patients with chest pain suggestive of MI should be directed It is indicated that healthcare systems imple-
through public awareness programmes to contact the EMS and wait ment strategies to facilitate transfer of all
to be transferred to the hospital by the EMS. patients in whom a MI is suspected directly I C
In patients following cardiac arrest and ST-segment elevation on to the hospital offering 24/7 PCI-mediated
the ECG, primary PCI is the strategy of choice.69–74 reperfusion therapy via one specialized EMS.
Given the high prevalence of coronary occlusions and the potential
It is indicated that all medical and paramedi-
difficulties in interpreting the ECG in patients after cardiac arrest,
cal personnel caring for patients with sus-
urgent angiography (within 2 h)2 should be considered in survivors of
pected MI have access to defibrillation I C
cardiac arrest, including unresponsive survivors, when there is a high
equipment and are trained in basic cardiac
index of suspicion of ongoing infarction (such as the presence of
life support.
chest pain before arrest, a history of established CAD, and abnormal
or uncertain ECG results).73,74 However, in patients without ST- Urgent angiography (and PCI if indicated)
segment elevation, a quick evaluation at the emergency department should be considered in patients with resus-
or intensive cardiac care unit (ICCU) to exclude non-coronary citated cardiac arrest without diagnostic ST- IIa C
causes (cerebrovascular event, respiratory failure, non-cardiogenic segment elevation but with a high suspicion
shock, pulmonary embolism, and intoxication), and to perform of ongoing myocardial ischaemia.69–71,73
urgent echocardiography, is reasonable. The decision to perform
Pre-hospital cooling using a rapid infusion of
urgent coronary angiography and PCI if indicated should also take
large volumes of cold i.v. fluid immediately
into account factors associated with poor neurological outcome. III B
after return of spontaneous circulation is
Unfavourable pre-hospital settings indicating a remote likelihood for 86
not recommended.
neurological recovery [i.e. unwitnessed cardiac arrest, late arrival of a
pre-hospital team without lay basic life support (>10 min), presence
of an initial non-shockable rhythm, or more than 20 min of advanced 24/7 = 24 h a day, 7 days a week; ECG = electrocardiogram; EMS = emergency
medical system; i.v. = intravenous; MI = myocardial infarction; PCI = percutane-
life support without return to spontaneous circulation]75 should be ous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
taken strongly into consideration to argue against an invasive coro- Class of recommendation.
nary strategy.73 c
Level of evidence.
Targeted temperature management refers to active methods (i.e. cooling cathe-
Unconscious patients admitted to critical care units after out-of- ters, cooling blankets, and application of ice applied around the body) to achieve
hospital cardiac arrest are at high risk for death, and neurologic defi- and maintain a constant specific body temperature between 32 and 36  C in a
cits are common among those who survive.76 Targeted temperature person for a specific duration of time (most commonly used  24 h).

management (also called therapeutic hypothermia), aiming for a con-
stant temperature between 32 and 36  C for at least 24 h, is indicated
in patients who remain unconscious after resuscitation from cardiac
arrest (of presumed cardiac cause).73,77–82 However, hypothermia 4.4 Pre-hospital logistics of care
conditions are associated with slow uptake, delayed onset of action, 4.4.1 Delays
and diminished effects of oral antiplatelet agents (i.e. clopidogrel, tica- Treatment delays are the most easily audited index of quality of care
grelor, and prasugrel). Moreover, metabolic conversion of clopidog- in STEMI; they should be recorded in every system providing care to
rel in the liver may be reduced in hypothermia conditions.83 Cooling STEMI patients and be reviewed regularly, to ensure that simple qual-
should not delay primary PCI and can be started in parallel in the ity of care indicators are met and maintained over time (see Chapter
ESC Guidelines 11

Figure 2 Modes of patient presentation, components of ischaemia time and flowchart for reperfusion strategy selection. EMS = Emergency
Medical System; FMC = First Medical Contact; PCI = Percutaneous Coronary Intervention; STEMI = ST-segment elevation myocardial infarction.
The recommended mode of patient presentation is by alerting the EMS (call national emergency number: 112 or similar number
according to region). When STEMI diagnosis is made in the out-of-hospital setting (via EMS) or in a non-PCI centre, the decision for
choosing reperfusion strategy is based on the estimated time from STEMI diagnosis to PCI-mediated reperfusion (wire crossing).
System delay for patients alerting the EMS starts at the time of phone alert, although FMC occurs when EMS arrives to the scene (see
Table 4).denotes minutes. aPatients with fibrinolysis should be transferred to a PCI centre immediately after administration of the lytic

10). If projected target times are not met, then interventions are .. to <_ 10 min. STEMI diagnosis refers to the time when the ECG is
needed to improve performance of the system. Components of the .. interpreted as ST-segment elevation or equivalent and it is the time
ischaemic time, delays of initial management, and selection of reperfu- .. zero to guide appropriate therapy.
sion strategy are shown in Figure 2.
.. System delay is more readily modifiable by organizational meas-
To minimize patient delay, it is recommended to increase public .. ures than is patient delay, and it is a predictor of outcomes.87
awareness of how to recognize common symptoms of AMI and to
.. When STEMI diagnosis is made in the pre-hospital setting (EMS),
call the emergency services. All components of the system delay rep- .. immediate activation of the catheterization laboratory not only
resent the quality of care and it is recommended to measure them as
.. reduces treatment delays but may also reduce patient mortality.88–91
quality indicators (see Chapter 10). .. When a STEMI diagnosis is made by the EMS in the pre-hospital set-
In hospitals and EMS participating in the care of STEMI patients,
.. ting and the patient is triaged for a primary PCI strategy, it is indicated
the goal is to reduce the delay between FMC and STEMI diagnosis .. to bypass the emergency department and bring the patient straight
12 ESC Guidelines

to the catheterization laboratory. Bypassing the emergency depart-
.. 䊏 Pre-hospital triage of STEMI patients to the appropriate institution,
ment is associated with a 20 min saving in the time from FMC to wire .. bypassing non-PCI hospitals or hospitals without a 24 h a day, 7 days a
crossing.92 For patients presenting in a non-PCI centre, door-in to
.. week (24/7) primary PCI programme.
door-out time, defined as the duration between arrival of the patient .. 䊏 On arrival at the appropriate hospital, the patient should immediately
at the hospital to discharge of the patient in an ambulance en route
.. be taken to the catheterization laboratory, bypassing the emergency
to the PCI centre, is a new clinical performance measure, and .. department.
<_30 min is recommended to expedite reperfusion care.93
.. 䊏 Patients presenting to a non-PCI-capable hospital and awaiting trans-
.. portation for primary or rescue PCI must be attended in an appropri-
.. ately monitored and staffed area.
.. 䊏 If the diagnosis of STEMI has not been made by the ambulance crew
4.4.2 Emergency medical system
.. and the ambulance arrives at a non-PCI-capable hospital, the ambu-
An EMS with an easily recalled and well publicized unique medical dis- .. lance should await the diagnosis and, if a STEMI diagnosis is made,
patching number (112 for most medical emergencies across Europe)
.. should continue to a PCI-capable hospital.
is important to speed up activation. Parallel circuits for referral and .. To maximize staff experience, primary PCI centres should perform
transport of patients with a STEMI that bypass the EMS should be .. the procedure systematically on a 24/7 basis for all STEMI patients.
avoided. The ambulance system has a critical role in the early man- ..
.. Other models, although not ideal, may include weekly or daily rotation
agement of STEMI patients and it is not only a mode of transport but .. of primary PCI centres or multiple primary PCI centres in the same
also a system to enhance early initial diagnosis, triage, and ..
.. region. Hospitals that cannot offer a 24/7 service for primary PCI
treatment.87,94 .. should be allowed to perform primary PCI in patients already admit-
It is indicated that all ambulances in the EMS are equipped with ..
.. ted for another reason who develop STEMI during their hospital stay.
ECG recorders, defibrillators, and at least one person trained in .. However, these hospitals should be discouraged from initiating a serv-
advanced life support. The quality of the care provided depends ..
.. ice limited to daytime- or within-hours primary PCI, as this may gener-
on the training of the staff involved. It is indicated that all ambulance .. ate confusion with the EMS operators and may affect the STEMI
personnel are trained to recognize the symptoms of an AMI, adminis- ..
.. diagnosis-to-reperfusion time and the quality of intervention of
ter oxygen when appropriate, relieve pain, and provide basic life sup- .. focused 24/7 true primary PCI centres. Therefore, it is indicated that
port.95 Ambulance staff should be able to record an ECG for ..
.. the EMS transports STEMI patients to hospitals with an established
diagnostic purposes and either interpret or transmit it, so that it can .. interventional cardiology programme available 24/7, if necessary
be reviewed by experienced staff in a coronary care unit (CCU)/ ..
.. bypassing a non-PCI-capable hospital (if the transfer time is within the
ICCU or elsewhere and establish a STEMI diagnosis. Paramedics .. recommended time-windows for primary PCI; see Figure 3).
trained to administer fibrinolytics do so safely and effectively.96 As
.. Geographic areas where the expected transfer time to the primary
pre-hospital fibrinolysis is indicated in patients presenting early when .. PCI centre makes it impossible to achieve the maximal allowable
anticipated STEMI diagnosis to PCI-mediated reperfusion time
.. delays indicated in the recommendations (Figure 2) should develop
is > 120 min,97–99 ongoing training of paramedics to undertake .. systems for rapid fibrinolysis, at the place of STEMI diagnosis, with
these functions is recommended, even in the current setting of pri-
.. subsequent immediate transfer to primary PCI centres. Such net-
mary PCI. .. works increase the proportion of patients receiving reperfusion with
.. the shortest possible treatment delay.100–102 The quality of care,
.. time delays, and patient outcomes should be measured and com-
.. pared at regular intervals for improvement.
4.4.3 Organization of ST-segment elevation myocardial
infarction treatment in networks .. General practitioners
Optimal treatment of STEMI should be based on the implementation
.. In some countries, general practitioners play a role in the early care
of networks between hospitals (‘hub’ and ‘spoke’) with various levels .. of patients with AMI and are often the first to be contacted by the
of technology, linked by a prioritized and efficient ambulance service. .. patients.
The goal of these networks is to provide optimal care while minimiz- .. If general practitioners respond quickly they can be very effective,
ing delays, thereby improving clinical outcomes. Cardiologists should .. as they usually know the patient and can perform and interpret the
actively collaborate with all stakeholders, particularly emergency .. ECG. Their first task after the STEMI diagnosis should be to alert the
physicians, in establishing such networks. The main features of such a .. EMS. In addition, they can administer opioids and antithrombotic
network are: .. drugs (including fibrinolytics, if that management strategy is indi-
.. cated), and can undertake defibrillation if needed. However, in most
䊏 Clear definition of geographic areas of responsibility.
.. settings, consultation with a general practitioner—instead of a direct
䊏 Shared written protocols, based on risk stratification and transportation .. call to the EMS—will increase pre-hospital delay. Therefore, in gen-
by a trained physician, nurse, or paramedic staff in appropriately
.. eral, the public should be educated to call the EMS rather than the
equipped ambulances or helicopters. . primary care physician for symptoms suggestive of MI.
ESC Guidelines 13

Logistics of pre-hospital care
.. 5. Reperfusion therapy
.. 5.1 Selection of reperfusion strategies
Recommendations Classa Levelb .. Table 4 lists the definitions of terms relating to reperfusion therapy.
It is recommended that the pre-hospital
management of STEMI patients is based on Table 4 Definitions of terms related to reperfusion
regional networks designed to deliver therapy
reperfusion therapy expeditiously and effec- I B
tively, with efforts made to make primary
PCI available to as many patients as

It is recommended that primary PCI-capable
centres deliver a 24/7 service and are able
to perform primary PCI without

It is recommended that patients transferred
to a PCI-capable centre for primary PCI
bypass the emergency department and I B
CCU/ICCU and are transferred directly to
the catheterization laboratory.92,107–110

It is recommended that ambulance teams
are trained and equipped to identify STEMI
(with use of ECG recorders and telemetry I C
as necessary) and administer initial therapy,
including fibrinolysis when applicable.95

It is recommended that all hospitals and
EMS participating in the care of patients
with STEMI record and audit delay times I C
and work to achieve and maintain quality

It is recommended that EMS transfer STEMI
patients to a PCI-capable centre, bypassing I C
non-PCI centres.
ECG = electrocardiogram; EMS = emergency medical system; FMC = first medi-
It is recommended that EMS, emergency
cal contact; IRA = infarct-related artery; PCI = percutaneous coronary interven-
departments, and CCU/ICCU have a writ- tion; STEMI = ST-segment elevation myocardial infarction.
ten updated STEMI management protocol, I C
preferably shared within geographic
networks. Primary PCI is the preferred reperfusion strategy in patients with
It is recommended that patients presenting STEMI within 12 h of symptom onset, provided it can be performed
to a non-PCI-capable hospital and awaiting expeditiously (i.e. 120 min from STEMI diagnosis, Figures 2 and 3) by
transportation for primary or rescue PCI an experienced team. An experienced team includes not only inter-
I C ventional cardiologists but also skilled support staff. Lower mortality
are attended in an appropriately monitored
area (e.g. the emergency department, CCU/ rates among patients undergoing primary PCI are observed in centres
ICCU, or intermediate care unit). with a high volume of PCI procedures.111 Real-life data confirm that
primary PCI is performed faster and results in lower mortality if per-
24/7 = 24 h a day, 7 days a week; CCU = coronary care unit; ECG = electrocar-
formed in high-volume centres.112 Randomized clinical trials in high-
diogram; EMS = emergency medical system; ICCU = intensive cardiac care unit; volume, experienced centres have repeatedly shown that, if delay to
PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myo- treatment is similar, primary PCI is superior to fibrinolysis in reducing
cardial infarction.
Class of recommendation.
mortality, reinfarction, or stroke.113–116 However, in some circum-
Level of evidence. stances, primary PCI is not an immediate option and fibrinolysis could
be initiated expeditiously. The extent to which the PCI-related time
delay diminishes the advantages of PCI over fibrinolysis has been
widely debated. Because no specifically designed study has addressed
14 ESC Guidelines

Figure 3 Maximum target times according to reperfusion strategy selection in patients presenting via EMS or in a non-PCI centre. ECG = electro-
cardiogram; PCI = Percutaneous Coronary Intervention; STEMI = ST-segment elevation myocardial infarction. STEMI diagnosis is the time 0 for the
strategy clock. The decision for choosing reperfusion strategy in patients presenting via EMS (out-of-hospital setting) or in a non-PCI centre is based
on the estimated time from STEMI diagnosis to PCI-mediated reperfusion. Target times from STEMI diagnosis represent the maximum time to do
specific interventions.
if fibrinolysis is contra-indicated, direct for primary PCI strategy regardless of time to PCI.
10 min is the maximum target delay time from STEMI diagnosis to fibrinolytic bolus administration, however, it should be given as
soon as possible after STEMI diagnosis (after ruling out contra-indications).

this issue, caution is needed when interpreting available data from .. trial randomized early STEMI presenters without the possibility of
post hoc analyses. A PCI-related time delay potentially mitigating the .. immediate PCI to immediate fibrinolysis (followed by routine early
benefits of PCI has been calculated as 60 min117, 110 min,118 and .. angiography) or transfer to primary PCI.121 The median PCI-related
120 min119 in different studies. Registry data estimated this time limit .. delay in this trial was 78 min, and there were no differences in clinical
as 114 min for in-hospital patients107 and 120 min in patients present- .. outcomes. This Task Force recognizes the lack of contemporaneous
ing in a non-PCI centre.120 All these data are old and patients under- .. data to set the limit to choose PCI over fibrinolysis. For simplicity, an
going fibrinolysis did not undergo routine early angiography, which .. absolute time from STEMI diagnosis to PCI-mediated reperfusion [i.e.
improves outcomes in patients receiving fibrinolysis. The recent .. wire crossing of the infarct-related artery (IRA)] rather than a relative
STrategic Reperfusion Early After Myocardial infarction (STREAM) . PCI-related delay over fibrinolysis has been chosen. This limit is set to
ESC Guidelines 15

120 min. Given the maximum limit of 10 min from STEMI diagnosis to
Recommendations for reperfusion therapy
bolus of fibrinolytics (see below), the 120 min absolute time would
correspond to a PCI-related delay in the range of 110–120 min, being
in the range of the times identified in old studies and registries as the Recommendation Classa Levelb
limit delay to choose PCI.107,117–120 Reperfusion therapy is indicated in all
If the reperfusion strategy is fibrinolysis, the goal is to inject the patients with symptoms of ischaemia
bolus of fibrinolytics within 10 min from STEMI diagnosis. This time is I A
of <_ 12 h duration and persistent ST-seg-
selected based on the median time from randomization to bolus ment elevation.119,138
recorded in the STREAM trial, which was 9 min.121 In previous ESC
STEMI guidelines,122 the target time was 30 min, but this was calcu- A primary PCI strategy is recommended
lated from FMC (as opposed to STEMI diagnosis). STEMI diagnosis over fibrinolysis within indicated I A
should occur within 10 min from FMC. timeframes.114,116,139,140
Figure 3 summarizes target times for patients presenting in the pre- If timely primary PCI cannot be performed
hospital setting or in a non-PCI centre. after STEMI diagnosis, fibrinolytic therapy is
To shorten time to treatment, fibrinolysis should be administered recommended within 12 h of symptom I A
in the pre-hospital setting if possible98,121,123 (Figures 2 and 3). onset in patients without
Patients should be transferred to a PCI-capable facility as soon as pos- contraindications.107,120,122
sible after bolus of lytics administration. Rescue PCI is indicated in the
case of failed fibrinolysis (i.e. ST-segment resolution < 50% within In the absence of ST-segment elevation, a
60–90 min of fibrinolytic administration), or in the presence of hae- primary PCI strategy is indicated in patients
modynamic or electrical instability, worsening ischaemia, or persis- with suspected ongoing ischaemic symp-
tent chest pain,121,124 while a routine early PCI strategy is indicated toms suggestive of MI and at least one of
after successful fibrinolysis (preferably 2–24 h after fibrinolysis) (see the following criteria present:
section 5.3).125–130 - haemodynamic instability or cardiogenic
Patients with a clinical presentation compatible with AMI and a shock
non-interpretable ST-segment on the ECG, such as those with bun- - recurrent or ongoing chest pain refrac-
dle branch block or ventricular pacing,55,131,132 should undergo a pri- tory to medical treatment
mary PCI strategy. - life-threatening arrhythmias or cardiac
There is general agreement that a primary PCI strategy should also arrest
be followed for patients with symptoms lasting >12 h in the presence - mechanical complications of MI
of: (1) ECG evidence of ongoing ischaemia; (2) ongoing or recurrent - acute heart failure
pain and dynamic ECG changes; and (3) ongoing or recurrent pain, - recurrent dynamic ST-segment or T-
symptoms, and signs of heart failure, shock, or malignant arrhythmias. wave changes, particularly with intermit-
However, there is no consensus as to whether PCI is also beneficial tent ST-segment elevation.
in patients presenting >12 h from symptom onset in the absence of
Early angiography (within 24 h) is recom-
clinical and/or electrocardiographic evidence of ongoing ischaemia. In
mended if symptoms are completely
asymptomatic patients without persistent symptoms 12–48 h after
relieved and ST-segment elevation is com-
symptom onset, a small (n = 347) randomized study showed I C
pletely normalized spontaneously or after
improved myocardial salvage and 4 year survival in patients treated
nitroglycerin administration (provided there
with primary PCI compared with conservative treatment alone.133,134
is no recurrence of symptoms or ST-seg-
However, in stable patients with persistent occlusion of the IRA
ment elevation).
3–28 days after MI, the large (n = 2166) Occluded Artery Trial
(OAT) revealed no clinical benefit from routine coronary interven- In patients with time from symptom onset
tion with medical management, beyond that from medical manage- >12 h, a primary PCI strategy is indicated in
ment alone.135,136 A meta-analysis of trials testing whether late the presence of ongoing symptoms sugges- I C
recanalization of an occluded IRA is beneficial showed no benefit of tive of ischaemia, haemodynamic instability,
reperfusion.137 Therefore, routine PCI of an occluded IRA in asymp- or life-threatening arrhythmias.141
tomatic patients >48 h after onset of symptoms is not indicated.
A routine primary PCI strategy should be
These patients should be managed like all patients with chronic total
considered in patients presenting late IIa B
occlusion, in which revascularization should be considered in the
(12–48 h) after symptom onset.133,134,142
presence of symptoms or objective evidence of viability/ischaemia in
the territory of the occluded artery.1 In asymptomatic patients, routine PCI of an
occluded IRA >48 h after onset of STEMI is III A
not indicated.135,137

IRA = infarct-related artery; MI, myocardial infarction; PCI = percutaneous coro-
nary intervention; STEMI = ST-segment elevation myocardial infarction.
Class of recommendation.
Level of evidence.
16 ESC Guidelines

Table 5 Summary of important time targets
.. stent (BMS) is associated with a lower risk of reinfarction and target
.. vessel revascularization but is not associated with a reduction in the
.. mortality rate.146,147 In primary PCI, drug-eluting stents (DES) reduce
.. the risk of repeated target vessel revascularization compared with
.. BMS.148
.. New-generation DES have shown superior safety and preserved
.. or even improved efficacy compared with first-generation DES, in
.. particular with respect to lower risks of stent thrombosis and recur-
.. rent MI. In two recent trials—the Effect of biolimus-eluting stents
.. with biodegradable polymer vs. bare-metal stents on cardiovascular
.. events among patients with AMI (COMFORTABLE AMI) trial149 and
.. the Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-
.. Segment Elevation Myocardial Infarction (EXAMINATION)
.. trial150—new-generation DES have been shown to be superior to
.. BMS in patients with AMI, mostly in terms of need for reintervention.
.. In the latter trial, the recently released 5 year follow-up results
.. showed a reduction in all-cause mortality by DES as compared to
.. BMS.151 In the Norwegian Coronary Stent (NORSTENT) trial,152
.. 9013 patients undergoing PCI (26% with STEMI) were randomized
.. to DES or BMS. There were no differences in the incidence of the pri-
.. mary endpoint (composite of death from any cause or non-fatal
.. spontaneous MI) after a median follow-up of 5 years. However, DES
.. were associated with lower rates of definite stent thrombosis (0.8%
ECG = electrocardiogram; FMC = first medical contact; PCI = percutaneous cor- .. vs. 1.2%; P = 0.0498) and of target lesion and any repeat revasculariza-
onary intervention; STEMI = ST-segment elevation myocardial infarction
.. tion (16.5% vs. 19.8%; P < 0.001).152
a ..
ECG should be interpreted immediately. .. Deferring stenting in primary PCI has been investigated as an
.. option to reduce microvascular obstruction (MVO) and preserve
.. microcirculatory function. Two small studies recently found opposite
Table 5 summarizes the important time targets in acute STEMI. .. results in the effect of deferred stenting on cardiac magnetic reso-
.. nance (CMR) imaging-measured MVO.153,154 In the larger DANish
5.2 Primary percutaneous coronary .. Study of Optimal Acute Treatment of Patients with ST-segment
intervention and adjunctive therapy .. Elevation Myocardial Infarction – Deferred versus conventional stent
5.2.1 Procedural aspects of primary percutaneous
.. implantation in patients with ST-segment elevation myocardial infarc-
coronary intervention .. tion (DANAMI 3-DEFER) trial,155 in 1215 STEMI patients, deferred Access route
.. stenting (48 h after the index procedure) had no effect on the pri-
Over recent years, several studies have provided robust evidence in .. mary clinical outcome (composite of all-cause mortality, non-fatal MI,
favour of the radial approach as the default access site in ACS patients
.. or ischaemia-driven revascularization of non-IRA lesions). Routine
undergoing primary PCI by experienced radial operators. The .. deferred stenting was associated with a higher need for target vessel
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site
.. revascularization. Based on these findings, routine use of deferred
and Systemic Implementation of angioX (MATRIX)143 trial recruited .. stenting is not recommended.
8404 ACS patients (48% STEMI) who were randomly allocated to ..
transradial or transfemoral access. Radial access was associated with .. Thrombus aspiration
.. A number of small-scale or single-centre studies and one meta-analysis
lower risks of access site bleeding, vascular complications, and need ..
for transfusion. Importantly, there was a significant mortality benefit .. of 11 small trials156 suggested that there could be benefits from routine
in patients allocated to the transradial access site, which reinforced .. manual thrombus aspiration during primary PCI. Recently, two large
previous observations from the Radial Versus Femoral Access for .. (>10 000 and >7000 patients) randomized controlled trials, which
Coronary Intervention (RIVAL) access for coronary intervention .. were adequately powered to detect superiority of routine manual
trial,144 and the Radial Versus Femoral Randomized Investigation in .. thrombus aspiration versus conventional PCI, showed no benefit on
ST-Elevation Acute Coronary Syndrome (RIFLE-STEACS) trial.145 .. clinical outcomes of routine aspiration strategy overall.157–160 A safety
No significant interaction was observed in the MATRIX trial between .. concern emerged in the Trial of Routine Aspiration Thrombectomy
the type of ACS and treatment benefit, suggesting that the results of .. with PCI versus PCI Alone in Patients with STEMI (TOTAL) trial (n =
this investigation can be extended with confidence to the treatment .. 10 732), with an increase in the risk of stroke.161 In the subgroup with
of patients with STEMI. .. high thrombus burden [TIMI (Thrombolysis in Myocardial Infarction)
.. thrombus grade  3], thrombus aspiration was associated with fewer
.. Stenting in primary percutaneous intervention .. cardiovascular deaths [170 (2.5%) vs. 205 (3.1%); hazard ratio (HR)
Coronary stenting is the technique of choice during primary PCI.
.. 0.80, 95% confidence interval (CI) 0.65–0.98; P = 0.03] and with more
Compared with balloon angioplasty alone, stenting with a bare-metal . strokes or transient ischaemic attacks [55 (0.9%) vs. 34 (0.5%); odds
ESC Guidelines 17

ratio 1.56, 95% CI 1.02–2.42, P =0.04]. However, the interaction P val- .. DANAMI-3–PRIMULTI). Based on these data, revascularization of
ues were 0.32 and 0.34, respectively.162 .. non-IRA lesions should be considered in STEMI patients with multives-
In the Taste157 and TOTAL trials159, 1–5% of randomized patients .. sel disease before hospital discharge. As the optimal timing of revascu-
crossed over from PCI alone to thrombus aspiration. Based on these .. larization (immediate vs. staged) has not been adequately investigated,
data and the results of a recent meta-analysis,162 routine thrombus .. no recommendation in favour of immediate vs. staged multivessel PCI
aspiration is not recommended, but in cases of large residual throm- .. can be formulated.
bus burden after opening the vessel with a guide wire or a balloon, ..
thrombus aspiration may be considered.
.. Intra-aortic balloon pump
.. The Counterpulsation to Reduce Infarct Size Pre-PCI-Acute Myocar- Multivessel coronary revascularization
.. dial Infarction (CRISP AMI) trial showed no benefit from a routine
Multivessel disease is common (in approximately 50%) in patients .. intra-aortic balloon pump (IABP) in anterior MI without shock,175 but
with STEMI.163,164 While it is recommended to always treat the IRA,
.. there was increased bleeding, which is consistent with previous data
evidence supporting immediate (preventive) revascularization of .. regarding the role of IABP in high-risk STEMI without cardiogenic
additional significant coronary stenoses is conflicting. It has been
.. shock.176 In addition, a recent randomized trial showed that IABP did
reported that patients with extensive CAD in vessels remote from .. not improve outcomes in MI with cardiogenic shock.177 Haemody-
the IRA have lower rates of ST-segment recovery and an adverse .. namic support in patients with cardiogenic shock is discussed in
prognosis following primary PCI.163 Data from the US National .. Chapter 8.
Cardiovascular Data Registry and New York State’s Percutaneous
Coronary Interventions Reporting System suggested an increase in Procedural aspects of the primary percutaneous cor-
onary intervention strategy
adverse events, including mortality, in patients treated with immedi-
ate multivessel revascularization versus IRA PCI only, while patients
Recommendations Classa Levelb
in cardiogenic shock were excluded from the analysis.165,166
Randomized clinical trials addressing this issue have been small (each IRA strategy
of them included from 69 to 885 patients). One study allocated 214 Primary PCI of the IRA is indicated.114,116,139,140 I A
STEMI patients with multivessel disease to three arms: IRA angioplasty-
New coronary angiography with PCI if indicated is
only, simultaneous treatment of non-IRA lesions, and staged revascula-
recommended in patients with symptoms or signs
rization of the non-IRA. At a mean follow-up of 2.5 years, patients allo- I C
of recurrent or remaining ischaemia after primary
cated to IRA angioplasty-only had more major adverse cardiac events PCI.
(MACE) (i.e. death, reinfarction, rehospitalization for ACS, and repeat
IRA technique
coronary revascularization) than the patients treated with other strat-
egies.167 After this study, four randomized clinical trials have compared Stenting is recommended (over balloon angio-
plasty) for primary PCI.146,147
PCI of the IRA only vs. complete revascularization: the Preventive
Angioplasty in Acute Myocardial Infarction (PRAMI) trial (n = 465, Stenting with new-generation DES is recom-
23 months follow-up),168 the Complete Versus Lesion-Only Primary mended over BMS for primary PCI.148–151,178,179
PCI Trial (CvLPRIT) (n = 296, 12 months follow-up),169 the Complete Radial access is recommended over femoral
revascularisation versus treatment of the culprit lesion only in patients access if performed by an experienced radial I A
with ST-segment elevation myocardial infarction and multivessel dis- operator.143–145,180
ease (DANAMI-3–PRIMULTI) trial (n = 627, 27 months follow-up),170 Routine use of thrombus aspiration is not
and the Comparison Between FFR Guided Revascularization Versus recommended.157,159
Conventional Strategy in Acute STEMI Patients With Multivessel dis-
Routine use of deferred stenting is not
ease (Compare-Acute, n = 885, 12 months follow-up) trial.171 PCI of recommended.153–155

non-IRA was done either during the index procedure (PRAMI and
Non-IRA strategy
Compare-Acute), staged during hospital admission (DANAMI-
3–PRIMULTI), or any time before discharge (immediate or staged) Routine revascularization of non-IRA lesions
(CVLPRIT). Indication for PCI in non-IRA was angiography-guided in should be considered in STEMI patients with mul- IIa A
tivessel disease before hospital discharge.167–173
lesions with 50% stenosis (PRAMI), >70% stenosis (CVLPRIT), or
fractional flow reserve (FFR)-guided (DANAMI-3–PRIMULTI and Non-IRA PCI during the index procedure should
Compare-Acute). Primary outcome (composite of different end- be considered in patients with cardiogenic shock.

points) was significantly reduced in the complete revascularization CABG should be considered in patients with
group in all four trials. Total mortality was not statistically different in ongoing ischaemia and large areas of jeopardized IIa C
any of the four trials. Repeat revascularization was significantly reduced myocardium if PCI of the IRA cannot be performed.
in the complete revascularization arm in the PRAMI, DANAMI-
3–PRIMULTI, and Compare-Acute trials. Non-fatal MI was reduced in CABG = coronary artery bypass graft surgery; DES = drug-eluting stent; IRA =
infarct-related artery; PCI = percutaneous coronary intervention; STEMI = ST-
the non-IRA PCI group only in PRAMI. The lack of significant treatment
segment elevation myocardial infarction.
effect of non-IRA lesion intervention on death or MI was confirmed by a
Class of recommendation.
three meta-analyses172–174 (none of these meta-analyses included b
Level of evidence.
the Compare-Acute trial, and one173 did not include the
18 ESC Guidelines

5.2.2 Periprocedural pharmacotherapy
.. lung abnormalities, and which rarely leads to permanent discontinua-
.. Platelet inhibition .. tion.189 Neither prasugrel nor ticagrelor should be used in patients
Patients undergoing primary PCI should receive DAPT, a combina-
.. with a previous haemorrhagic stroke, in patients on oral anticoagu-
tion of aspirin and a P2Y12 inhibitor, and a parenteral anticoagulant. .. lants, or in patients with moderate-to-severe liver disease.
Aspirin can be given orally including chewing, or i.v. to ensure com-
.. When neither of these agents is available (or if they are contraindi-
plete inhibition of thromboxane A2-dependent platelet aggregation. .. cated), clopidogrel 600 mg p.o. should be given instead.190
The oral dose of plain aspirin (non-enteric-coated formulation) .. Clopidogrel has not been evaluated against placebo in any large out-
should preferably be 150–300 mg. There are few clinical data on the .. comes studies in the setting of primary PCI, but a higher regimen of a
optimal i.v. dosage. Given a 50% oral bioavailability of oral aspirin, a .. 600 mg loading dose/150 mg maintenance dose in the first week was
corresponding dose is 75–150 mg. Pharmacological data suggest that .. superior to the 300/75 mg regimen in the subset of patients under-
this lower dose range avoids inhibition of cyclooxygenase-2- .. going PCI in the Clopidogrel and aspirin Optimal Dose usage to
dependent prostacyclin. A recent randomized study showed that a .. reduce recurrent events–Seventh organization to assess strategies in
single dose of 250 or 500 mg acetylsalicylic acid i.v. compared to .. ischaemic syndromes (CURRENT-OASIS 7) trial,190 and use of high
300 mg orally was associated with a faster and more complete inhibi- .. clopidogrel loading doses has been demonstrated to achieve more
tion of thromboxane generation and platelet aggregation at 5 min, .. rapid inhibition of the adenosine diphosphate receptor. All P2Y12
with comparable rates of bleeding complications.181 .. inhibitors should be used with caution in patients at high risk of bleed-
There is limited evidence with respect to when the P2Y12 inhibitor .. ing or with significant anaemia.
should be initiated in STEMI patients. The Administration of .. Cangrelor is a potent i.v. reversible P2Y12 inhibitor with a rapid
Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation .. onset and offset of action. It has been assessed in three random-
Myocardial Infarction to Open the Coronary Artery (ATLANTIC)
.. ized controlled trials enrolling patients with PCI for stable angina
trial182 is the only randomized study testing the safety and efficacy of .. or ACS against clopidogrel loading or placebo.191–193 A pooled
different timings of P2Y12 inhibitor initiation in STEMI. In this trial,
.. analysis of these three trials showed that cangrelor reduced peri-
patients were randomized to receive ticagrelor either during transfer .. procedural ischaemic complications at the expense of an increased
to a primary PCI centre or immediately before angiography.182 The
.. risk of bleeding.194 The fact that no potent P2Y12 inhibitors (prasu-
median difference between the two tested loading treatment strat- .. grel or ticagrelor) were used in patients with an ACS, and only
egies was only 31 min. This study failed to meet the pre-specified pri-
.. about 18% of the enrolled patients presented with STEMI,193 limits
mary endpoint in terms of improved ST-segment elevation .. the applicability of the results to current practice of management
.. of STEMI patients. Nevertheless, cangrelor may be considered in
resolution or TIMI flow before intervention. Rates of major and ..
minor bleeding events were identical in both treatment arms. While .. patients not pre-treated with oral P2Y12 receptor inhibitors at the
the evidence of a clinical benefit of P2Y12 inhibitor pre-treatment in .. time of PCI or in those who are considered unable to absorb oral
this setting is lacking, early initiation of a P2Y12 inhibitor while the .. agents.
patient is being transported to a primary PCI centre is common prac- .. The pre-hospital routine upstream use of glycoprotein (GP) IIb/IIIa
tice in Europe and is consistent with the pharmacokinetic data. .. inhibitors before primary PCI has not been demonstrated to offer a
Furthermore, early treatment with high-dose clopidogrel was supe- .. benefit and increases bleeding risk compared with routine use in the
rior to in-catheterization laboratory treatment in observational stud- .. catheterization laboratory.195,196 Procedural use of abciximab plus
ies and one small randomized trial.183–185 In all, the data suggest that .. unfractionated heparin (UFH) showed no benefit compared to biva-
the earliest administration may be preferable to achieve early efficacy, .. lirudin.197 Using GP IIb/IIIa inhibitors as bailout therapy in the event of
particularly for long delays. However, in cases in which the STEMI .. angiographic evidence of a large thrombus, slow- or no-reflow, and
diagnosis is not clear, delaying P2Y12 inhibitor loading until the anat- .. other thrombotic complications is reasonable, although this strategy
omy is known should be considered. .. has not been tested in a randomized trial. Overall, there is no evi-
The preferred P2Y12 inhibitors are prasugrel [60 mg loading dose .. dence to recommend the routine use of GP IIb/IIIa inhibitors for pri-
and 10 mg maintenance dose once daily per os (p.o.)] or ticagrelor .. mary PCI. The intracoronary administration of GP IIb/IIIa inhibitors is
(180 mg p.o. loading dose and 90 mg maintenance dose twice daily).
.. not superior to its i.v. use.198
These drugs have a more rapid onset of action, greater potency, and ..
are superior to clopidogrel in clinical outcomes.186,187 Prasugrel is
.. Anticoagulation
contraindicated in patients with previous stroke/transient ischaemic .. Anticoagulant options for primary PCI include UFH, enoxaparin, and
attack, and its use is generally not recommended in patients aged
.. bivalirudin. Use of fondaparinux in the context of primary PCI was
75 years or in patients with lower body weight (<60 kg) as it was .. associated with potential harm in the Organization for the
not associated with net clinical benefit in these subsets. In case prasu-
.. Assessment of Strategies for Ischemic Syndromes 6 (OASIS 6) trial
grel is used in these patients, a reduced dose (5 mg)188 is recom- .. and is not recommended.199
mended. Ticagrelor may cause transient dyspnoea at the onset of .. There has been no placebo-controlled trial evaluating UFH in pri-
therapy, which is not associated with morphological or functional .. mary PCI, but there is a large body of experience with this agent.
ESC Guidelines 19

Dosage should follow standard recommendations for PCI (i.e. initial
Periprocedural and post-procedural antithrombotic
bolus 70–100 U/kg). There are no robust data recommending the
therapya in patients undergoing primary percutaneous
use of activated clotting time to tailor dose or monitor UFH, and if coronary intervention
activated clotting time is used, it should not delay recanalization of
the IRA. An i.v. bolus of enoxaparin 0.5 mg/kg was compared with
Recommendations Classb Levelc
UFH in the randomized open-label Acute myocardial infarction
Treated with primary angioplasty and inTravenous enOxaparin or Antiplatelet therapy
unfractionated heparin to Lower ischaemic and bleeding events at
A potent P2Y12 inhibitor (prasugrel or tica-
short- and Long-term follow-up (ATOLL) trial, including 910 STEMI
grelor), or clopidogrel if these are not avail-
patients.200 The primary composite endpoint of 30 day death, MI,
able or are contraindicated, is
procedural failure, or major bleeding was not significantly reduced by
recommended before (or at latest at the
enoxaparin (17% relative risk reduction, P = 0.063), but there was a I A
time of) PCI and maintained over
reduction in the composite main secondary endpoint of death, recur-
12 months, unless there are contraindica-
rent MI or ACS, or urgent revascularization. Importantly, there was
tions such as excessive risk of
no evidence of increased bleeding following the use of enoxaparin
over UFH.200 In the per-protocol analysis of the ATOLL trial (87% of
the study population), i.v. enoxaparin was superior to UFH in reduc- Aspirin (oral or i.v. if unable to swallow) is
ing the primary endpoint, ischaemic endpoints, mortality, and major recommended as soon as possible for all I B
bleeding.201 In a meta-analysis of 23 PCI trials (30 966 patients, 33% patients without contraindications.213,214
primary PCI), enoxaparin was associated with a significant reduction
GP IIb/IIIa inhibitors should be considered
in death compared to UHF. This effect was particularly significant in
for bailout if there is evidence of no-reflow IIa C
the primary PCI context and was associated with a reduction in major
or a thrombotic complication.
bleeding.202 Based on these considerations, enoxaparin should be
considered in STEMI. Cangrelor may be considered in patients
Five dedicated randomized controlled trials have compared bivalir- who have not received P2Y12 receptor IIb A
udin with UFH with or without planned use of GP IIb/IIIa inhibitors in inhibitors.192–194
patients with STEMI.197,203–207 A meta-analysis of these trials showed
Anticoagulant therapy
no mortality advantage with bivalirudin and a reduction in the risk of
major bleeding, but at the cost of an increased risk of acute stent Anticoagulation is recommended for all
thrombosis.208 In the recent MATRIX trial including 7213 ACS patients in addition to antiplatelet therapy I C
patients (56% with STEMI), bivalirudin did not reduce the incidence during primary PCI.
of the primary endpoint (composite of death, MI, or stroke) com-
Routine use of UFH is recommended. I C
pared to UFH. Bivalirudin was associated with lower total and cardio-
vascular mortality, lower bleeding, and more definite stent In patients with heparin-induced thrombo-
thrombosis.209 The recently published STEMI subanalysis confirmed cytopenia, bivalirudin is recommended as I C
a lack of statistical interaction between the type of ACS and out- the anticoagulant agent during primary PCI.
comes within the study.210 The MATRIX trial showed that prolonging
Routine use of enoxaparin i.v. should be
bivalirudin infusion after PCI did not improve the outcomes com- IIa A
pared with bivalirudin infusion confined to the duration of PCI.209
However, a post hoc analysis suggested that prolonging bivalirudin Routine use of bivalirudin should be
with a full-PCI dose after PCI was associated with the lowest risk of considered.209,215
ischaemic and bleeding events, which is in accordance with the cur-
rent label of the drug.209 Based on these data, bivalirudin should be Fondaparinux is not recommended for pri-
considered in STEMI, especially in patients at high bleeding mary PCI.199
risk.197,211,212 Bivalirudin is recommended for patients with heparin-
induced thrombocytopenia. GP = glycoprotein; i.v. = intravenous; PCI = percutaneous coronary intervention;
UFH = unfractionated heparin.
Routine post-procedural anticoagulant therapy is not indicated a
Dose regimens are specified in Table 6.
after primary PCI, except when there is a separate indication for b
Class of recommendation.
either full-dose anticoagulation [due, for instance, to atrial fibrillation Level of evidence.

(AF), mechanical valves, or LV thrombus)2 or prophylactic doses for
the prevention of venous thromboembolism in patients requiring
prolonged bed rest.
20 ESC Guidelines

.. Therapies to reduce infarct size and microvascular obstruction
Table 6 Doses of antiplatelet and anticoagulant
.. Final infarct size and MVO are major independent predictors of
cotherapies in patients undergoing primary percutane- ..
ous coronary intervention or not reperfused .. long-term mortality and heart failure in survivors of STEMI.216,217
.. MVO is defined as inadequate myocardial perfusion after success-
.. ful mechanical opening of the IRA, and is caused by several fac-
.. tors.218 MVO is diagnosed immediately after PCI when post-
.. procedural angiographic TIMI flow is < 3, or in the case of a TIMI
.. flow of 3 when myocardial blush grade is 0 or 1, or when ST reso-
.. lution within 60–90 min of the procedure is < 70%. Other non-
.. invasive techniques to diagnose MVO are late gadolinium
.. enhancement (LGE) CMR (the current state of the art for MVO
.. identification and quantification), contrast echocardiography,
.. single-photon emission computed tomography (SPECT), and posi-
.. tron emission tomography (PET).218 Different strategies, such as
.. coronary post-conditioning, remote ischaemic conditioning, early
.. i.v. metoprolol, GP IIb/IIIa inhibitors, drugs targeting mitochondrial
.. integrity or nitric oxide pathways, adenosine, glucose modulators,
.. hypothermia, and others, have been shown to be beneficial in pre-
.. clinical and small-scale clinical trials,217,219 but still there is no ther-
.. apy aimed at reducing ischaemia/reperfusion injury (MI size) that is
.. clearly associated with improved clinical outcomes. The reduction
.. of ischaemia/reperfusion injury in general, and MVO in particular,
.. remains an unmet need to further improve long-term ventricular
.. function in STEMI.
.. 5.3 Fibrinolysis and pharmacoinvasive
.. strategy
.. 5.3.1 Benefit and indication of fibrinolysis
.. Fibrinolytic therapy is an important reperfusion strategy in settings
.. where primary PCI cannot be offered in a timely manner, and pre-
.. vents 30 early deaths per 1000 patients treated within 6 h after
.. symptom onset.220 The largest absolute benefit is seen among
.. patients at highest risk, including the elderly, and when treatment
.. is offered <2 h after symptom onset.138,221 Fibrinolytic therapy is
.. recommended within 12 h of symptom onset if primary PCI can-
.. not be performed within 120 min from STEMI diagnosis (see Figure
.. 3) and there are no contraindications. The later the patient
.. presents (particularly after 3 h),98,120,121 the more consideration
.. should be given to transfer for primary PCI (as opposed to admin-
.. istering fibrinolytic therapy) because the efficacy and clinical bene-
.. fit of fibrinolysis decrease as the time from symptom onset
.. increases.120 In the presence of contraindications for fibrinolytic
.. treatment, it is important to weigh the potentially life-saving
... effect of fibrinolysis against potentially life-threatening side effects,
.. taking into account alternative treatment options such as delayed
.. primary PCI.

b.i.d. = twice a day; GP = glycoprotein; i.v. = intravenous; IU = international units;
PCI = percutaneous coronary intervention; UFH = unfractionated heparin.
ESC Guidelines 21

Fibrinolytic therapy

Recommendations Classa Levelb

When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after STEMI
diagnosis, preferably in the pre-hospital setting.96,98,123,222

A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended.223,224 I B

A half-dose of tenecteplase should be considered in patients 75 years of age.121 IIa B

Antiplatelet co-therapy with fibrinolysis

Oral or i.v. aspirin is indicated.213 I B

Clopidogrel is indicated in addition to aspirin.225,226 I A
DAPT (in the form of aspirin plus a P2Y12 inhibitor ) is indicated for up to 1 year in patients undergoing fibrinolysis and
subsequent PCI.

Anticoagulation co-therapy with fibrinolysis

Anticoagulation is recommended in patients treated with lytics until revascularization (if performed) or for the duration of I A
hospital stay up to 8 days.199,224,227–233 The anticoagulant can be:
• Enoxaparin i.v. followed by s.c. (preferred over UFH).227–232
UFH given as a weight-adjusted i.v. bolus followed by infusion.224 I B

• In patients treated with streptokinase: fondaparinux i.v. bolus followed by an s.c. dose 24 h later.199,233 IIa B

Transfer after fibrinolysis

Transfer to a PCI-capable centre following fibrinolysis is indicated in all patients immediately after fibrinolysis.121,124,126–130,234 I A

Interventions following fibrinolysis

Emergency angiography and PCI if indicated is recommended in patients with heart failure/shock.124, 235 I A

Rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-segment resolution at 60–90 min) or at any time in
the presence of haemodynamic or electrical instability, or worsening ischaemia.121,124,236

Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful fibrinolysis.125–128,234 I A

Emergency angiography and PCI if needed is indicated in the case of recurrent ischaemia or evidence of reocclusion after initial
successful fibrinolysis.124

DAPT = dual antiplatelet therapy; IRA = infarct-related artery; i.v. = intravenous; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; s.c. = subcutaneous;
STEMI = ST-segment elevation myocardial infarction; UFH = unfractionated heparin.
Class of recommendation.
Level of evidence.
Clopidogrel is the P2Y12 inhibitor of choice as co-adjuvant and after fibrinolysis, but 48 h after fibrinolysis, switch to prasugrel/ticagrelor may be considered in patients who
underwent PCI.

Doses of fibrinolytic agents and antithrombotic co-therapies are .. initiation of fibrinolytic treatment when a reperfusion strategy is indi-
listed in Table 7. .. cated.97,99,100,237 The STREAM trial showed that pre-hospital fibrinol-
.. ysis followed by an early PCI strategy was associated with a similar
5.3.2 Pre-hospital fibrinolysis .. outcome as transfer for primary PCI in STEMI patients presenting
In a meta-analysis of six randomized trials (n = 6434), pre-hospital .. within 3 h after symptom onset who could not undergo primary PCI
fibrinolysis reduced early mortality by 17% compared with in-hospital
.. within 1 h after FMC.121,238
fibrinolysis,123 particularly when administered in the first 2 h of symp- .. If trained medical or paramedical staff are able to analyse the ECG on-
tom onset.138 These and more recent data support pre-hospital
.. site or to transmit the ECG to the hospital for interpretation, it is
22 ESC Guidelines

Table 7 Doses of fibrinolytic agents and antithrombotic co-therapies

PTT = activated partial thromboplastin time; eGFR = estimated glomerular filtration rate; i.v. = intravenous; IU = international units; rPA = recombinant plasminogen activator;
s.c. = subcutaneous; tPA = tissue plasminogen activator; UFH = unfractionated heparin.

recommended to initiate fibrinolytic therapy in the pre-hospital .. compared with a ‘watchful waiting’ strategy, in which angiography
setting. The aim is to start fibrinolytic therapy within 10 min from STEMI .. and revascularization were indicated only in patients with spontane-
.. ous or induced severe ischaemia or LV dysfunction, or in those with a
.. positive outpatient ischaemia test. The benefits of early routine PCI
.. after fibrinolysis were seen in the absence of an increased risk of
5.3.3 Angiography and percutaneous coronary ..
intervention after fibrinolysis (pharmacoinvasive .. adverse events (stroke or major bleeding), and across patient sub-
.. groups.241 Thus, early angiography with subsequent PCI if indicated is
strategy) ..
Following initiation of lytic therapy, it is recommended to transfer the .. also the recommended standard of care after successful fibrinolysis
patients to a PCI centre (Figure 3). In cases of failed fibrinolysis, or if .. (see Figure 3).
there is evidence of reocclusion or reinfarction with recurrence of .. A crucial issue is the optimal time delay between successful lysis and
ST-segment elevation, immediate angiography and rescue PCI is indi- .. PCI; there was a wide variation in delay in trials, from a median of 1.3 h
cated.124 In this setting, re-administration of fibrinolysis has not been .. in the Combined Angioplasty and Pharmacological Intervention versus
shown to be beneficial and should be discouraged.124 Even if it is .. Thrombolytics ALone in Acute Myocardial Infarction (CAPITAL AMI)
likely that fibrinolysis will be successful (ST-segment resolution .. trial240 to 17 h in the Grupo de Analisis de la Cardiopatıa Isquémica
> 50% at 60–90 min; typical reperfusion arrhythmia; and disappear- .. Aguda (GRACIA)-1234 and STREAM trials.121 In a pooled patient-level
ance of chest pain), a strategy of routine early angiography is recom- .. analysis of six randomized trials, very early angiography (<2 h) after
mended if there are no contraindications. Several randomized .. fibrinolysis was not associated with an increased risk of 30 day death/
trials126–128,234,239,240 and meta-analyses129,130 have shown that early
.. reinfarction or in-hospital major bleeding, and a shorter time from
routine angiography with subsequent PCI (if needed) after .. symptom onset to angiography (<4 h) was associated with reduced
fibrinolysis reduced the rates of reinfarction and recurrent ischaemia
.. 30 day and 1 year death/reinfarction and 30 day recurrent ischaemia.125
ESC Guidelines 23

Based on this analysis, as well as on trials having a median delay .. lower weight, female sex, previous cerebrovascular disease, and systolic
between start of lysis and angiography of 2–17 h,121,126–128 a time- .. and diastolic hypertension on admission are significant predictors of
window of 2–24 h after successful lysis is recommended. .. intracranial haemorrhage.245 In the latest trials, intracranial bleeding
.. occurred in 0.9–1.0% of the total population studied.121,223,246 In the
5.3.4 Comparison of fibrinolytic agents .. STREAM trial, the initial excess in intracranial haemorrhage in patients
A fibrin-specific agent should be preferred.224 Single-bolus weight- .. 75 years was reduced after the protocol amendment to reduce the
adjusted tenecteplase tissue plasminogen activator (TNK-tPA) is .. dose of tenecteplase by 50%. Data from a number of studies suggest
equivalent to accelerated tPA in reducing 30 day mortality, but is .. that major non-cerebral bleeds occurred in 4–13% of the patients
safer in preventing non-cerebral bleeds and blood transfusion, and is .. treated.121,223,224,246 Administration of streptokinase may be associated
easier to use in the pre-hospital setting.223 .. with hypotension, but severe allergic reactions are rare. Re-
.. administration of streptokinase should be avoided because of antibodies
.. that can impair its activity, and because of the risk of allergic reactions.
5.3.5 Adjunctive antiplatelet and anticoagulant therapies ..
An early study showed that the benefits of aspirin and fibrinolytics ..
(i.e. streptokinase) were additive.213 The first dose of aspirin should ..
.. 5.3.7 Contraindications to fibrinolytic therapy
be chewed or given i.v. and a low dose (75–100 mg) given orally daily
.. Short successful resuscitation does not contraindicate fibrinolytic
thereafter. Clopidogrel added to aspirin reduces the risk of cardio- .. therapy. In patients in refractory cardiac arrest, lytic therapy is not
vascular events and overall mortality in patients treated with fibrinol- ..
.. effective, increases the risk of bleeding, and is therefore not recom-
ysis225,226 and should be added to aspirin as an adjunct to lytic
... mended. Prolonged, or traumatic but successful, resuscitation
therapy. Prasugrel and ticagrelor have not been studied as adjuncts to .. increases bleeding risk and is a relative contraindication to fibrinoly-
fibrinolysis. There is no evidence that administration of GP IIb/IIIa ..
.. sis.247 Table 8 lists the absolute and relative contraindications to fibri-
inhibitors improves myocardial perfusion or outcomes in patients .. nolytic therapy.
treated with fibrinolysis, and bleeding may increase.242
Parenteral anticoagulation should preferably be given until revascula-
rization (if performed). Otherwise, it should be given for at least 48 h Table 8 Contra-indications to fibrinolytic therapy
or for the duration of hospital stay, up to 8 days. In spite of an increased
risk of major bleeding, the net clinical benefit favoured enoxaparin over
UFH in the ASsessment of the Safety and Efficacy of a New
Thrombolytic 3 (ASSENT 3) trial (n = 6095).227 In the large
Enoxaparin and Thrombolysis Reperfusion for Acute myocardial
infarction Treatment–Thrombolysis In Myocardial Infarction
25 (ExTRACT–TIMI 25) trial (n = 20 506), a lower dose of enoxaparin
was given to patients 75 years of age and to those with impaired renal
function (estimated creatinine clearance <30 mL/min). Enoxaparin was
associated with a reduction in the risk of death and reinfarction at 30
days when compared with a weight-adjusted UFH dose, but at the cost
of a significant increase in non-cerebral bleeding complications. The net
clinical benefit (i.e. absence of death, non-fatal infarction, and intracra-
nial haemorrhage) favoured enoxaparin.229,230 Finally, fondaparinux
was shown in the large OASIS-6 trial to be superior in this setting to
placebo or UFH in preventing death and reinfarction,199,233 especially
in patients who received streptokinase.
In a large trial with streptokinase,243 significantly fewer reinfarc-
tions were seen with bivalirudin given for 48 h compared with UFH,
though at the cost of a modest and non-significant increase in non-
cerebral bleeding complications. Bivalirudin has not been studied
with fibrin-specific agents. Thus, there is no evidence in support of
direct thrombin inhibitors as an adjunct to fibrinolysis.
Weight-adjusted i.v. tenecteplase, aspirin, and clopidogrel given
orally, and enoxaparin i.v. followed by s.c. administration until the
time of PCI (revascularisation), comprise the antithrombotic cocktail
most extensively studied as part of a pharmacoinvasive

5.3.6 Hazards of fibrinolysis
Fibrinolytic therapy is associated with a small but significant excess of
strokes, largely attributable to cerebral haemorrhage, with the excess DBP = diastolic blood pressure; SBP = systolic blood pressure.
hazard appearing on the first day after treatment.220 Advanced age,
24 ESC Guidelines

.. patients. Longer monitoring should be considered in patients at
5.4 Coronary artery bypass graft surgery ..
Emergent coronary artery bypass graft surgery (CABG) should be .. intermediate- to high-risk for cardiac arrhythmias (those
.. with more than one of the following criteria: haemodynamically
considered for patients with a patent IRA but with unsuitable anat- ..
omy for PCI, and either a large myocardial area at jeopardy or with .. unstable, presenting major arrhythmias, LVEF <40%, failed reper-
.. fusion, additional critical coronary stenoses of major vessels, or
cardiogenic shock.248 In patients with MI-related mechanical compli- ..
cations who require coronary revascularization, CABG is recom-
.. complications related to PCI). Further monitoring for arrhythmias
.. depends on estimated risk. When a patient leaves the CCU/ICCU
mended at the time of repair. In STEMI patients with failed PCI or ..
coronary occlusion not amenable to PCI, emergent CABG is infre-
.. or equivalent, monitoring may be continued by telemetry. It is
.. recommended that personnel adequately equipped and trained
quently performed because the benefits of surgical revascularization ..
in this setting are uncertain. As the delay to reperfusion is long, the
.. to manage life-threatening arrhythmias and cardiac arrest accom-
probabilities of myocardial salvage affecting prognosis are low and .. pany patients who are transferred between facilities during
the surgical risks are elevated.
.. the time-window in which they require continuous rhythm
In the absence of randomized data, optimal timing for non- .. monitoring.
emergent CABG in stabilized post-MI patients should be determined ..
individually. A review of California discharge data compared patients ..
.. 6.3 Ambulation
who underwent early (<3 days, n = 4676) versus delayed (3 days, ..
n = 4800) post-MI CABG.249 Patients who underwent early CABG .. Early ambulation (day 1) is recommended in the majority of patients
.. and is facilitated by using the radial access for PCI. Patients with
had a higher mortality rate (unadjusted mortality 5.6% vs. 3.8%; ..
propensity-adjusted odds ratio 1.40, 95% CI 1.12–1.74; P < 0.001), .. extensive myocardial damage, heart failure, hypotension, or arrhyth-
.. mias may initially rest in bed before assessment of myocardial func-
with the highest mortality observed in patients on whom surgery was ..
performed on the day of the MI (8.2%). However, no differentiation .. tion and achievement of clinical stabilization. Prolongation of bed rest
.. and limitation of physical activity may occasionally be needed for
was made between NSTEMI and STEMI, and higher-risk patients were ..
more likely to be treated rapidly. Patients with haemodynamic deteri- .. patients with large infarcts or with severe complications depending
.. on symptoms and ability.
oration or who are at high risk of recurrent ischaemic events (i.e. ..
patients with a large area of myocardium at jeopardy due to critical ..
coronary stenoses or recurrent ischaemia) should be operated on as ..
soon as possible without waiting for the full recovery of platelet func- .. 6.4 Length of stay
.. The optimal length of stay in the CCU/ICCU and hospital should
tion following discontinuation of DAPT. For all other patients, a wait- ..
ing period of 3–7 days may be the best compromise (at least 3 days
.. be determined on an individual basis, according to the patient’s
.. cardiac risk, comorbidities, functional status, and social support.
following interruption of ticagrelor,187,250 5 days for clopidogrel, and 7 ..
days for prasugrel),7 while it is recommended that aspirin is contin-
.. Generalization of successful reperfusion and knowledge of coro-
.. nary anatomy has led to progressive reductions in length of stay
ued.251 The first aspirin administration post-CABG is recommended ..
6–24 h after surgery in the absence of ongoing bleeding events.252,253
.. after STEMI, with significant reductions in 30 day mortality, sug-
.. gesting that earlier discharge is not associated with late mortal-
.. ity.255,256 Several studies have shown that low-risk patients with
.. successful primary PCI and complete revascularization can safely
6. Management during ..
.. be discharged from hospital on day 2 or day 3 after PCI.256–262
hospitalization and at discharge .. Candidates for early discharge after STEMI can be identified using
.. simple criteria [e.g. the Second Primary Angioplasty in Myocardial
6.1 Coronary care unit/intensive cardiac ..
.. Infarction (PAMI-II) criteria, the Zwolle primary PCI Index, or
care unit .. other criteria].257,258 The PAMI-II criteria designate as low risk
Following reperfusion, it is recommended to admit STEMI patients to
.. patients aged <70 years, with an LVEF >45%, one- or two-vessel
a CCU/ICCU or equivalent unit where continuous monitoring and .. disease, successful PCI, and no persistent arrhythmias. A short
specialized care can be provided. The staff should be thoroughly famil-
.. hospital stay implies limited time for proper patient education and
iar with the management of ACS, arrhythmias, heart failure, mechani- .. up-titration of secondary prevention treatments. Consequently,
cal circulatory support, invasive and non-invasive haemodynamic
.. these patients should have early post-discharge consultations with
monitoring (arterial and pulmonary artery pressures), respiratory .. a cardiologist, primary care physician, or specialized nurse sched-
monitoring, mechanical ventilation, and targeted temperature man- .. uled and be rapidly enrolled in a formal rehabilitation programme,
agement. The unit should also be able to manage patients with serious .. either in-hospital or on an outpatient basis.
renal and pulmonary disease. The desirable organization, structure, .. Early (i.e. same day) transfer to a local hospital following successful
and criteria of the CCU/ICCU have been described in an ESC-Acute .. primary PCI is routine practice. This can be done safely under
Cardiovascular Care Association (ACCA) position paper.254 .. adequate monitoring and supervision in selected patients, i.e. those
.. without signs or symptoms consistent with ongoing myocardial
6.2 Monitoring .. ischaemia, without arrhythmia, who are haemodynamically stable,
ECG monitoring for arrhythmias and ST-segment deviations is
.. not requiring vasoactive or mechanical support, and are not sched-
recommended for at least 24 h after symptom onset in all STEMI . uled for further revascularization.263
ESC Guidelines 25

Logistical issues for hospital stay
.. should be avoided. Loading of aspirin should be done as in all STEMI
.. patients, and clopidogrel is the P2Y12 inhibitor of choice (600 mg
.. loading dose) before or at the latest at the time of PCI. Prasugrel and
Recommendations Classa Levelb .. ticagrelor are not recommended. Ideally, a chronic anticoagulation
It is indicated that all hospitals participating in the .. regimen should not be stopped during admission. Gastric protection
care of STEMI patients have a CCU/ICCU equipped .. with a proton pump inhibitor (PPI) is recommended.
to provide all aspects of care for STEMI patients, .. Maintenance after STEMI: In general, continuation of oral anticoa-
including treatment of ischaemia, severe heart failure, .. gulation in patients with an indication for DAPT (e.g. after STEMI)
arrhythmias, and common comorbidities. ..
.. should be evaluated carefully and continued only if compelling evi-
Transfer back to a referring non-PCI hospital
.. dence exists. Ischaemic and bleeding risks should be taken into con-
Same day transfer should be considered appropri-
.. sideration. While there is a considerable overlap of risk factors
.. associated with ischaemic with bleeding outcomes, multiple bleeding
ate in selected patients after successful primary ..
PCI, i.e. those without ongoing myocardial ischae- .. risk scores outperform CHA2DS2-VASc [Cardiac failure,
mia, arrhythmia, or haemodynamic instability, not
IIa C .. Hypertension, Age 75 (Doubled), Diabetes, Stroke (Doubled) –
requiring vasoactive or mechanical support, and .. VAScular disease, Age 65–74 and Sex category (Female)] in predict-
not needing further early revascularization.263 .. ing bleeding risk.270,271
Monitoring .. For most patients, triple therapy (in the form of oral anticoagula-
.. tion, aspirin, and clopidogrel) should be considered for 6 months.
It is indicated that all STEMI patients have ECG
I C .. Then, oral anticoagulation plus aspirin or clopidogrel should be con-
monitoring for a minimum of 24 h. .. sidered for an additional 6 months. After 1 year, it is indicated to
Length of stay in the CCU .. maintain only oral anticoagulation. In cases of very high bleeding risk,
It is indicated that patients with successful reperfu- .. triple therapy can be reduced to 1 month after STEMI, continuing on
sion therapy and an uncomplicated clinical course .. dual therapy (oral anticoagulation plus aspirin or clopidogrel) up to
are kept in the CCU/ICCU for a minimum of 24 h
I C .. 1 year, and thereafter only anticoagulation.5,7
whenever possible, after which they may be .. The dose intensity of oral anticoagulation should be carefully
moved to a step-down monitored bed for an addi- ..
.. monitored with a target international normalized ratio in the lower
tional 24–48 h. .. part of the recommended target range. When non-vitamin K antago-
Hospital discharge .. nist oral anticoagulants are used, the lowest effective tested dose for
.. stroke prevention should be applied. In general, dose reduction
Early discharge (within 48–72 h) should be consid- ..
ered appropriate in selected low-risk patientsc if .. below the approved dose is not recommended. Recently, the Open-
IIa A .. Label, Randomized, Controlled, Multicenter Study Exploring Two
early rehabilitation and adequate follow-up are ..
arranged.257,259–262,264,265 .. Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral
.. Vitamin K Antagonist Treatment Strategy in Subjects with Atrial
CCU = coronary care unit; ICCU = intensive cardiac care unit; LVEF = left ven- .. Fibrillation who Undergo Percutaneous Coronary Intervention
tricular ejection fraction; PAMI-II, Second Primary Angioplasty in Myocardial .. (PIONEER AF-PCI) study randomized 2124 patients with non-
Infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment ele- ..
vation myocardial infarction.
.. valvular AF, who had undergone PCI with stenting (12% STEMI
.. patients), to receive low-dose rivaroxaban [15 mg o.d. (once a day)]
Class of recommendation. ..
Level of evidence. .. plus a P2Y12 inhibitor (93% clopidogrel) and no aspirin for 12 months,
For example, PAMI-II criteria: age <70 years, LVEF >45%, one- or two-vessel dis- .. very-low-dose rivaroxaban (2.5 mg b.i.d.) plus DAPT (95% clopidog-
ease, successful PCI and no persistent arrhythmias. ..
.. rel) for 1, 6, or 12 months, or standard therapy with a dose-adjusted
.. vitamin K antagonist plus DAPT (96% clopidogrel) for 1, 6, or
.. 12 months.272 The primary safety endpoint (TIMI clinically significant
6.5 Special patient subsets .. bleeding) was lower in the two groups receiving rivaroxaban. No dif-
Several specific patient subsets deserve particular consideration.
.. ference in major bleeding or transfusion was observed across groups.
.. However, this study was underpowered for assessing differences in
6.5.1 Patients taking oral anticoagulation .. ischaemic events such as stent thrombosis or stroke rates.
Many patients presenting with STEMI are previously on oral anticoa- .. Therefore, uncertainty remains regarding the comparative perform-
gulation or require long-term anticoagulation afterwards. The addi- .. ance of three tested antithrombotic regimens in patients at high
tion of DAPT to oral anticoagulation increases the risk of bleeding .. stroke and/or stent thrombosis risk.
complications two- to three-fold compared to anticoagulation ..
alone.266–269 ..
Management during STEMI: Given that oral anticoagulation is a rel- .. 6.5.2 Elderly patients
ative contraindication for fibrinolysis, when these patients present .. Owing to the ageing of the population, a higher proportion of elderly
with a STEMI, they should be triaged for primary PCI strategy regard- .. patients is expected to present with STEMI. As these patients may
less of the anticipated time to PCI-mediated reperfusion. Patients .. present with atypical symptoms, the diagnosis of MI may be delayed
should receive additional parenteral anticoagulation, regardless of the
.. or missed.27 In addition, the elderly have more comorbidities and are
timing of the last dose of oral anticoagulant. GP IIb/IIIa inhibitors . less likely to receive reperfusion therapy compared with younger
26 ESC Guidelines

Table 9 Recommended doses of antithrombotic agents in the acute care of patients with chronic kidney disease

30 mL/min/1.73 m2)
(eGFR 15 to <30

70-100 IU/kg i.v. (50-70 IU/kg if concomitant with
GP IIb/IIIa inhibitors)

aPTT = activated partial thromboplastin time; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; GP = glycoprotein; IU = international units; i.v. =
intravenous; PCI = percutaneous coronary intervention; s.c. = subcutaneous; UFH = unfractionated heparin.
Double bolus if administered during primary PCI.

patients.273,274 Elderly patients are also at particular risk of bleeding .. (less frequent presentation with chest pain and fewer typical ECG
and other complications from acute therapies because bleeding risk .. signs) diagnosis may be delayed.
increases with age, renal function tends to decrease, and the preva-
.. Although decisions on reperfusion in patients with STEMI have to
lence of comorbidities is high. Observational studies have shown fre- .. be made before any assessment of renal function is available, it is
quent excess dosing of antithrombotic therapies in elderly
.. important to estimate the GFR as soon as possible. The type and
patients.275 Furthermore, they have a higher risk of mechanical .. dose of antithrombotic agent (see Table 9) and the amount of con-
.. trast agent should be considered based on renal function.277 ACS
It is key to maintain a high index of suspicion for MI in elderly .. patients with chronic kidney disease (CKD) receive frequently excess
patients who present with atypical complaints, treating them as rec-
.. dosing with antithrombotics, contributing to the increased bleeding
ommended, and using specific strategies to reduce bleeding risk; .. risk.275 Consequently, in patients with known or anticipated reduc-
these include paying attention to proper dosing of antithrombotic .. tion of renal function, several antithrombotic agents should either be
therapies, particularly in relation to renal function, frailty, or comor- .. withheld or their doses reduced appropriately. Ensuring proper
bidities, and using radial access whenever possible. There is no upper .. hydration during and after primary PCI and limiting the dose of con-
age limit with respect to reperfusion, especially with primary PCI.276 .. trast agents, preferentially low-osmolality contrast agents, are impor-
.. tant steps in minimizing the risk of contrast-induced nephropathy.1
6.5.3 Renal dysfunction ..
Renal dysfunction [estimated glomerular filtration rate (eGFR) .. 6.5.4 Non-reperfused patients
<30 mL/min/1.73 m2] is present in approximately 30–40% of patients
.. Patients who, for specific reasons (e.g. long delay), fail to receive reper-
with ACS and is associated with a worse prognosis and increased risk .. fusion therapy within the recommended time (first 12 h) should imme-
of in-hospital complications.277 Owing to differences in presentation
.. diately be evaluated clinically to rule out the presence of clinical,
ESC Guidelines 27

Figure 4 Reperfusion strategies in the infarct-related artery according to time from symptoms onset. PCI = percutaneous coronary intervention;
STEMI = ST-segment elevation myocardial infarction.
In early presenters (i.e. those with STEMI diagnosis within 3 hours from symptoms onset), a primary PCI strategy is the reperfusion
strategy of choice. If the anticipated time from STEMI diagnosis to PCI-mediated reperfusion is > 120 min, then immediate fibrinolysis is
indicated. After 3 hours (and up to 12 hours) of symptoms onset, the later the patient presents, the more consideration should be given
to a primary PCI strategy as opposed to administering fibrinolytic therapy. In evolved STEMI (12–48 hours after symptoms onset), a
routine primary PCI strategy (urgent angiography and subsequent PCI if indicated) should be considered in all patients. After 48 hours
(recent STEMI) angiography should be performed but routine PCI of a total occluded IRA is not recommended. Regardless of the time
from symptoms onset, the presence of ongoing symptoms suggestive of ischaemia, haemodynamic instability, or lifethreatening arrhyth-
mias is an indication for a primary PCI strategy.

haemodynamic, or electrical instability. A primary PCI strategy is indi- .. ischaemia/viability to decide a late invasive strategy or elective coronary
cated in the presence of signs or symptoms suggestive of ongoing myo- .. angiography should be considered. However, routine PCI is not indi-
cardial ischaemia, heart failure, haemodynamic instability, or life- .. cated in totally occluded IRA beyond the first 48 h from symptom onset
threatening arrhythmias,141 and should be considered in stable asympto- .. due to the increased risk of late complications (see Figure 4).135,137
matic patients between 12–48 h after symptom onset.133,142 After that .. Early echocardiography with LVEF assessment is indicated in all
time, either a non-invasive test for the presence of residual myocardial .. patients. Medical therapy should include DAPT, anticoagulation, and
28 ESC Guidelines

secondary prevention therapies. In patients in whom PCI is finally
.. 6.6. Risk assessment
performed, ticagrelor or prasugrel are preferred,186,187 while in .. 6.6.1 Clinical risk assessment
patients who do not undergo PCI, clopidogrel is indicated.225 .. All patients with STEMI should have an early assessment of short-
Anticoagulation, preferably with fondaparinux, is indicated until coro- .. term risk, including an evaluation of the extent of myocardial damage,
nary revascularisation is done or hospital discharge.199 These patients .. the occurrence of successful reperfusion, and the presence of clinical
are often undertreated. Therefore, it is important to emphasize that ..
.. markers of high risk of further events including older age, fast heart
they should receive all the same secondary prevention medical thera- .. rate, hypotension, Killip class >I, anterior MI, previous MI, elevated
pies as those who receive timely reperfusion. ..
.. initial serum creatinine, history of heart failure, or peripheral arterial
.. disease. Several risk scores have been developed, based on readily
6.5.5 Patients with diabetes .. identifiable parameters in the acute phase before reperfusion.264,283
Patients with diabetes are known to present with atypical chest .. The Global Registry of Acute Coronary Events (GRACE) risk score
pain more frequently than patients without diabetes and conse- .. is recommended for risk assessment and adjustment.283,284 All
quently may receive delayed initiation of treatment.278 In addition,
.. patients should also have an evaluation of long-term risk before
diabetic patients are characterized by a more diffuse atheroscler- .. discharge, including LVEF, severity of CAD and completeness of cor-
otic disease.279 Although patients with diabetes are at higher risk of
.. onary revascularization, residual ischaemia, occurrence of complica-
death and complications (including repeat revascularization after .. tions during hospitalization, and levels of metabolic risk markers,
PCI), selection of antithrombotic therapies and reperfusion ther-
.. including total cholesterol, low-density lipoprotein cholesterol (LDL-
apy is the same as in patients without diabetes. Regarding the use .. C), high-density lipoprotein cholesterol (HDL-C), fasting triglycer-
of antiplatelet drugs, the more potent oral P2Y12 receptor inhibi-
.. ides, and plasma glucose, as well as renal function. As LDL-C levels
tors (prasugrel or ticagrelor) have consistently shown increased .. tend to decrease during the first days after MI, they should be meas-
.. ured as soon as possible after admission.
relative benefits with higher absolute risk reductions in patients ..
with diabetes compared with clopidogrel.280 On admission, it is .. Patients who do not get successful reperfusion are at higher risk of
.. early complications and death. These patients should have an assess-
recommended to evaluate glycaemic status in all STEMI patients ..
with and without a known history of diabetes or hyperglycaemia, .. ment of the presence of residual ischaemia and, if appropriate, myo-
and to monitor it frequently in diabetic patients and patients with ... cardial viability. Because the risk of events decreases with time, early
.. risk assessment is indicated.
hyperglycaemia. In critically ill patients, there is a high risk of ..
hypoglycaemia-related events when using intensive insulin ther- ..
apy.281 In the absence of robust data to guide the optimal glucose .. 6.6.2 Non-invasive imaging in management and risk
management (e.g. treatment thresholds and glucose targets) in .. stratification
STEMI patients, a close but not too strict glucose control seems .. LV dysfunction is a key prognostic factor. Therefore, it is recom-
the best approach. In the acute phase, it is reasonable to manage .. mended that the LVEF is determined before hospital discharge in all
hyperglycaemia (i.e. maintain a blood glucose concentration .. STEMI patients. Emergency echocardiography at presentation is indi-
<_11.0 mmol/L or 200 mg/dL) but absolutely avoid hypoglycae- .. cated in patients with cardiac arrest, cardiogenic shock, haemody-
mia.282 To assess the risk of renal insufficiency, it is recommended .. namic instability or suspected mechanical complications, and if the
to measure eGFR in patients on metformin and/or sodium-glucose
.. diagnosis of STEMI is uncertain. Routine echocardiography after pri-
co-transporter-2 (SGLT2) inhibitors. . mary PCI is recommended to assess resting LV function, as well as

Management of hyperglycaemia

Recommendations Classa Levelb

It is recommended to measure glycaemic status at initial evaluation in all patients, and perform frequent monitoring in patients
with known diabetes or hyperglycaemia (defined as glucose levels 11.1 mmol/L or  200 mg/dL)

In patients on metformin and/or SGLT2 inhibitors, renal function should be carefully monitored for at least 3 days after
coronary angiography/PCI.c

Glucose-lowering therapy should be considered in ACS patients with glucose levels >10 mmol/L (>180 mg/dL), while
episodes of hypoglycaemia (defined as glucose levels <_3.9 mmol/L or <_ 70 mg/dL) should be avoided.

Less stringent glucose control should be considered in the acute phase in patients with more advanced cardiovascular
disease, older age, longer diabetes duration, and more comorbidities.

ACS = acute coronary syndrome; PCI = percutaneous coronary intervention; SGLT2 = sodium-glucose co-transporter-2.
Class of recommendation.
Level of evidence.
A short withdrawal of metformin may be considered after an invasive coronary procedure.
ESC Guidelines 29

RV and valve function, to exclude early post-infarction mechanical
Summary of indications for imaging and stress testing
complications and LV thrombus. This assessment is usually per-
in ST-elevation myocardial infarction patients
formed with echocardiography, but in the limited cases in which
echocardiography may be suboptimal or inconclusive, CMR may be a
Recommendations Classa Levelb
good alternative. Patients with multivessel disease in which only the
IRA lesion has been treated, or patients with late-presenting STEMI, At presentation
may benefit from additional assessment for residual ischaemia or via-
Emergency echocardiography is indicated in
bility. Treatment of non-IRA lesions in patients with multivessel dis-
patients with cardiogenic shock and/or haemody-
ease is discussed in section In patients presenting days after I C
namic instability or suspected mechanical compli-
the acute event with a completed MI, the presence of recurrent
cations without delaying angiography.295
angina or documented ischaemia and proven viability in a large myo-
cardial territory may help define a strategy of planned revasculariza- Emergency echocardiography before coronary
tion of an occluded IRA,135,285,286 although the evidence is angiography should be considered if the diagnosis IIa C

controversial. is uncertain.295

The timing of and best imaging technique (echocardiography, Routine echocardiography that delays emergency
SPECT, CMR, or PET) to detect residual ischaemia and myocardial III C
angiography is not recommended.295
viability remains to be determined, but will also depend on local avail-
Coronary CT angiography is not recommended III C
ability and expertise. The best validated and widely available tests are
stress echocardiography and SPECT (both used in combination with During hospital stay (after primary PCI)
exercise or pharmacological stress), but PET and CMR are equally
Routine echocardiography to assess resting LV
indicated. However, in post-MI patients, the detection of residual
and RV function, detect early post-MI mechanical
ischaemia by echocardiography is challenging due to existing wall I B
complications, and exclude LV thrombus is rec-
motion abnormalities.287 LGE-CMR imaging has a high diagnostic
ommended in all patients.296,297
accuracy for assessing the transmural extent of myocardial scar tis-
sue.288 However, the ability to detect viability and predict recovery Emergency echocardiography is indicated in hae-
of wall motion is not significantly superior to other imaging techni- modynamically unstable patients.295
ques.289 The presence of dysfunctional viable myocardium by LGE-
When echocardiography is suboptimal/inconclu-
CMR is an independent predictor of mortality in patients with ischae-
sive, an alternative imaging method (CMR prefera- IIa C
mic LV dysfunction.290
bly) should be considered.
More recently, the presence of wall thinning with limited scar bur-
den was shown to be associated with improved contractility and res- Either stress echo, CMR, SPECT, or PET may be
olution of wall thinning after revascularization, emphasizing the used to assess myocardial ischaemia and viability, IIb C

importance of viability beyond wall thickness and myocardial revascu- including in multivessel CAD.1,298–300

larization to improve prognosis.291 PET is also a high-resolution tech- After discharge
nique but its use is limited by cost and availability. A randomized
clinical trial with PET imaging demonstrated that patients with a sub- In patients with pre-discharge LVEF <_40%, repeat
echocardiography 6–12 weeks after MI, and after
stantial amount of dysfunctional but viable myocardium are likely to
complete revascularization and optimal medical
benefit from myocardial revascularization and may show improve- I C
therapy, is recommended to assess the potential
ments in regional and global contractile function, symptoms, exercise
need for primary prevention ICD
capacity, and long-term prognosis.292 The association between viabil-
ity and improved survival after revascularisation was also demon-
strated by a meta-analysis.293 When echo is suboptimal or inconclusive, alterna-
In patients with a pre-discharge LVEF <_40%, re-evaluation of tive imaging methods (CMR preferably) should be IIa C
LVEF 6–12 weeks after complete revascularization and optimal considered to assess LV function.
medical therapy is recommended to assess the potential need for
primary prevention implantable cardioverter defibrillator (ICD) CAD = coronary artery disease; CMR = cardiac magnetic resonance; CT = com-
implantation.3 Additional parameters that are measured by imag- puted tomography; ICD = implantable cardioverter defibrillator; LV = left ven-
tricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI
ing in these patients and that could be used as endpoints in clinical = percutaneous coronary intervention; PET = positron emission tomography; RV
trials are: (1) infarct size (CMR, SPECT, and PET); (2) myocar- = right ventricular; SPECT = single-photon emission computed tomography.
dium at risk (SPECT, CMR); (3) MVO (CMR); and (4) intra- Class of recommendation.
Level of evidence.
myocardial haemorrhage (CMR). Infarct size and MVO are pre-
dictors of long-term mortality and heart failure in STEMI
30 ESC Guidelines

7. Long-term therapies for ..
with STEMI. However, it has not been established that weight reduc-
tion per se reduces mortality.
ST-segment elevation myocardial ..
infarction .. 7.1.3 Exercise-based cardiac rehabilitation
.. All AMI patients should participate in an exercise-based cardiac reha-
7.1 Lifestyle interventions and risk factor ..
.. bilitation programme,309 taking into account their age, pre-infarction
control .. level of activity, and physical limitations. A cardiac rehabilitation pro-
Key lifestyle interventions include cessation of smoking, optimal
.. gramme preferably includes exercise training, risk factor modification,
blood pressure control, diet advice and weight control, and encour- .. education, stress management, and psychological support.309 In a large
aging physical activity. Detailed recommendations are available from
.. meta-analysis, exercise training as part of a cardiac rehabilitation pro-
the ESC Guidelines on prevention.4 During hospitalization, the time .. gramme was associated with a 22% reduction in cardiac mortality rate
for implementing secondary prevention is limited and a close collabo- .. in patients with CAD.309 The benefit of cardiac rehabilitation appears
ration between the cardiologist and the general practitioner, special- .. to be through direct physiological effects of exercise training and
ist rehabilitation nurses, pharmacists, dieticians, and physiotherapists .. through cardiac rehabilitation effects on risk factor control, lifestyle
is critically important. Habits of a lifetime are not easily changed, and .. behaviours, and mood.310 An additional benefit in the context of a
the implementation and follow-up of these changes are a long-term .. short hospital stay is to ensure proper titration and monitoring of key,
undertaking. .. evidence-based therapies after STEMI. Nowadays, most rehabilitation
.. is offered as an outpatient programme of 8–24 weeks’ duration.311,312
7.1.1 Smoking cessation .. 7.1.4 Resumption of activities
Smoking has a strong pro-thrombotic effect, and smoking cessation is ..
.. Return to work after AMI represents an important indicator of
potentially the most (cost) effective of all secondary prevention .. recovery. Younger women in particular are at greater risk of not
measures.301 Smoking cessation interventions should start during ..
.. returning to work, given evidence of their worse recovery after MI
hospitalization, when smoking is not allowed, and continue during the .. than similarly aged men.313 Decisions should be individualized, based
post-discharge follow-up period.302,303 The beneficial effect of smok- ..
.. on LV function, completeness of revascularization and rhythm con-
ing cessation in patients with CAD, including a majority suffering an .. trol, and the job characteristics. Extended sick leave is usually not
MI, has been shown in a meta-analysis (20 observational studies, ..
.. beneficial and light-to-moderate physical activity after discharge
including 12 603 patients) reporting a 36% reduction of mortality in .. should be encouraged. Sexual activity can be resumed early if
.. adjusted to physical ability.
A significant number of CAD patients continue or restart smoking, .. Guidance on air travel including repatriation for patients suffering
illustrating the addictive nature of the smoking habit.305 There is a
.. an MI abroad is constrained by limited data. Factors related to the
strong evidence base for brief interventions, with a combination of ..
behavioural support and pharmacotherapies including nicotine
.. clinical circumstances as well as length of travel, whether accompa-
.. nied, and the degree of anxiety also play a role. For uncomplicated
replacement therapy, bupropion, and varenicline.305,306 Electronic ..
cigarettes may also be helpful in achieving smoking cessation, as there
.. completely revascularized MI with LVEF >40% the risk is low and
.. travelling is regarded as safe after hospital discharge (from day 3
is some evidence from two pooled randomized clinical trials (662 ..
patients) showing that electronic cigarettes with nicotine had higher
.. onwards). In complicated STEMI, including patients with heart failure,
.. LVEF <40%, residual ischaemia, and arrhythmia, travelling should be
quit or reduced smoking rates when compared with placebo.307 ..
.. deferred until the condition is stable.314
.. 7.1.5 Blood pressure control
7.1.2 Diet, alcohol, and weight control ..
Current guidelines on prevention recommend: (i) a diet similar to the .. Hypertension is a prevalent risk factor in patients admitted with
.. STEMI and, consequently, blood pressure should be well controlled.
Mediterranean diet, which includes a maximum of 10% of total ..
energy intake from saturated fat, by replacing it with polyunsaturated .. In addition to lifestyle changes, including reduced salt intake,
.. increased physical activity, and weight loss, pharmacotherapy with a
fatty acids and as little as possible of trans fatty acids; (ii) salt intake ..
of < 5 g per day; (iii) 30–45 g fibre per day; (iv) 200 g fruits and 200 g .. systolic blood pressure (SBP) target of < 140 mmHg should be initi-
.. ated. In elderly, frail patients, the target can be more lenient, whereas
vegetables per day; (v) fish 1–2 times per week (especially oily vari- ..
eties); (vi) 30 g unsalted nuts daily; (vii) limited alcohol intake [maxi- .. in patients at very high risk who tolerate multiple blood pressure-
.. lowering drugs, a target of < 120 mmHg may be considered.4,315,316
mum of 2 glasses (20 g of alcohol) daily for men and 1 for women]; ..
and (viii) discouraging sugar-sweetened drinks.4 Moderate alcohol .. Despite the proven efficacy of this treatment, non-adherence to life-
.. style interventions and medications may affect treatment effect.
consumption in abstainers is not recommended. ..
Overweight and obesity [body mass index (BMI) 25 kg/m2] is ..
associated with higher all-cause mortality compared with a healthy .. 7.1.6 Adherence to treatment
weight (BMI between 20 kg/m2 and <25 kg/m2). Abdominal fat is par- .. Low treatment adherence is an important barrier to achieving opti-
ticularly harmful and weight loss has beneficial effects on cardiovascu- .. mal treatment targets and is associated with worse outcomes.317
lar disease risk factors. Consequently, maintaining a healthy weight or
.. Delayed outpatient follow-up after AMI results in worse short- and
losing weight is recommended for all subjects,308 including patients . long-term medication adherence.318 In a meta-analysis of 376 162
ESC Guidelines 31

patients, adherence to cardiovascular medications was estimated to .. 7.2.2 Duration of dual antiplatelet therapy and
be about 57% after a median of 2 years.319 .. antithrombotic combination therapies
It is generally recognized that adherence is determined by the .. DAPT, combining aspirin and a P2Y12 inhibitor (i.e. prasugrel, ticagre-
interplay of socioeconomic, medication-related, condition-related, .. lor, or clopidogrel), is recommended in patients with STEMI who are
health system-related, and patient-related factors.320 A strategy to .. undergoing primary PCI (for up to 12 months).186,187 Clopidogrel is
reduce poor adherence is the use of a fixed-dose combination or pol- .. recommended for 1 month in patients treated with fibrinolysis with-
ypill, including key medications to reduce cardiovascular risk, as a .. out subsequent PCI.225,226 Expanding the duration of DAPT up to
once-daily dose pill.321,322 The only study dedicated to post-MI .. 12 months should be considered in these patients.
patients is the recent phase 2 Fixed-Dose Combination Drug for .. For patients undergoing fibrinolysis and subsequent PCI, DAPT is
Secondary Cardiovascular Prevention (FOCUS) trial,323 in which 695 .. recommended for 12 months. Clopidogrel is the P2Y12 inhibitor of
patients post-MI were randomized to usual care or to a polypill- .. choice as co-adjuvant and after fibrinolysis. Potent P2Y12 inhibitors
based strategy [polypill containing aspirin, an angiotensin-converting .. have not been properly tested in patients undergoing fibrinolysis, and
enzyme (ACE) inhibitor, and a statin]. In this trial, after 9 months of .. safety (i.e. bleeding complications) is not well established. However,
follow-up, the polypill group showed improved adherence compared .. in patients who underwent PCI after fibrinolysis, after a safety period
with the group receiving separate medications. Larger trials are .. (arbitrarily considered 48 h), there are no biological grounds to con-
needed to confirm a clinical benefit in secondary prevention.
.. sider that potent P2Y12 inhibitors will add risk and not exert a benefit
Although low adherence has been qualified as an ubiquitous prob- .. over clopidogrel as in the primary PCI setting.
lem,324 healthcare professionals and patients should be aware of this
.. Whereas no dedicated study exists on optimal DAPT duration in
challenge and optimize communication by providing clear informa- .. patients at high bleeding risk, multiple studies have shown that short-
tion, simplify treatment regimens, aim at shared decision-making, and
.. ening DAPT to 6 months, compared with 12 months or longer,
implement repetitive monitoring and feedback. .. reduces the risk of major bleeding complications, with no apparent
.. trade-off in ischaemic events.331,332
.. Two major studies have shown the benefit towards reduction of
Behavioural aspects after ST-elevation myocardial ..
infarction .. non-fatal ischaemic events in patients receiving longer than
.. 12 months of DAPT.333,334 The DAPT Study included only roughly
Classa Levelb
.. 10% of STEMI patients and no information has so far been provided
Recommendations .. with respect to the benefit of prolonging clopidogrel or prasugrel
It is recommended to identify smokers and .. from 12 to 30 months in this patient subset. Hence, no formal recom-
provide repeated advice on stopping, with offers .. mendations are possible for the use of clopidogrel or prasugrel
to help with the use of follow-up support, nicotine I A .. beyond 1 year.334
replacement therapies, varenicline, and bupropion .. More recently, the Prevention of Cardiovascular Events in Patients
individually or in combination.4,302,303,325–327 .. with Prior Heart Attack Using Ticagrelor Compared to Placebo on a
.. Background of Aspirin–Thrombolysis in Myocardial Infarction 54
Participation in a cardiac rehabilitation programme ..
is recommended.4,309,328
I A .. (PEGASUS-TIMI 54) trial examined two doses of ticagrelor (60 mg
.. and 90 mg b.i.d.) vs. placebo in patients with a history of MI 1–3 years
A smoking cessation protocol is indicated for each
I C .. previously and with high-risk features; the study showed a reduction
hospital participating in the care of STEMI patients. .. in MACE with 90 mg ticagrelor.333 There was no reduction in total
The use of the polypill and combination therapy
.. mortality, but there was a borderline signal towards reduced cardio-
.. vascular mortality (when both doses were pooled) consistent with
to increase adherence to drug therapy may be IIb B ..
considered.4,322,323 .. the reduction in non-fatal outcomes.333 The 60 mg (but not the
.. 90 mg) ticagrelor (plus aspirin) regimen also significantly reduced the
.. stroke risk compared with aspirin monotherapy. The ticagrelor regi-
STEMI = ST-segment elevation myocardial infarction.
.. men was associated with a significantly increased bleeding risk.
Class of recommendation. ..
Level of evidence. .. Patients with previous STEMI comprised more than 50% of the over-
.. all PEGASUS-TIMI 54 population, and subgroup analysis has shown
.. consistent results in patients with previous STEMI vs. NSTEMI.333
7.2 Antithrombotic therapy ..
.. According to the available data, extension of DAPT beyond 1 year
Full text about long-term antithrombotic therapy can be found in the .. (up to 3 years) in the form of aspirin plus ticagrelor 60 mg b.i.d. may
online Web Addenda. In addition, this topic is covered in great detail ..
.. be considered in patients who have tolerated DAPT without a bleed-
in the ESC Focused Update on DAPT in CAD published simultane- .. ing complication and having one additional risk factor for ischaemic
ously with these guidelines.7 ..
.. events.
.. Gastric protection with a PPI is recommended for patients with a
7.2.1 Aspirin .. history of gastrointestinal bleeding and is appropriate for patients
Aspirin is recommended indefinitely in all patients with STEMI.329,330 .. with multiple risk factors for bleeding, such as advanced age, concur-
For long-term prevention, low aspirin doses (75–100 mg) are indi- .. rent use of anticoagulants, steroids or non-steroidal anti-inflamma-
cated due to similar anti-ischaemic and less adverse events than
.. tory drugs including high-dose aspirin, and Helicobacter pylori
higher doses, as demonstrated in the CURRENT-OASIS 7 trial.330 . infection.335–337
32 ESC Guidelines

In the Acute Coronary Syndrome–Thrombolysis In Myocardial .. (METOCARD-CNIC) trial (n = 270) showed that the very early
Infarction 51 (ATLAS ACS 2–TIMI 51) trial (n = 15 526, 50% STEMI), .. administration of i.v. metoprolol (15 mg) at the time of diagnosis
a low dose of rivaroxaban (2.5 mg twice daily), on top of aspirin plus .. in patients with anterior STEMI, no signs of heart failure, and
clopidogrel, reduced the composite primary endpoint of cardiovas- .. SBP >120 mmHg was associated with a reduction in infarct
cular death, MI, or stroke, but also all-cause mortality, over a mean .. size measured by CMR at 5–7 days (25.6 g vs. 32.0 g; P = 0.012),
follow-up of 13 months.338 Stent thrombosis was reduced by one- .. and higher LVEF at 6 months CMR (48.7% vs. 45.0%; P = 0.018)
third. However, this was associated with a three-fold increase in non- .. compared with control treatment.347,348 All patients without con-
CABG-related major bleeding and intracranial haemorrhage.338 .. traindications received oral metoprolol within 24 h. The
Based on the ATLAS ACS 2–TIMI 51 trial, in selected patients at low .. incidence of MACE (composite of death, admission as a result of
bleeding risk, the 2.5 mg dose of rivaroxaban may be considered in .. heart failure, reinfarction, or malignant ventricular arrhythmias) at
patients who receive aspirin and clopidogrel after STEMI. .. 2 years was 10.8% vs. 18.3% in the i.v. metoprolol and control

Maintenance antithrombotic strategy after ST-elevation myocardial infarction

Recommendations Classa Levelb

Antiplatelet therapy with low-dose aspirin (75–100 mg) is indicated.329 I A

DAPT in the form of aspirin plus ticagrelor or prasugrel (or clopidogrel if ticagrelor or prasugrel are not available or are contraindicated), is
recommended for 12 months after PCI, unless there are contraindications such as excessive risk of bleeding.186,187

A PPI in combination with DAPT is recommended in patients at high risk of gastrointestinal bleedingc.335–337 I B

In patients with an indication for oral anticoagulation, oral anticoagulants are indicated in addition to antiplatelet therapy.5 I C

In patients who are at high risk of severe bleeding complications, discontinuation of P2Y12 inhibitor therapy after 6 months should be

In STEMI patients with stent implantation and an indication for oral anticoagulation, triple therapyd should be considered for 1–6 months
(according to a balance between the estimated risk of recurrent coronary events and bleeding).5

DAPT for 12 months in patients who did not undergo PCI should be considered unless there are contraindications such as excessive risk of

In patients with LV thrombus, anticoagulation should be administered for up to 6 months guided by repeated imaging.341–343 IIa C

In high ischaemic-risk patientse who have tolerated DAPT without a bleeding complication, treatment with DAPT in the form of ticagrelor
60 mg twice a day on top of aspirin for longer than 12 months may be considered for up to 3 years.333

In low bleeding-risk patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered.338 IIb B

The use of ticagrelor or prasugrel is not recommended as part of triple antithrombotic therapy with aspirin and oral anticoagulation. III C

AMI = acute myocardial infarction; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; eGFR = estimated glomerular filtration rate; LV = left ventricular; PCI =
percutaneous coronary intervention; PPI = proton pump inhibitor; STEMI = ST-segment elevation myocardial infarction.
Class of recommendation.
Level of evidence.
History of gastrointestinal bleeding, anticoagulant therapy, chronic non-steroidal anti-inflammatory drug/corticosteroid user, and 2 or more of the following: age 65 years,
dyspepsia, gastro-oesophageal reflux disease, H. pylori infection, and chronic alcohol use.
Oral anticoagulant, aspirin, and clopidogrel.
Defined as age 50 years, and at least one of the following additional high-risk features: age 65 years, diabetes mellitus on medication, a prior spontaneous AMI, multivessel
CAD, or chronic renal dysfunction (eGFR <60 ml/min/1.73 m2).

7.3 Beta-blockers arms (P = 0.065).348 Metoprolol treatment was associated with a
7.3.1 Early intravenous beta-blocker administration significant reduction in the incidence and extent of MVO.349 The
In patients undergoing fibrinolysis, early i.v. beta-blocker treatment Early Intravenous Beta-Blockers in Patients With ST-Segment
reduces the incidence of acute malignant ventricular arrhythmias, Elevation Myocardial Infarction Before Primary Percutaneous
although there is no clear evidence of long-term clinical Coronary Intervention (EARLY-BAMI) trial randomized
benefit.344–346 683 patients with STEMI within 12 h of onset to i.v. metoprolol
In patients undergoing primary PCI, the Effect of Metoprolol in (5 mg at recruitment and an additional 5 mg immediately before
Cardioprotection During an Acute Myocardial Infarction PCI) or placebo.350 All patients without contraindications
ESC Guidelines 33

received oral metoprolol within 12 h. Early i.v. metoprolol admin- .. of early and intensive statin therapy in ACS.364,365 A meta-analysis
istration did not show any benefit in reducing CMR-based .. of trials comparing more- vs. less-intensive LDL-C lowering with
infarct size, the trial primary endpoint, available only in 342 .. statins indicated that more-intensive statin therapy produced
patients (55%), or the level of cardiac biomarker release. Early i.v. .. greater reductions in the risks of cardiovascular death, non-fatal
metoprolol was associated with a borderline reduction of malig- .. MI, ischaemic stroke, and coronary revascularization.366 For every
nant ventricular arrhythmias (3.6% vs. 6.9%; P = 0.050). Patients .. 1.0 mmol/L reduction in LDL-C, these further reductions in risk
treated with i.v. metoprolol showed no increased risk of haemo- .. were similar to the proportional reductions in the trials of statins
dynamic instability, atrioventricular (AV) block, or MACE at .. vs. control. Therefore, statins are recommended in all patients
30 days. Post hoc analyses from primary PCI trials testing .. with AMI, irrespective of cholesterol concentration at presenta-
other hypotheses have suggested that early i.v. beta-blocker .. tion. Lipid-lowering treatment should be started as early as possi-
administration might be associated with a clinical benefit, but a .. ble, as this increases patient adherence after discharge, and given
selection bias cannot be excluded even after correction for imbal- .. as high-intensity treatment, as this is associated with early and sus-
ances in baseline characteristics.351,352 Based on the current avail- .. tained clinical benefits.4 The intensity of statin therapy should be
able evidence, early administration of i.v. beta-blockers at the .. increased in those receiving a low- or moderate-intensity statin
time of presentation followed by oral beta-blockers should .. treatment at presentation, unless they have a history of intoler-
be considered in haemodynamically stable patients undergoing
.. ance to high-intensity statin therapy or other characteristics that
primary PCI. .. may influence safety.366–368 The treatment goal is an LDL-C con-
.. centration of < 1.8 mmol/L (<70 mg/dL) or at least 50% reduction
7.3.2 Mid- and long-term beta-blocker treatment .. in LDL-C if the baseline LDL-C level is 1.8–3.5 mmol/L.4,367,369
The benefit of long-term treatment with oral beta-blockers after
.. The use of lower-intensity statin therapy should be considered in
STEMI is well established, although most of the supporting data .. patients at increased risk of side effects from statins (e.g. elderly,
come from trials performed in the pre-reperfusion era.353 A
.. hepatic or renal impairment, previous side effects, or a potential
recent multicentre registry enrolling 7057 consecutive patients .. for interaction with essential concomitant therapy). Following MI,
with AMI showed a benefit in terms of mortality reduction at a .. the lipid profile goes through phasic changes, with small reduc-
median follow-up of 2.1 years associated with beta-blocker pre- .. tions in total cholesterol, LDL-C, and HDL-C, and increases in tri-
scription at discharge, although no relationship between dose and .. glycerides within the first 24 h.370,371 A lipid profile should be
outcomes could be identified.354 Using registry data, the impact of .. obtained as early as possible after admission for STEMI and can be
newly introduced beta-blocker treatment on cardiovascular .. non-fasting, as total and HDL-C show little diurnal variation and
events in 19 843 patients with either ACS or undergoing PCI was .. LDL-C variation is within 10%.372 Lipids should be re-evaluated
studied.355 At an average of 3.7 years of follow-up, the use of beta- .. 4–6 weeks after the ACS to determine whether the target levels
blockers was associated with a significant mortality reduction .. have been reached and regarding safety issues; the lipid lowering
(adjusted HR 0.90, 95% CI 0.84–0.96). The association between .. therapy can then be adjusted accordingly. Trial results with high
beta-blockers and outcomes differed significantly between .. doses of atorvastatin and simvastatin366,373–375 favour a high-
patients with and without a recent MI (HR for death 0.85 vs. 1.02; .. intensity statin.
Pint = 0.007). Opposing these results, in a longitudinal observatio- .. In patients known to be intolerant of any dose of statin, treat-
nal propensity-matched study including 6758 patients with pre- .. ment with ezetimibe should be considered. In the Improved
vious MI, beta-blocker use was not associated with a lower risk of .. Reduction of Outcomes: Vytorin Efficacy International Trial
cardiovascular events or mortality.356 Based on the current evi- .. (IMPROVE-IT), 18 144 patients with a recent ACS (29% with
dence, routine administration of beta-blockers in all post-STEMI
.. STEMI) were randomized to either ezetimibe 10 mg/simvastatin
patients should be considered as discussed in detail in the heart .. 40 mg or simvastatin 40 mg alone (simvastatin was up-titrated to
failure guidelines;6 beta-blockers are recommended in patients
.. 80 mg if LDL-C was >79 mg/dL or 2.04 mmol/L).376 Over a period
with reduced systolic LV function (LVEF <_40%), in the absence of .. of 7 years, the composite primary endpoint of cardiovascular
contraindications such as acute heart failure, haemodynamic insta-
.. death, MI, hospital admission for unstable angina, coronary revas-
bility, or higher degree AV block. Agents and doses of proven effi- .. cularization, or stroke was significantly lower in the combined
cacy should be administered.357–361 As no study has properly
.. treatment arm compared with the statin-only arm (32.7% vs.
addressed beta-blocker duration to date, no recommendation in .. 34.7%; HR 0.94, 95% CI 0.89–0.99).
this respect can be made. Regarding the timing of initiation of oral .. Recent data from phase I–III trials show that proprotein con-
beta-blocker treatment in patients not receiving early i.v. beta- .. vertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease LDL-
blockade, a retrospective registry analysis on 5259 patients sug- .. C up to 60%, either as monotherapy or in addition to a statin
gested that early (i.e. <24 h) beta-blocker administration con- .. dose, and also have beneficial effects on triglycerides and HDL-
veyed a survival benefit compared with a delayed one.362 .. C.377–380 Meta-analyses of existing trials with more than 10 000
Therefore, in haemodynamically stable patients, oral beta-blocker .. patients indicate a significant mortality benefit (HR 0.45, 95% CI
initiation should be considered within the first 24 h. .. 0.23–0.86) but are based on relatively few endpoints.378,381 In
.. the Further Cardiovascular Outcomes Research with PCSK9
7.4 Lipid-lowering therapy .. Inhibition in Subjects with Elevated Risk (FOURIER) trial consist-
The benefits of statins in secondary prevention have been
.. ing of 27 564 patients with atherosclerotic cardiovascular disease,
unequivocally demonstrated,363 and trials have shown the benefits . additional risk factors, and LDL 70 mg/dL (1.8 mmol/L), who
34 ESC Guidelines

were already receiving moderate or high intensity statin therapy
.. week.383,393 Treatment with ACE inhibitors is recommended in
as compared to placebo, evolocumab injections reduced the pri- .. patients with systolic LV dysfunction or heart failure, hyperten-
mary composite endpoint of cardiovascular death, MI, stroke,
.. sion, or diabetes, and should be considered in all STEMI
hospitalization for unstable angina, or coronary revascularization .. patients.394,395 Patients who do not tolerate an ACE inhibitor
by 15% in relative rate and by 1.5% in absolute rate. There were
.. should be given an angiotensin II receptor blocker (ARB). In the
no differences in all-cause mortality or cardiovascular mortality .. context of STEMI, valsartan was found to be non-inferior to cap-
and no significant differences in adverse events.382 Given the .. topril in the VALsartan In Acute myocardial iNfarcTion
moderate effect over 2 years and the absence of mortality reduc- .. (VALIANT) trial.396
tion, its use should still be restricted to selected high-risk ..
patients. ..
Based on this relatively limited body of evidence, clinicians should .. 7.8 Mineralocorticoid/aldosterone
consider adding a non-statin treatment to patients at high risk who .. receptor antagonists
do not reach treatment targets after STEMI despite the maximum .. Mineralocorticoid receptor antagonist (MRA) therapy is recom-
tolerated dose of statin. ..
.. mended in patients with LV dysfunction (LVEF <_40%) and heart
.. failure after STEMI.397–400 Eplerenone, a selective aldosterone
7.5 Nitrates .. receptor antagonist, has been shown to reduce morbidity and
The routine use of nitrates in STEMI was of no benefit in a .. mortality in these patients. The Eplerenone Post-AMI Heart fail-
randomized controlled trial against placebo and is therefore not .. ure Efficacy and SUrvival Study (EPHESUS) randomized 6642
recommended.383 Intravenous nitrates may be useful during the .. post-MI patients with LV dysfunction (LVEF <_40%) and symptoms
acute phase in patients with hypertension or heart failure, pro- .. of heart failure/diabetes to eplerenone or placebo within 3–14
vided there is no hypotension, RV infarction, or use of phospho- .. days after their infarction.397 After a mean follow-up of 16 months,
diesterase type 5 inhibitors in the previous 48 h. Following the .. there was a 15% relative reduction in total mortality and a 13%
acute phase, nitrates remain valuable agents to control residual
.. reduction in the composite of death and hospitalization for cardi-
angina symptoms. .. ovascular events.
.. Two recent studies have indicated a beneficial effect of early
7.6 Calcium antagonists .. treatment with MRA in the setting of STEMI without heart failure.
.. The Double-Blind, Randomized, Placebo-Controlled Trial
A meta-analysis of 17 trials involving calcium antagonists early in ..
the course of STEMI showed no beneficial effect on death or rein-
.. Evaluating The Safety And Efficacy Of Early Treatment With
.. Eplerenone In Patients With Acute Myocardial Infarction
farction, with a trend of higher mortality for patients treated with ..
nifedipine. Therefore, routine use of calcium antagonists in the
.. (REMINDER) trial randomized 1012 patients with acute STEMI
.. without heart failure to eplerenone or placebo within 24 h of
acute phase is not indicated.384,385 In the chronic phase, a random- ..
ized controlled trial allocating 1775 patients with MI not on beta-
.. symptom onset.401 After 10.5 months, the primary combined end-
.. point [CV mortality, re-hospitalization, or extended initial hospital
blockers to verapamil or placebo found that the risk of mortality ..
.. stay due to diagnosis of heart failure, sustained ventricular tachy-
and reinfarction was reduced with verapamil.386 Thus, in patients .. cardia or fibrillation, ejection fraction <_40%, or elevated B-type
with contraindications to beta-blockers, particularly in the pres- ..
.. natriuretic peptide (BNP)/N-terminal pro B-type natriuretic pep-
ence of obstructive airway disease, calcium antagonists are a rea- ..
sonable option for patients without heart failure or impaired LV .. tide (NT-proBNP)] occurred in 29.4% of the active group vs.
.. 18.2% in the placebo group (P < 0.0001), with the difference pri-
function. Routine use of dihydropyridines, on the other hand, has ..
failed to show benefit after STEMI,387 and they should therefore .. marily driven by BNP levels.401 The Aldosterone Lethal effects
.. Blockade in Acute myocardial infarction Treated with or without
only be prescribed for clear additional indications such as hyper- ..
tension or residual angina.388 .. Reperfusion to improve Outcome and Survival at Six months
.. follow-up (ALBATROSS) trial randomized 1603 patients with
.. acute STEMI or high-risk NSTEMI to a single i.v. bolus of potassium
7.7 Angiotensin-converting enzyme .. canrenoate (200 mg) followed by spironolactone (25 mg daily) vs.
inhibitors and angiotensin II receptor ..
.. placebo. Overall, the study found no effect on the composite out-
blockers .. come (death, resuscitated cardiac arrest, significant ventricular
ACE inhibitors are recommended in patients with an impaired .. arrhythmia, indication for implantable defibrillator, or new or
LVEF (<_40%) or who have experienced heart failure in the early .. worsening heart failure) at 6 months. In an exploratory analysis of
phase.383,389–392 A systematic overview of trials of ACE inhibition .. the STEMI subgroup (n = 1229), the outcome was significantly
early in STEMI indicated that this therapy is safe, well tolerated,
.. reduced in the active treatment group (HR 0.20, 95% CI
and associated with a small but significant reduction in 30-day .. 0.06–0.70).402 Future studies will clarify the role of MRA treat-
mortality, with most of the benefit observed in the first
.. ment in this setting.
ESC Guidelines 35

Routine therapies in the acute, subacute, and long-term phases: beta-blockers, angiotensin-converting enzyme inhibi-
tors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, and lipid-lowering treatments after ST-
elevation myocardial infarction

Recommendations Classa Levelb


Oral treatment with beta-blockers is indicated in patients with heart failure and/or LVEF <_40% unless contraindicated.357–361 I A

Intravenous beta-blockers should be considered at the time of presentation in patients undergoing primary PCI without con-
traindications, with no signs of acute heart failure, and with an SBP >120 mmHg.346–348,350,403

Routine oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all patients
without contraindications.344,354–356,404,405

Intravenous beta-blockers must be avoided in patients with hypotension, acute heart failure or AV block, or severe

Lipid lowering therapies

It is recommended to start high-intensity statin therapyc as early as possible, unless contraindicated, and maintain it long-

An LDL-C goal of < 1.8 mmol/L (70 mg/dL) or a reduction of at least 50% if the baseline LDL-C is between 1.8–3.5 mmol/L
(70–135 mg/dL) is recommended.367,369,376,382

It is recommended to obtain a lipid profile in all STEMI patients as soon as possible after presentation.369,406 I C

In patients with LDL-C 1.8 mmol/L (70 mg/dL) despite a maximally tolerated statin dose who remain at high risk, further
therapy to reduce LDL-C should be considered.376,382

ACE inhibitors/ARBs

ACE inhibitors are recommended, starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic
dysfunction, diabetes, or an anterior infarct.383

An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure and/or LV systolic dysfunction,
particularly those who are intolerant of ACE inhibitors.396,407

ACE inhibitors should be considered in all patients in the absence of contraindications.394,395 IIa A


MRAs are recommended in patients with an LVEF <_40% and heart failure or diabetes, who are already receiving an ACE inhib-
itor and a beta-blocker, provided there is no renal failure or hyperkalaemia.397

AV = atrioventricular; ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular; LVEF
= left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; STEMI = ST-seg-
ment elevation myocardial infarction.
Class of recommendation.
Level of evidence.
High-intensity statin defined as atorvastatin 40–80 mg and rosuvastatin 20–40 mg.

When using MRA, care should be taken with reduced renal func- ..
.. 8. Complications following ST-
tion [creatinine concentration >221 mmol/L (2.5 mg/dL) in men and ..
>177 mmol/L (2.0 mg/dL) in women] and routine monitoring of .. segment elevation myocardial
serum potassium is warranted. .. infarction
Figures 5 and 6 present the mostly prescribed interventions ..
(class I and IIa) in patients undergoing primary PCI or fibrinolysis
.. Expanded information about complications following STEMI is pre-
.. sented in the Web Addenda.
strategies. ..
36 ESC Guidelines

Figure 5 “Do not forget” interventions in STEMI patients undergoing a primary PCI strategy. ACE = angiotensin-converting enzyme; DAPT = dual
antiplatelet therapy; DES = drug eluting stent; ECG = electrocardiogram; echo = echocardiogram; ED = emergency department; HF = heart failure;
i.v. = intravenous; IRA = infarct related artery; LVEF = left ventricular ejection fraction; MRA = mineralcorticoid receptor antagonist; PCI = percuta-
neous coronary intervention; STEMI = ST-segment elevation myocardial infarction; UFH = Unfractionated heparin.
Mostly prescribed interventions (class I, green, and IIa, yellow) are presented along with the expected timing of delivery. Solid lines represent recur-
rent (daily) intervention. Double-arrowed dashed lines represent a time-window in which the intervention can be delivered.
Aspirin loading dose: 150–300 mg chewed or 75–250 mg intravenous (in patients not already on an aspirin maintenance dose).
Prasugrel loading dose: 60 mg. Ticagrelor loading dose: 180 mg. If there are contra-indications for prasugrel/ticagrelor or these are not
available, a loading dose of clopidogrel (600 mg) is indicated.
If the interventional cardiologist is not expert in radial access, the femoral route is then preferred.
Enoxaparin or bivalirudin are alternatives to unfractionated heparin (Class IIa A).
Aspirin maintenance dose: 75–100 mg oral.
Prasugrel maintenance dose: 10 mg once daily. Ticagrelor maintenance dose: 90 mg twice daily. If there are contra-indications for pra-
sugrel/ticagrelor or these are not available, clopidogrel maintenance (75 mg daily) is indicated.
90 min represents the maximum target time to PCI-mediated reperfusion. For patients presenting in a PCI-centre, this target time is
60 min.
Prolongation of ticagrelor (60 mg twice daily) in addition to aspirin may be considered for up to 36 months in patients at high ischaemic
risk who have tolerated DAPT without a bleeding complication.
ESC Guidelines 37

Figure 6 “Do not forget” interventions in STEMI patients undergoing a successful fibrinolysis strategy. ACE = angiotensin-converting enzyme;
DAPT = dual antiplatelet therapy; DES = drug eluting stent; ECG = electrocardiogram; echo = echocardiogram; HF = heart failure; i.v. = intravenous;
IRA = infarct related artery; LVEF = left ventricular ejection fraction; MRA = mineralcorticoid receptor antagonist; PCI = percutaneous coronary
intervention; STEMI = ST-segment elevation myocardial infarction; UFH = Unfractionated heparin.
Mostly prescribed interventions (class I, green, and IIa, light yellow) are presented along with the expected timing of delivery. Solid lines represent
recurrent (daily) intervention. Double-arrowed dashed lines represent a time-window in which the intervention can be delivered.
Enoxaparin dose: 30 mg i.v. bolus followed by 1 mg/kg subcutaneous every 12 hours (dose adjustment for 75 years and renal insuffi-
ciency is presented in Table 9). Unfractionated heparin is an alternative to enoxaparin.
Aspirin loading dose: 150–300 mg chewed or 75–250 mg intravenous.
Clopidogrel loading dose: 300 mg oral (75 mg in  75 years).
Aspirin maintenance dose: 75–100 mg oral
Clopidogrel maintenance therapy: 75 mg daily.
48 hours after fibrinolysis, switch to prasugrel/ticagrelor may be considered in PCI-treated patients.
38 ESC Guidelines

.. Patients with pulmonary congestion and SaO2 <90% or partial
8.1 Myocardial dysfunction ..
8.1.1 Left ventricular dysfunction .. pressure of oxygen (PaO2) <60 mmHg (8.0 kPa) require oxygen
.. therapy and SaO2 monitoring to correct hypoxaemia, with a tar-
See Web Addenda. ..
.. get of 95%, and may require periodic blood-gas assessment. Initial
.. pharmacological treatment includes i.v. loop diuretics (e.g. furose-
8.1.2 Right ventricular involvement ..
.. mide 20–40 mg i.v. with repeated doses at intervals as needed
See Web Addenda. .. according to clinical evolution and diuresis) and, if blood pressure
.. allows it, i.v. nitrates, avoiding hypotension or excessive falls in
8.2 Heart failure ..
.. blood pressure. The early use of beta-blockers, ACE inhibitors/
8.2.1 Clinical presentations .. ARBs, and MRA is recommended in the absence of hypotension,
See Web Addenda. ..
.. hypovolaemia, or renal dysfunction. Causal treatment is essential.
.. Coronary revascularization should be performed early when sig-
8.2.2 Management .. nificant CAD is still present. Rhythm disturbances, valvular dys-
Patients with heart failure should be under continuous monitoring .. function, and hypertension should be corrected as soon as
of heart rhythm, blood pressure, and urinary output. The mecha- .. possible. Hypertension should be treated promptly with oral ACE
nism of heart failure should be assessed early by physical examina- .. inhibitors/ARBs and i.v. nitrates. In very severe cases, sodium
tion, ECG, echocardiography, and (when not rapidly controlled) .. nitroprusside infusion may be necessary. Persistent myocardial
with invasive haemodynamic monitoring, and corrected as soon as
.. ischaemia should be treated with early coronary revascularization.
possible. . Atrial and ventricular dysrhythmias, and valvular dysfunction or

Recommendations for the management of left ventricular dysfunction and acute heart failure in ST-elevation myocar-
dial infarction

Recommendations Classa Levelb

ACE inhibitor (or if not tolerated, ARB) therapy is indicated as soon as haemodynamically stable for all patients with
evidence of LVEF <_40% and/or heart failure to reduce the risk of hospitalization and death.390,396,412,413

Beta-blocker therapy is recommended in patients with LVEF <_40% and/or heart failure after stabilization, to reduce the risk
of death, recurrent MI, and hospitalization for heart failure.358–361,414–416

An MRA is recommended in patients with heart failure and LVEF <_40% with no severe renal failure or hyperkalaemia to reduce
the risk of cardiovascular hospitalization and death.397

Loop diuretics are recommended in patients with acute heart failure with symptoms/signs of fluid overload to improve

Nitrates are recommended in patients with symptomatic heart failure with SBP >90 mmHg to improve symptoms and
reduce congestion.

Oxygen is indicated in patients with pulmonary oedema with SaO2 <90% to maintain a saturation >95%. I C

Patient intubation is indicated in patients with respiratory failure or exhaustion, leading to hypoxaemia, hypercapnia, or acidosis,
and if non-invasive ventilation is not tolerated.

Non-invasive positive pressure ventilation (continuous positive airway pressure, biphasic positive airway pressure) should
be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SaO2 <90%) without IIa B

Intravenous nitrates or sodium nitroprusside should be considered in patients with heart failure and elevated SBP to control
blood pressure and improve symptoms.

Opiates may be considered to relieve dyspnoea and anxiety in patients with pulmonary oedema and severe dyspnoea.
Respiration should be monitored.6,408

>Inotropic agents may be considered in patients with severe heart failure with hypotension refractory to standard medical

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; LV = left ventricular; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor
antagonist; SaO2 = arterial oxygen saturation; SBP = systolic blood pressure; STEMI = ST-segment elevation myocardial infarction.
Class of recommendation.
Level of evidence.
ESC Guidelines 39

mechanical complications, should be treated as appropriate (see .. The first step in patients with cardiogenic shock is to identify
specific sections in this document). .. the mechanism and to correct any reversible cause such as hypo-
Severely symptomatic patients with pulmonary congestion may .. volaemia, drug-induced hypotension, or arrhythmias; alternatively,
also need i.v. morphine to reduce dyspnoea and anxiety, but rou- .. initiate the treatment of potential specific causes, such as mechani-
tine use is not recommended due to concerns about its safety, as .. cal complications or tamponade.
it may induce nausea and hypopnea.408,409 Non-invasive positive .. Treatments include immediate reperfusion, with primary PCI
pressure ventilation (continuous positive airway pressure, bipha- .. whenever possible,248,427 and complete revascularisation if multives-
sic positive airway pressure) or high-flow nasal cannula is effective
.. sel disease is present. In addition, patients at the highest risk for devel-
in treating pulmonary oedema and should be considered in .. opment of shock might benefit from an early transfer to tertiary
patients with respiratory distress (respiratory rate >25 breaths/
.. centres before the onset of haemodynamic instability.
min, SaO2 <90%) and started soon.410,411 Endotracheal intubation .. Antithrombotic therapy does not differ from that in any STEMI
and ventilatory support may be required in patients unable to
.. patient. The specificities of the management of low-output cardio-
achieve adequate oxygenation, or in those with excess respiratory .. genic shock associated with RV infarction are mentioned in the Web
work or evidence of hypercapnia due to respiratory exhaustion.
.. Addenda.
Ultrafiltration to reduce fluid overload may be considered in .. Invasive monitoring with an arterial line is recommended.6 A
patients who are refractory to diuretics, especially in patients with .. pulmonary artery catheter may be considered, in order to per-
hyponatraemia. .. form a careful adjustment of filling pressures and assessment of
In patients with heart failure and adequate blood pressure .. cardiac output or in cases of shock of unexplained cause.
(SBP >90 mmHg), but a severe reduction in cardiac output resulting .. Hypovolaemia should be ruled out first and corrected with fluid
in compromised vital organ perfusion not responding to standard .. loading. Pharmacological therapy aims to improve organ perfusion
therapy, treatment with dobutamine or levosimendan may .. by increasing cardiac output and blood pressure. Diuretic therapy
be considered. However, the clinical evidence of levosimendan in .. is recommended when adequate perfusion is attained.
cardiogenic shock is limited. Further details on the management .. Intravenous inotropic agents or vasopressors are usually required
of acute heart failure can be found in the 2016 ESC Guidelines .. to maintain an SBP >90 mmHg, and to increase cardiac output and
for the diagnosis and treatment of acute and chronic heart failure.6 .. improve vital organ perfusion. Dobutamine is the initial therapy
.. for patients with predominant low cardiac output, whereas nore- Management of hypotension .. pinephrine may be safer and more effective than dopamine in
In patients with hypotension and normal perfusion without evidence .. patients with cardiogenic shock and severe hypotension.428
of congestion or volume overload (i.e. collapsible inferior vena cava), .. Levosimendan may be considered as an alternative, especially
gentle volume loading should be attempted after ruling out complica- .. for patients on chronic beta-blocker therapy, because its
tions such as mechanical or severe mitral regurgitation, with central
.. inotropic effect is independent of beta-adrenergic stimulation.
pressure monitoring. Bradycardia or tachyarrhythmias should be cor- .. Phosphodiesterase III inhibitors are not recommended in STEMI
rected or controlled. In patients with RV infarction, volume overload-
.. patients.
ing should be avoided because it might worsen haemodynamics.420 .. IABP counterpulsation does not improve outcomes in patients
If hypotension persists, inotropic therapy, preferably with dobut-
.. with STEMI and cardiogenic shock without mechanical complica-
amine, may be considered.420 .. tions,177 nor does it significantly limit infarct size in those with
.. potentially large anterior MIs.175 Therefore, routine IABP coun-
.. Management of cardiogenic shock .. terpulsation cannot be recommended, but may be considered for
Cardiogenic shock is defined as persistent hypotension (SBP .. haemodynamic support in selected patients (i.e. severe mitral
<90 mmHg) despite adequate filling status with signs of hypoperfu- .. insufficiency or ventricular septal defect). A small exploratory trial
sion. It complicates 6–10% of all STEMI cases and remains a leading .. studying the Impella CP percutaneous circulatory support device
cause of death, with in-hospital mortality rates 50%.421 Shock is also .. did not find any benefit compared with IABP in AMI complicated
considered to be present if i.v. inotropes and/or mechanical support .. by cardiogenic shock.429
are needed to maintain an SBP >90 mmHg. In STEMI patients present- .. Mechanical LV assist devices (LVADs), including percutaneous
ing with cardiogenic shock in which PCI-mediated reperfusion is esti- .. short-term mechanical circulatory support devices (i.e. intra-cardiac
mated to occur >120 min, immediate fibrinolysis and transfer to a PCI .. axial flow pumps and arterial-venous extracorporeal membrane oxy-
centre should be considered. In these cases, upon arrival at the PCI .. genation), have been used in patients not responding to standard
centre, emergent angiography is indicated, regardless of the .. therapy, including inotropes, fluids, and IABP, but evidence regarding
ST resolution and the time from fibrinolysis administration. It is usually .. their benefits is limited.430 Therefore, short-term mechanical
associated with extensive LV damage, but may occur in RV infarction. .. circulatory support may be considered as a rescue therapy in order
Cardiogenic shock characterization and management do not necessa- .. to stabilize the patients and preserve organ perfusion (oxygenation)
rily need invasive haemodynamic monitoring, but ventricular and valve
.. as a bridge to recovery of myocardial function, cardiac transplanta-
function should be urgently evaluated by transthoracic echocardiogra- .. tion, or even LV assist device destination therapy on an individual
phy and associated mechanical complications ruled out.422–426
.. basis.431,432
40 ESC Guidelines

Recommendations for the management of cardio-
.. 8.3 Management of arrhythmias and
genic shock in ST-elevation myocardial infarction .. conduction disturbances in the acute
.. phase
Recommendations Classa Levelb .. Arrhythmias and conduction disturbances are common during the
Immediate PCI is indicated for patients with
.. early hours of STEMI and are also important prognostic factors.438
.. Despite increased awareness and improved basic and advanced life
cardiogenic shock if coronary anatomy is ..
.. support, the incidence of sudden cardiac death, mainly due to fast
suitable. If coronary anatomy is not suitable .. ventricular tachycardia (VT) and VF in the pre-hospital phase,
for PCI, or PCI has failed, emergency CABG ..
.. remains high.438,439 Early reperfusion therapy reduces the risk of ven-
is recommended.248 .. tricular arrhythmias and cardiovascular death.440,441 The presence of
Invasive blood pressure monitoring with an .. life-threatening arrhythmias requires an urgent need for a fast and
arterial line is recommended.
I C .. complete revascularization in STEMI.438,442 The evidence for benefits
.. of antiarrhythmic drugs in STEMI patients is limited and negative
Immediate Doppler echocardiography is .. effects of antiarrhythmic drugs on early mortality have been demon-
indicated to assess ventricular and valvular ..
I C .. strated.439 Careful use of antiarrhythmic drugs is generally recom-
functions, loading conditions, and to detect .. mended and alternative treatment options such as electrical
mechanical complications. ..
.. cardioversion, a ‘wait and see’ strategy for arrhythmias with no or
.. moderate haemodynamic relevance, or in selected cases cardiac pac-
It is indicated that mechanical complications ..
are treated as early as possible after discus- I C ... ing and catheter ablation, should be considered. Correction of elec-
sion by the Heart Team. .. trolyte imbalances and early treatment with beta-blockers, ACE
.. inhibitors/ARBs, and statins is recommended.438,443
Oxygen/mechanical respiratory support is
I C ..
indicated according to blood gases. ..
Fibrinolysis should be considered in patients ..
.. 8.3.1 Supraventricular arrhythmias
presenting with cardiogenic shock if a pri- .. The most frequent supraventricular arrhythmia is AF, with up to
mary PCI strategy is not available within IIa C ..
.. 21% of STEMI patients affected.444 AF may be pre-existing, first-
120 min from STEMI diagnosis and mechani- .. time detected, or of new onset. Patients with AF have more
cal complications have been ruled out.
.. comorbidities and are at higher risk for complications.445 In many
.. cases, the arrhythmia is well tolerated and no specific treatment is
Complete revascularization during the index ..
procedure should be considered in patients IIa C .. required, other than anticoagulation.5 Prompt treatment is
.. required in acute haemodynamic instability. There is scarce infor-
presenting with cardiogenic shock. ..
.. mation indicating preferences for rate control over rhythm control
Intra-aortic balloon pumping should be con- .. in this situation.446 Electrical cardioversion should be considered
sidered in patients with haemodynamic
IIa C .. but early recurrence of AF is frequent after successful cardiover-
instability/cardiogenic shock due to mechan- .. sion. Acute rhythm control with antiarrhythmic drugs is limited to
ical complications. .. the use of amiodarone.5,444 Adequate rate control can be accom-
.. plished by administration of beta-blockers.438,446 In patients with
Haemodynamic assessment with pulmonary ..
artery catheter may be considered for con- IIb B
.. extensive myocardial damage or severe LV dysfunction, rate con-
firming diagnosis or guiding therapy.433 .. trol is more safely achieved with i.v. digoxin with or without con-
.. comitant administration of i.v. amiodarone. When co-
Ultrafiltration may be considered for ..
.. administering i.v. digoxin and amiodarone, close monitoring for
patients with refractory congestion, who .. digoxin toxicity is necessary as digoxin serum concentrations may
failed to respond to diuretic-based
IIb B ..
.. be increased. Several, but not all, studies have suggested that new-
strategies.434–436 .. onset AF may be reduced by beta-blockers, ACE inhibitors/ARBs,
Inotropic/vasopressor agents may be con- .. and also early-onset statin therapy.444 Patients with AF and risk fac-
IIb C .. tors for thromboembolism should be adequately treated with
sidered for haemodynamic stabilization. ..
.. chronic oral anticoagulation.5 STEMI patients with documented AF
Short-term mechanical supportc may be .. have worse short- and long-term prognoses when compared with
IIb C ..
considered in patients in refractory shock. .. patients in sinus rhythm.445,447 Presence of AF is associated with a
.. higher reinfarction rate, higher stroke rate, higher risk for heart fail-
Routine intra-aortic balloon pumping is not ..
III B .. ure, and may also increase the risk for sudden cardiac
.. death.444,445,448 Of note, also transient, self-terminating AF during
.. STEMI relates to a significantly higher stroke rate during long-term
CABG = coronary artery bypass graft surgery; ECLS = extracorporeal life sup- .. follow-up.445,448
port; ECMO = extracorporeal membrane oxygenation; PCI = percutaneous cor-
onary intervention; STEMI = ST-segment elevation myocardial infarction.
Class of recommendation.
Level of evidence.
Percutaneous cardiac support devices, ECLS, and ECMO.
ESC Guidelines 41

.. 8.3.2 Ventricular arrhythmias
Management of atrial fibrillation ..
.. The incidence of VT and VF has declined over recent decades,
.. most probably due to the uptake of reperfusion strategies and the
Recommendations Classa Levelb
... early use of beta-blockers.3 However, 6–8% of patients still
.. develop haemodynamically significant VT or VF during this
Acute rate control of AF ..
.. phase.439 The typical arrhythmia presentation is unstable, fre-
Intravenous beta-blockers are indicated for .. quently polymorphic, and relatively fast VT, often degenerating
rate control if necessary and there are no
I C .. into VF. Urgent reperfusion is most important as ischaemia often
clinical signs of acute heart failure or .. triggers these arrhythmias.72 Beta-blockers are recommended if no
.. contraindications exist.346,347,350,454 Repetitive electrical cardiover-
.. sion or defibrillation may be necessary.455 If there is no sufficient
Intravenous amiodarone is indicated for rate ..
control if necessary in the presence of con- .. control, i.v. administration of amiodarone should be consid-
I C .. ered.439,456 In case of contraindications to amiodarone, i.v. lido-
comitant acute heart failure and no ..
.. caine may be considered, although no studies comparing
.. superiority of either drug in STEMI patients are available. The prog-
Intravenous digitalis should be considered .. nostic role of early VT/VF within the first 48 h of STEMI is still con-
for rate control if necessary in the presence .. troversial. Available data suggest that patients with early VT/VF
IIa B ..
of concomitant acute heart failure and .. have increased 30-day mortality but no increased long-term
hypotension.451 .. arrhythmic risks.442,457,458
.. VT or VF may occur at the time of restoration of coronary blood
Cardioversion .. flow (reperfusion arrhythmias). No specific antiarrhythmic drug
Immediate electrical cardioversion is indi- .. therapy is necessary due to the benign long-term course.
cated when adequate rate control cannot
.. Ventricular premature beats are very frequent on the first day of
be achieved promptly with pharmacological .. the acute phase and complex arrhythmias (multiform complexes,
agents in patients with AF and ongoing
I C ..
.. short runs, or the R-on-T phenomenon) are common. Their value
ischaemia, severe haemodynamic compro- .. as predictors of VF is questionable and no specific therapy is
mise, or heart failure.
.. required. Sustained VT or VF outside the early phase (usually 48 h
.. after STEMI onset) not triggered by recurrent ischaemia has a poor
Intravenous amiodarone is indicated to pro- ..
mote electrical cardioversion and/or .. prognostic implication, and evaluation for ICD implantation for sec-
.. ondary prevention of sudden cardiac death is recommended
decrease risk for early recurrence of AF I C ..
.. according to current guidelines.3 Primary prevention of sudden car-
after electrical cardioversion in unstable ..
.. diac death with the ICD within 40 days after MI in the absence of
patients with recent onset AF.
.. VT/VF is generally not indicated.3 Patients should be re-evaluated
In patients with documented de novo AF .. for ICD implantation 6–12 weeks after revascularization, although
during the acute phase of STEMI, long-term .. those with pre-existing impaired LVEF may be considered for ICD
oral anticoagulation should be considered .. implantation for primary prevention even within the early post-
IIa C ..
depending on CHA2DS2-VASc score and .. infarction period.3,438
taking concomitant antithrombotic therapy .. Some patients may develop electrical storm and/or incessant VT
into account.5,444 .. despite complete revascularization and treatment with antiarrhyth-
.. mic drugs. Overdrive stimulation may help to control this situation;
Digoxin is ineffective in converting recent ..
.. however, recurrence of VT/VF upon cessation of stimulation is fre-
onset AF to sinus rhythm and is not indi- III A .. quent and catheter ablation of such triggers appears to be the only
cated for rhythm control.452,453 ..
.. treatment option. Successful radiofrequency ablation has been
Calcium channel blockers and beta-blockers
.. shown to abolish recurrent VT/VF.459–461
including sotalol are ineffective in converting III B ..
recent onset AF to sinus rhythm.453

Prophylactic treatment with antiarrhythmic
drugs to prevent AF is not indicated.438,444

AF = atrial fibrillation; CHA2DS2-VASc = Cardiac failure, Hypertension, Age 75
(Doubled), Diabetes, Stroke (Doubled) – VAScular disease, Age 65–74 and Sex
category (Female); STEMI = ST-segment elevation myocardial infarction.
Class of recommendation.
Level of evidence.
42 ESC Guidelines

Management of ventricular arrhythmias and conduc- Long-term management of ventricular arrhythmias
tion disturbances in the acute phase and risk evaluation for sudden death

Recommendations Classa Levelb Recommendations Classa Levelb

Intravenous beta-blocker treatment is indicated ICD therapy is recommended to reduce sudden
for patients with polymorphic VT and/or VF unless I B cardiac death in patients with symptomatic heart
contraindicated.462,463 failure (NYHA class II–III) and LVEF <_35% despite
optimal medical therapy for >3 months and I A
Prompt and complete revascularization is recom-
6 weeks after MI, who are expected to survive
mended to treat myocardial ischaemia that may
I C for at least 1 year with good functional
be present in patients with recurrent VT and/or
ICD implantation or temporary use of a wearable
Intravenous amiodarone is recommended for
I C cardioverter defibrillator may be considered <40
treatment of recurrent polymorphic VT.3
days after MI in selected patients (incomplete
Correction of electrolyte imbalances (especially revascularization, pre-existing LVEF dysfunction,
hypokalaemia and hypomagnesemia) is recom- I C occurrence of arrhythmias >48 h after STEMI
mended in patients with VT and/or VF.3 onset, polymorphic VT or VF).

In cases of sinus bradycardia with haemodynamic
ICD = implantable cardioverter defibrillator; LVEF = left ventricular ejection frac-
intolerance or high degree AV block without
tion; MI = myocardial infarction; NYHA = New York Heart Association; STEMI =
stable escape rhythm: ST-segment elevation myocardial infarction; VF = ventricular fibrillation; VT =
 i.v. positive chronotropic medication (epinephrine, ventricular tachycardia.
I C a
Class of recommendation.
vasopressin, and/or atropine) is indicated b
Level of evidence.
 temporary pacing is indicated in cases of failure to
respond to positive chronotropic medication
 urgent angiography with a view to revasculariza-
tion is indicated if the patient has not received pre- I C
vious reperfusion therapy.
Intravenous amiodarone should be considered for .. 8.3.3 Sinus bradycardia and atrioventricular block
recurrent VT with haemodynamic intolerance IIa C ..
.. Sinus bradycardia is common in the first hours of STEMI, especially in
despite repetitive electrical cardioversion.438 .. inferior MI. In some cases, opioids are responsible.468 It often
Transvenous catheter pace termination and/or .. requires no treatment. If accompanied by severe hypotension, sinus
overdrive pacing should be considered if VT can- .. bradycardia should be treated with i.v. atropine. Second-degree type
IIa C ..
not be controlled by repetitive electrical .. I (Mobitz I or Wenckebach) AV block is usually associated with infe-
cardioversion. .. rior wall MI and seldom causes adverse haemodynamic effects. If so,
Radiofrequency catheter ablation at a specialized .. atropine should be used first; if it fails, pacing should be instituted.
ablation centre followed by ICD implantation ..
.. Agents that slow AV conduction (such as beta-blockers, digitalis,
should be considered in patients with recurrent IIa C .. verapamil, or amiodarone) should be used with caution. Second-
VT, VF, or electrical storm despite complete ..
revascularization and optimal medical therapy. .. degree type II (Mobitz II) AV block and complete AV block may be
... indications for pacing. AV sequential pacing should be considered in
Recurrent VT with haemodynamic repercussion .. patients with complete AV block, RV infarction, and haemodynamic
despite repetitive electrical cardioversion may be ..
.. compromise. Revascularization should be considered in patients with
treated with lidocaine if beta-blockers, amiodar- IIb C .. AV block who have not yet received reperfusion therapy (e.g. late
one, and overdrive stimulation are not effective/ ..
applicable.438 .. arrival).
.. AV block associated with inferior wall infarction is usually supra-
Prophylactic treatment with antiarrhythmic drugs
III B .. Hisian and usually resolves spontaneously or after reperfusion. AV
is not indicated and may be harmful.464,465 .. block associated with anterior wall MI is usually infra-Hisian and has a
Asymptomatic and haemodynamically irrelevant .. high mortality rate due to the extensive myocardial necrosis. The
ventricular arrhythmias should not be treated III C
.. development of a new bundle branch block or hemiblock usually indi-
with antiarrhythmic drugs. .. cates extensive anterior MI. A transvenous pacing electrode should
.. be inserted in the presence of advanced AV block with a low escape
AV = atrioventricular; i.v. = intravenous; ICD = implantable cardioverter defibril- .. rhythm, as described above, and considered if bifascicular or trifascic-
lator; VF = ventricular fibrillation; VT = ventricular tachycardia. .. ular block develops. Indications for pacing are outlined in detail in the
Class of recommendation. ..
Level of evidence. .. ESC Guidelines for cardiac pacing and cardiac resynchronization
.. therapy.469
ESC Guidelines 43

8.4 Mechanical complications Table 10 Diagnostic criteria for myocardial infarction
Mechanical complications may occur in the first days following with non-obstructive coronary arteries (adapted from
STEMI, although incidence has fallen significantly in the era of primary Agewall et al12)
PCI. Mechanical complications are life-threatening and need prompt
detection and management. Sudden hypotension, recurrence of
chest pain, new cardiac murmurs suggestive of mitral regurgitation or
ventricular septal defect, pulmonary congestion, or jugular vein dis-
tension should raise suspicion. Immediate echocardiographic assess-
ment is needed when mechanical complications are suspected. A full
section describing mechanical complications can be found in the
Web Addenda.

8.4.1 Free wall rupture
See Web Addenda.
AMI = acute myocardial infarction; IRA = infarct-related artery; MINOCA = myo-
8.4.2 Ventricular septal rupture cardial infarction with non-obstructive coronary arteries.
See Web Addenda.
.. secondary to epicardial coronary artery disorders (e.g. atheroscler-
8.4.3 Papillary muscle rupture ..
See Web Addenda.
.. otic plaque rupture, ulceration, fissuring, erosion, or coronary dissec-
.. tion with non-obstructive or no CAD) (MI type 1); (2) imbalance
.. between oxygen supply and demand (e.g. coronary artery spasm and
8.5 Pericarditis ..
.. coronary embolism) (MI type 2); (3) coronary endothelial dysfunc-
Three major pericardial complications may occur: early infarct-
.. tion (e.g. microvascular spasm) (MI type 2); and (4) secondary to
associated pericarditis, late pericarditis or post-cardiac injury ..
.. myocardial disorders without involvement of the coronary arteries
(Dressler syndrome), and pericardial effusion. These are expanded .. (e.g. myocarditis470 or Takotsubo syndrome). The last two entities
upon in the Web Addenda. ..
.. may mimic MI but are better classified as myocardial injury condi-
.. tions. The identification of the underlying cause of MINOCA should
8.5.1 Early and late (Dressler syndrome) ..
infarct-associated pericarditis
.. lead to specific treatment strategies. Although the outcome of
.. MINOCA strongly depends on the underlying cause, its overall prog-
See Web Addenda. ..
.. nosis is serious, with a 1 year mortality of about 3.5%.10
.. To determine the cause of MINOCA, the use of additional diag-
8.5.2 Pericardial effusion ..
.. nostic tests beyond coronary angiography is recommended. In gen-
See Web Addenda. .. eral, after ruling out obstructive CAD in a patient presenting with
.. STEMI, an LV angiogram or echocardiography should be considered
.. in the acute setting to assess wall motion or pericardial effusion. In
9. Myocardial infarction with ..
.. addition, if any of the possible aetiologies described above is sus-
non-obstructive coronary arteries .. pected, additional diagnostic tests may be considered.
.. CMR is a very helpful imaging technique due to its unique non-
A sizeable proportion of MIs, ranging between 1–14%, occur in the .. invasive tissue characterization, allowing the identification of wall
absence of obstructive (>50% stenosis) CAD.10,11 The demonstra- .. motion abnormalities, presence of oedema, and myocardial scar/fib-
tion of non-obstructive (<50%) CAD in a patient presenting with .. rosis presence and pattern. Performance of CMR within 2 weeks
symptoms suggestive of ischaemia and ST-segment elevation or .. after onset of symptoms should be considered to increase the diag-
equivalent does not preclude an atherothrombosis aetiology, as .. nostic accuracy of the test for identifying the aetiological cause of
thrombosis is a very dynamic phenomenon and the underlying athe- .. MINOCA.471–473
rosclerotic plaque can be non-obstructive. ..
The diagnostic criteria of MINOCA are presented in Table 10. ..
MINOCA is a working diagnosis and should lead the treating physician
.. 10. Assessment of quality of care
to investigate underlying causes. Failure to identify the underlying cause ..
may result in inadequate and inappropriate therapy in these patients. .. There is a wide practice gap between optimal and actual care
The description of the pathophysiology of the different aetiological .. for patients with STEMI in hospitals around the world.474,475 To
entities leading to MINOCA is beyond the scope of the present .. reduce this gap and improve quality of care, it is recommended that
document, and has been extensively described and defined in posi- .. STEMI networks and their individual components establish measura-
tion papers from the ESC12 and in dedicated review papers.10,11 .. ble quality indicators, systems to measure and compare these indica-
MINOCA patients can fulfil the criteria for both MI type 1 and type 2 .. tors, perform routine audits, and implement strategies to ensure that
according to the universal definition of MI.8 There are disparate aeti-
.. every patient with STEMI receives the best possible care according
ologies causing MINOCA and they can be grouped into: (1) . to accepted standards and has the best possible outcomes
44 ESC Guidelines

Figure 7 Diagnostic test flow chart in MINOCA. CMR = Cardiac Magnetic Resonance; IVUS = IntraVascular UltraSound; LV = Left Ventricle;
MINOCA = Myocardial Infarction with Non-Obstructed Coronary Arteries; OCT = Optical Coherence Tomography; STEMI = ST segment
Elevation Myocardial Infarction; TOE = Trans-Oesofageal Echocardiography; TTE = Trans-Thoracic Echocardiography. Takotsubo syndrome cannot
be diagnosed with certainty in the acute phase as the definition requires follow up imaging to document recovery of left ventricular function. IVUS
and OCT frequently show more atherosclerotic plaque than may be appreciated on angiography. They also increase sensitivity for dissection. If intra-
coronary imaging is to be performed, it is appropriate to carry out this imaging at the time of the acute cardiac catheterization, after diagnostic angiog-
raphy. Patients should be made aware of the additional information the test can provide and the small increase in risk associated with intracoronary
1 • Provocative testing for coronary artery spasm might be considered in selected patients with a recent AMI with suspected vasospas-
tic angina. Provocative manoeuvres have to be always performed by operators with experience and not necessarily in the acute phase
2 • Clinically suspected myocarditis by ESC Task Force criteria = No angiographic stenosis 50% plus non ischemic pattern on CMR.
Definite myocarditis by ESC Task Force criteria = No angiographic stenosis 50% plus endomyocardial biopsy confirmation (histology,
immunohistology, polymerase-chain reaction based techniques to search for genome of infectious agents, mainly viruses).
ESC Guidelines 45

Table 11 Quality indicators

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; DAPT = dual antiplatelet therapy; ECG = electrocardiogram; GRACE = Global Registry of
Acute Coronary Events; IRA = Infarct-related artery; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myo-
cardial infarction.

(see Web Addenda). Quality indicators are intended to measure and ..
11. Gaps in the evidence and areas
compare the quality of health service provision and serve as a founda- ..
for future research
tion for quality improvement initiatives.476 Proposed quality indica-
tors to assess the quality of the care for patients are presented in .. Despite the great advances in STEMI management over recent deca-
Table 11. .. des, important areas of uncertainty persist that should be explored in
Expanded text about quality indicators can be found in the Web .. the future. Here, we identify some, but not all, specific areas that
Addenda. .. should be addressed within the next few years.
46 ESC Guidelines

Public awareness and emergency care .. STEMI has not been prospectively tested in dedicated clinical trials of
.. reperfused patients. Similar limitations apply to the use of mainte-
The very early stages of STEMI are the most vulnerable time, when ..
most sudden cardiac deaths occur. Public campaigns aiming to .. nance ACE inhibitors.
increase early alerting of patients with ischaemic symptoms should ..
clearly state that the safest way to alert is to call the EMS. While ..
.. Post-STEMI risk stratification
selected centres and geographic areas have made great progress in .. The optimal therapeutic strategy to minimize the risk of sudden
ensuring high-quality rapid care for STEMI patients with routine pre- ..
.. death in patients who develop VT or VF during or early after STEMI
alert of the interventional team, there remains a need for streamlining ..
.. is not entirely clear. Despite the clinical benefit of ICDs in patients
of (pre-)hospital management in a homogeneous fashion worldwide, .. with low LVEF and reduced functional class weeks after STEMI being
including rural areas. Educational programmes and cross-country ..
exchange of experiences should help in this matter. .. well established, there is a need for better sudden death risk stratifi-
.. cation algorithms.
The selection of a 120 min from STEMI diagnosis to PCI-mediated ..
reperfusion as the cut-off to choose PCI or fibrinolysis is based on .. The best management of non-IRA lesions should be addressed.
.. Unresolved issues are the best criteria to guide PCI (angiography,
relatively old registries and trials with different treatment strategies ..
from those presented in this document. The identification of the best
.. FFR, or assessment of plaque vulnerability) and the best timing for
.. complete revascularization if indicated (during index PCI or staged,
cut-off timing to choose a strategy is of extreme importance. ..
.. including staged during hospitalization vs. after discharge).
Reduction of ischaemia/reperfusion ...
.. Shock and left ventricular assist devices
injury ..
Final infarct size is one of the best predictors of long-term adverse .. Severe heart failure and shock are among the most important nega-
events in STEMI survivors. The introduction of a specific infarct- .. tive prognostic predictors in patients with STEMI. In addition to
limiting therapy in clinical practice might have a massive clinical and .. urgent revascularization of IRA and standard medical therapies for
socioeconomic impact. Several strategies, including pharmacological .. pre- and afterload reduction, there is limited evidence for the system-
and mechanical therapies, have shown a reduction of infarct size by .. atic use of inotropic and vasopressor agents as well as mechanical
reducing ischaemia/reperfusion injury (including MVO) in experimen- .. support. Similarly, the benefit of routine complete revascularization
tal and small-scale clinical trials, but to date no large trial has demon- .. during the index PCI procedure has not been formally demonstrated.
strated a clinical benefit. One potential reason for this poor .. The use of IABP has not met prior expectations of benefit, while LV
translation is the difficulty of securing funds to conduct proper large- .. assist devices and ECMO are increasingly popular but have not been
scale clinical trials in this context. .. sufficiently evaluated in clinical trials. Systematic evaluation of phar-
.. macological and interventional strategies and LV assist devices for
Refinement of (acute and long-term) .. patients with shock are urgently needed.
antithrombotic regimes ..
Antithrombotic therapy is the cornerstone of the pharmacological .. Myocardial repair/rescue
approach in STEMI. Despite major recent advances, important ques- ..
.. The effectiveness and safety of novel therapies able to replace dead
tions remain unaddressed. What is the best acute and maintenance .. myocardium or prevent poor remodelling (e.g. cell therapy or gene
antithrombotic regimen in patients who have an indication for oral ..
.. therapy) is an unfulfilled promise. There is a strong need for basic
anticoagulants? What is the best timing for the loading dose of oral .. research studies to better understand the biological processes
P2Y12 inhibitors and what are the best strategies for i.v. antithrom- ..
.. involved in cardiac development and repair, in order for there to be
botic therapies? What is the role of potent P2Y12 inhibitors in .. strong grounds to translate studies into clinically relevant animal
patients undergoing fibrinolysis? What is the real role of aspirin in this ..
.. models and finally into humans.
new era of potent antiplatelet agents and low dose anticoagulation? ..
What is the best duration of maintenance therapy with P2Y12 inhibi- ..
tors as single or multiple antithrombotic regimens? .. Need for observational data and real-
.. world evidence
Beta-blockers and ACE inhibitors .. In order to understand shortcomings and challenges in clinical prac-
Although research regarding these classes of drugs was intense sev- .. tice, for quality assessment and for benchmarking, unselected and
eral decades ago, more recently, there has been a lack of properly .. validated registries and clinical databases are needed. In this docu-
powered clinical trials. The best timing for initiation (and route of .. ment, we have specified quality indicators intended to measure and
administration) of beta-blockers is still not well established. The role
.. compare the quality of health service provision and serve as a founda-
of maintenance beta-blocker therapy is well established for patients .. tion for quality improvement initiatives. Their effects on procedural
with heart failure and/or low LVEF, but its clinical value for the rest of
.. and clinical outcomes need to be evaluated.
ESC Guidelines 47

.. (6) Cardiac arrest and reperfusion strategy: Patients with ST-elevation
Need for pragmatic real-life clinical trials ..
One major limitation of highly selective controlled clinical trials is
.. on post-resuscitation ECG should undergo a primary PCI strategy.
their applicability in the real world. Strict inclusion criteria, tailored .. In cases without ST-segment elevation on post-resuscitation ECG
management, and very close follow-up results in a bias that precludes
.. but with a high suspicion of ongoing myocardial ischaemia, urgent
universal implementation. An opportunity is the implementation of .. angiography should be done within 2 h after a quick evaluation to
.. exclude non-coronary causes. In all cases, the decision to perform
pragmatic clinical trials including registry-based randomized clinical ..
trials.477 These trials are less selective and less expensive alternatives .. urgent coronary angiography should take into account factors
.. associated with poor neurological outcome.
to classical ones, especially for therapies used in clinical practice. ..
.. (7) Technical aspects during primary PCI: Routine radial access and
.. routine DES implant is the standard of care during primary PCI.
12. Key messages .. Routine thrombus aspiration or deferred stenting are
.. contraindicated.
(1) Epidemiology of STEMI: Although the rate of mortality associated .. (8) Management of non-IRA lesions: Treatment of severe stenosis
.. (evaluated either by angiography or FFR) should be considered
with ischaemic heart disease have reduced in Europe over the last ..
few decades, this is still the single most common cause of death .. before hospital discharge (either immediately during the index PCI
.. or staged at a later time). In cardiogenic shock, non-IRA PCI should
worldwide. The relative incidences of STEMI and NSTEMI are ..
decreasing and increasing, respectively. Despite the decline in .. be considered during the index procedure.
.. (9) Antithrombotic therapy: Anticoagulants and DAPT are the cor-
acute and long-term death associated with STEMI, in parallel with ..
the widespread use of reperfusion, mortality remains substantial. .. nerstone of the pharmacological approach in the acute phase of
.. STEMI. Primary PCI: unfractionated heparin (enoxaparin and biva-
The in-hospital mortality rates of unselected patients with STEMI ..
in national European registries vary between 4–12%. .. lirudin may be alternative), and loading dose of aspirin and prasu-
.. grel/ticagrelor. Fibrinolysis: enoxaparin (unfractionated heparin
(2) Gender aspects: Women tend to receive reperfusion therapy and ..
other evidence-based treatments less frequently and/or in a .. may be alternative), and loading dose of aspirin and clopidogrel.
delayed way than men. It is important to highlight that women and .. Maintenance therapy in the majority of patients is based on one
men receive equal benefit from a reperfusion and other STEMI-
.. year DAPT in the form of aspirin plus prasugrel/ticagrelor.
related therapies, and so both genders must be managed equally. .. (10) Early care: After reperfusion therapy, patients should be moni-
(3) ECG and STEMI diagnosis: In some cases, patients may have coro-
.. tored for at least 24 h. Early ambulation and early discharge are the
nary artery occlusion/global ischaemia in the absence of character- .. best option in uncomplicated patients. Consequently, time for
istic ST elevation (e.g. bundle branch block, ventricular pacing,
.. implementing secondary prevention is limited highlighting the
hyperacute T-waves, isolated ST-depression in anterior leads, and/ .. importance of close collaboration between all stakeholders.
or universal ST depression with ST-elevation in aVR). In patients
.. (11) Special patient subsets: Patients taking oral anticoagulants with
with the mentioned ECG changes and clinical presentation com- .. renal insufficiency and/or the elderly represent a challenge in terms
.. of optimal antithrombotic therapy. Special attention should be
patible with ongoing myocardial ischaemia, a primary PCI strategy ..
(i.e. urgent angiography and PCI if indicated) should be followed. .. paid to dose adjustment of some pharmacological strategies in
.. these subsets. Patients with diabetes and those not undergoing
(4) Reperfusion strategy selection: STEMI diagnosis (defined as the ..
time at which the ECG of a patient with ischaemic symptoms is .. reperfusion represent another subset of patients that require addi-
.. tional attention.
interpreted as presenting ST-segment elevation or equivalent) is ..
the time zero in the reperfusion strategy clock. STEMI patients .. (12) Imaging in STEMI: Non-invasive imaging is very important for the
.. acute and long-term management of STEMI patients.
should undergo a primary PCI strategy unless the anticipated abso- ..
lute time from STEMI diagnosis to PCI-mediated reperfusion .. (13) MINOCA: A sizeable proportion of STEMI patients do not present
.. significant coronary artery stenosis on urgent angiography. It is
is > 120 min, when fibrinolysis should be initiated immediately (i.e. ..
within 10 min of STEMI diagnosis). .. important to perform additional diagnostic tests in these patients
.. to identify the aetiology and tailor appropriate therapy, which may
(5) STEMI management networks: Coordination between EMS and ..
hospitals with common written protocols is at the centre of .. be different from typical STEMI.
.. (14) Quality indicators: In some cases, there is a gap between optimal
STEMI management. EMS should transfer patients to 24/7 high- ..
volume PCI centres irrespective of whether the primary treatment ... guideline-based treatment and actual care of STEMI patients. In
strategy is PCI or pre-hospital fibrinolysis. EMS should always alert
.. order to reduce this gap, it is important to measure established
the PCI centre immediately after selection of the reperfusion strat- .. quality indicators to audit practice and improve outcomes in real-
egy. Patient transfer to the PCI centre should bypass the emer-
.. life. The use of well-defined and validated quality indicators to
gency department. . measure and improve STEMI care is recommended.
48 ESC Guidelines

13. Evidenced-based ‘to do and not to do’ messages from the Guidelines


Recommendations for initial diagnosis Classa Levelb

Twelve-lead ECG recording and interpretation is indicated as soon as possible at the point of FMC, with a maximum target
delay of 10 min.

ECG monitoring with defibrillator capacity is indicated as soon as possible in all patients with suspected STEMI. I B

Recommendations for relief of hypoxaemia and symptoms

Routine oxygen is not recommended in patients with SaO2 90%. III B

Recommendations for cardiac arrest

A primary PCI strategy is recommended in patients with resuscitated cardiac arrest and an ECG consistent with STEMI. I B

Targeted temperature management is indicated early after resuscitation of cardiac arrest patients who remain unresponsive. I B

Pre-hospital cooling using a rapid infusion of large volumes of cold i.v. fluid immediately after return of spontaneous circulation
is not recommended.

Recommendations for logistics of pre-hospital care

It is recommended that the pre-hospital management of STEMI patients is based on regional networks designed to deliver
reperfusion therapy expeditiously and effectively, with efforts made to make primary PCI available to as many patients as I B

It is recommended that primary PCI-capable centres deliver a 24/7 service and are able to perform primary PCI without delay. I B

It is recommended that patients transferred to a PCI-capable centre for primary PCI bypass the emergency department and
CCU/ICCU and are transferred directly to the catheterization laboratory.

Recommendations for reperfusion therapy

Reperfusion therapy is indicated in all patients with symptoms of ischaemia of <_ 12 h duration and persistent ST-segment

If primary PCI cannot be performed in a timely way after STEMI diagnosis, fibrinolytic therapy is recommended within 12 h of
symptom onset in patients without contraindications.

In asymptomatic patients, routine PCI of an occluded IRA >48 h after onset of STEMI is not indicated. III A

Recommendations for procedural aspects of the primary PCI strategy

Primary PCI of the IRA is indicated. I A

Stenting is recommended (over balloon angioplasty) for primary PCI. I A

Stenting with new-generation DES is recommended over BMS for primary PCI. I A

Radial access is recommended over femoral access if performed by an experienced radial operator. I A

Routine use of thrombus aspiration is not recommended. III A

Routine use of deferred stenting is not recommended. III B

Recommendations for periprocedural and post-procedural antithrombotic therapy in patients undergoing primary PCI

A potent P2Y12 inhibitor (prasugrel or ticagrelor), or clopidogrel if these are not available or are contraindicated, is recom-
mended before (or at latest at the time of) PCI and maintained over 12 months unless there are contraindications such as I A
excessive risk of bleeding.
ESC Guidelines 49

Aspirin oral or i.v. (if unable to swallow) is recommended as soon as possible for all patients without contraindications. I B

Fondaparinux is not recommended for primary PCI. III B

Recommendations for Fibrinolytic therapy

When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after STEMI diag-
nosis, preferably in the pre-hospital setting.

A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended. I B

Oral or i.v. aspirin is indicated. I B

Clopidogrel is indicated in addition to aspirin. I A

Anticoagulation is recommended in patients treated with lytics until revascularization (if performed) or for the duration of hos-
pital stay up to 8 days. The anticoagulant can be:

 Enoxaparin i.v. followed by s.c. (preferred over UFH). I A

 UFH given as a weight-adjusted i.v. bolus followed by infusion. I B

Transfer to a PCI-capable centre following fibrinolysis is indicated in all patients immediately after fibrinolysis. I A

Emergency angiography and PCI if indicated is recommended in patients with heart failure/shock. I A

Rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-segment resolution at 60–90 min) or at any time in
the presence of haemodynamic or electrical instability, or worsening ischaemia.

Angiography and PCI of the IRA, if indicated, is recommended between 2–24 h after successful fibrinolysis. I A

Emergency angiography and PCI if needed is indicated in the case of recurrent ischaemia or evidence of reocclusion after initial
successful fibrinolysis.

Recommendations for imaging and stress testing in STEMI patients

Routine echocardiography during hospital stay to assess resting LV and RV function, detect early post-MI mechanical complica-
tions, and exclude LV thrombus is recommended in all patients.

Recommendations for behavioural aspects after STEMI

It is recommended to identify smokers and provide repeated advice on stopping, with offers to help with the use of follow-up
support, nicotine replacement therapies, varenicline, and bupropion individually or in combination.

Participation in a cardiac rehabilitation programme is recommended. I A

Recommendations for maintenance antithrombotic strategy after STEMI

Antiplatelet therapy with low-dose aspirin (75–100 mg) is indicated. I A

DAPT in the form of aspirin plus ticagrelor or prasugrel (or clopidogrel if ticagrelor or prasugrel are not available or are contra-
indicated) is recommended for 12 months after PCI, unless there are contraindications such as excessive risk of bleeding.

A PPI in combination with DAPT is recommended in patients at high risk of gastrointestinal bleeding. I B

Recommendations for routine therapies in the acute, subacute, and long-term phases

Oral treatment with beta-blockers is indicated in patients with heart failure and/or LVEF <_40% unless contraindicated. I A

Intravenous beta-blockers must be avoided in patients with hypotension, acute heart failure, or AV block or severe bradycardia. III B

It is recommended to start high-intensity statin therapy as early as possible, unless contraindicated, and maintain it long-term. I A

An LDL-C goal of < 1.8 mmol/L (70 mg/dL) or a reduction of at least 50% if the baseline LDL-C is between 1.8–3.5 mmol/L
(70–135 mg/dL) is recommended.

ACE inhibitors are recommended, starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic
dysfunction, diabetes, or an anterior infarct.
50 ESC Guidelines

An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure and/or LV systolic dysfunction,
particularly those who are intolerant of ACE inhibitors.

MRAs are recommended in patients with an ejection fraction <_40% and heart failure or diabetes, who are already receiving an
ACE inhibitor and a beta-blocker, provided there is no renal failure or hyperkalaemia.

Recommendations for the management of LV dysfunction and acute heart failure in STEMI

ACE inhibitor (or if not tolerated, ARB) therapy is indicated as soon as haemodynamically stable for all patients with evidence
of LVEF <_40% and/or heart failure to reduce the risk of hospitalization and death.

Beta-blocker therapy is recommended in patients with LVEF <_40% and/or heart failure after stabilization, to reduce the risk of
death, recurrent MI, and hospitalization for heart failure.

An MRA is recommended in patients with heart failure and LVEF <_40% with no severe renal failure or hyperkalaemia to reduce
the risk of cardiovascular hospitalization and death.

Recommendations for the management of cardiogenic shock in STEMI

Immediate PCI is indicated for patients with cardiogenic shock if coronary anatomy is suitable. If coronary anatomy is not suit-
able for PCI, or PCI has failed, emergency CABG is recommended.

Routine intra-aortic balloon pumping is not indicated. III B

Recommendations for management of atrial fibrillation

Digoxin is ineffective in converting recent onset AF to sinus rhythm and is not indicated for rhythm control. III A

Calcium channel blockers and beta-blockers including sotalol are ineffective in converting recent onset AF to sinus rhythm. III B

Prophylactic treatment with antiarrhythmic drugs to prevent AF is not indicated. III B

Recommendations for management of ventricular arrhythmias and conduction disturbances in the acute phase

Intravenous beta-blocker treatment is indicated for patients with polymorphic VT and/or VF unless contraindicated. I B

Prophylactic treatment with antiarrhythmic drugs is not indicated and may be harmful. III B

Recommendations for long-term management of ventricular arrhythmias and risk evaluation for sudden death

ICD therapy is recommended to reduce sudden cardiac death in patients with symptomatic heart failure (New York Heart
Association class II–III) and LVEF <_35%, despite optimal medical therapy for >3 months and at least 6 weeks after MI, who are I A
expected to survive for at least 1 year with good functional status.

Recommendations with a class I or III and a level of evidence A or B. See ‘Abbreviations and acronyms’ list for explanation of abbreviations.
Class of recommendation.
Level of evidence.

14. Web addenda ..
Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland),
.. Gerhard Hindricks (Germany), Bernard Iung (France), Peter Jüni
All Web figures and Web tables are available in the online Web .. (Canada), Hugo A. Katus (Germany), Juhani Knuuti (Finland), Patrizio
Addenda at: European Heart Journal online and also via the ESC ... Lancellotti (Belgium), Christophe Leclercq (France), Theresa McDonagh
Website at: .. (UK), Massimo Francesco Piepoli (Italy), Piotr Ponikowski (Poland),
Guidelines/Acute-Myocardial-Infarction-in-patients-presenting-with- .. Dimitrios J. Richter (Greece), Marco Roffi (Switzerland), Evgeny
ST-segment-elevation-Ma .. Shlyakhto (Russia), Iain A. Simpson (UK), Jose Luis Zamorano (Spain).
.. ESC National Cardiac Societies actively involved in the
.. review process of the 2017 ESC Guidelines for the manage-
15. Appendix .. ment of acute myocardial infarction in patients presenting
.. with ST-segment elevation:
ESC Committee for Practice Guidelines (CPG): Stephan ..
.. Algeria: Algerian Society of Cardiology, Mohamed Chettibi;
Windecker (Chairperson) (Switzerland), Victor Aboyans (France), .. Armenia: Armenian Cardiologists Association, Hamlet G.
Stefan Agewall (Norway), Emanuele Barbato (Italy), Héctor Bueno
.. Hayrapetyan; Austria: Austrian Society of Cardiology, Bernhard
(Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan Mircea ..
.. Metzler; Azerbaijan: Azerbaijan Society of Cardiology, Firdovsi
Coman (Romania), Veronica Dean (France), Victoria Delgado (The
ESC Guidelines 51

.. Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS,
Ibrahimov; Belarus: Belorussian Scientific Society of Cardiologists, ..
Volha Sujayeva; Belgium: Belgian Society of Cardiology, Christophe .. Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis
.. Zamorano J. 2015 ESC Guidelines for the management of acute coronary syn-
Beauloye; Bosnia and Herzegovina: Association of Cardiologists .. dromes in patients presenting without persistent ST-segment elevation: Task
of Bosnia and Herzegovina, Larisa Dizdarevic-Hudic; Bulgaria: .. Force for the Management of Acute Coronary Syndromes in Patients
.. Presenting without Persistent ST-Segment Elevation of the European Society of
Bulgarian Society of Cardiology, Kiril Karamfiloff; Croatia: Croatian .. Cardiology (ESC). Eur Heart J 2016;37(3):267–315.
Cardiac Society, Bosko Skoric; Cyprus: Cyprus Society of .. 3. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,
Cardiology, Loizos Antoniades; Czech Republic: Czech Society of .. Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck
Cardiology, Petr Tousek; Denmark: Danish Society of Cardiology, .. KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van
.. Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ven-
Christian Juhl Terkelsen; Egypt: Egyptian Society of Cardiology, .. tricular arrhythmias and the prevention of sudden cardiac death: The Task
Sameh Mohamad Shaheen; Estonia: Estonian Society of Cardiology, .. Force for the Management of Patients with Ventricular Arrhythmias and the
.. Prevention of Sudden Cardiac Death of the European Society of Cardiology
Toomas Marandi; Finland: Finnish Cardiac Society, Matti Niemel€a; .. (ESC). Endorsed by: Association for European Paediatric and Congenital
The Former Yugoslav Republic of Macedonia: Macedonian ..
.. Cardiology (AEPC). Eur Heart J 2015;36(41):2793–2867.
Society of Cardiology, Sasko Kedev; France: French Society of .. 4. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney
Cardiology, Martine Gilard; Georgia: Georgian Society of .. MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML,
.. Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,
Cardiology, Alexander Aladashvili; Germany: German Cardiac .. Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM. 2016
Society, Albrecht Elsaesser; Greece: Hellenic Society of Cardiology,
.. European Guidelines on cardiovascular disease prevention in clinical practice:
.. The Sixth Joint Task Force of the European Society of Cardiology and Other
Ioannis Georgios Kanakakis; Hungary: Hungarian Society of ..
Cardiology, Béla Merkely; Iceland: Icelandic Society of Cardiology,
.. Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted
.. by representatives of 10 societies and by invited experts). Developed with the
Thorarinn Gudnason; Israel: Israel Heart Society, Zaza Iakobishvili; .. special contribution of the European Association for Cardiovascular Prevention

Italy: Italian Federation of Cardiology, Leonardo Bolognese;
.. & Rehabilitation (EACPR). Eur Heart J 2016;37(29):2315–2381.
.. 5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
Kazakhstan: Association of Cardiologists of Kazakhstan, Salim .. Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
.. Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron
Berkinbayev; Kosovo: Kosovo Society of Cardiology, Gani Bajraktari; ..
Kyrgyzstan: Kyrgyz Society of Cardiology, Medet Beishenkulov; .. Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R,
.. Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B,
Latvia: Latvian Society of Cardiology, Ilja Zake; Libya: Libyan .. Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski
Cardiac Society, Hisham Ben Lamin; Lithuania: Lithuanian Society .. P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL,
.. Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld
of Cardiology, Olivija Gustiene; Luxembourg: Luxembourg Society .. K. 2016 ESC Guidelines for the management of atrial fibrillation developed in
of Cardiology, Bruno Pereira; Malta: Maltese Cardiac Society, .. collaboration with EACTS. Eur Heart J 2016;37(38):2893–2962.
.. 6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V,
Robert G. Xuereb; Morocco: Moroccan Society of Cardiology, ..
Samir Ztot; Norway: Norwegian Society of Cardiology, Vibeke .. Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
.. Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
Juliebø; Poland: Polish Cardiac Society, Jacek Legutko; Portugal: .. Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagno-
Portuguese Society of Cardiology, Ana Teresa Tim oteo; Romania: .. sis and treatment of acute and chronic heart failure: The Task Force for the
.. diagnosis and treatment of acute and chronic heart failure of the European
Romanian Society of Cardiology, Gabriel Tatu-Chiţoiu; Russian .. Society of Cardiology (ESC). Developed with the special contribution of the
Federation: Russian Society of Cardiology, Alexey Yakovlev; San .. Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):
Marino: San Marino Society of Cardiology, Luca Bertelli; Serbia: .. 2129–2200.

Cardiology Society of Serbia, Milan Nedeljkovic; Slovakia: Slovak .. 7. Valgimigli M, OTHER AUTHORS TO BE INSERTED HERE. 2017 ESC Focused
.. Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collabora-
Society of Cardiology, Martin Studencan; Slovenia: Slovenian .. tion with the European Association for Cardio-Thoracic Surgery (EACTS). The
Society of Cardiology, Matjaz Bunc; Spain: Spanish Society of
.. Task Force for the Management of Dual Antiplatelet Therapy in Coronary
.. Artery Disease of the European Society of Cardiology (ESC). Eur Heart J 2017.
Cardiology, Ana Maria Garcıa de Castro; Sweden: Swedish Society .. 8. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Writing
of Cardiology, Petur Petursson; Switzerland: Swiss Society of
.. Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal
Cardiology, Raban Jeger; Tunisia: Tunisian Society of Cardiology and .. Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS,

Cardio-Vascular Surgery, Mohamed Sami Mourali; Turkey: Turkish
.. Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM,
.. Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox
Society of Cardiology, Aylin Yildirir; Ukraine: Ukrainian Association .. KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W,
of Cardiology, Alexander Parkhomenko; United Kingdom: British
.. Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC,
.. Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M,
Cardiovascular Society, Chris P. Gale. ..
.. Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D,
.. Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M,
.. Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, ESC Committee for
16. References .. Practice Guidelines. Third universal definition of myocardial infarction. Eur
1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, .. Heart J 2012;33(20):2551–2567.
Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, .. 9. Gehrie ER, Reynolds HR, Chen AY, Neelon BH, Roe MT, Gibler WB, Ohman
Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG,
.. EM, Newby LK, Peterson ED, Hochman JS. Characterization and outcomes of
.. women and men with non-ST-segment elevation myocardial infarction and non-
Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/ ..
EACTS Guidelines on myocardial revascularization: The Task Force on .. obstructive coronary artery disease: results from the Can Rapid Risk
Myocardial Revascularization of the European Society of Cardiology (ESC) and .. Stratification of Unstable Angina Patients Suppress Adverse Outcomes with
the European Association for Cardio-Thoracic Surgery (EACTS). Developed .. Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality
with the special contribution of the European Association of Percutaneous .. improvement initiative. Am Heart J 2009;158(4):688–694.
Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541–2619. .. 10. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of
2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
.. patients presenting with suspected myocardial infarction and nonobstructive
.. coronary arteries. Circulation 2015;131(10):861–870.
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, ..
Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, .. 11. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive
Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, .. coronary atherosclerosis: mechanisms and management. Eur Heart J
Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, . 2015;36(8):475–481.
52 ESC Guidelines

12. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, De
.. 27. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G.
Caterina R, Zimarino M, Roffi M, Kjeldsen K, Atar D, Kaski JC, Sechtem U, .. Acute coronary syndromes without chest pain, an underdiagnosed and under-
Tornvall P, on behalf of the WG on Cardiovascular Pharmacotherapy. ESC .. treated high-risk group: insights from the Global Registry of Acute Coronary
working group position paper on myocardial infarction with non-obstructive .. Events. Chest 2004;126(2):461–469.
coronary arteries. Eur Heart J 2017;38(3):143–153. .. 28. Kaul P, Armstrong PW, Sookram S, Leung BK, Brass N, Welsh RC. Temporal
13. Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. .. trends in patient and treatment delay among men and women presenting with
Trends in mortality from ischemic heart disease and cerebrovascular disease in .. ST-elevation myocardial infarction. Am Heart J 2011;161(1):91–97.
Europe: 1980 to 2009. Circulation 2016;133(20):1916–1926.
.. 29. Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, Wiviott S,
14. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. .. Peterson ED. Gender differences in time to presentation for myocardial infarc-
Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J .. tion before and after a national women’s cardiovascular awareness campaign: a
2016;37(42):3232–3245. .. temporal analysis from the Can Rapid Risk Stratification of Unstable Angina
15. Sugiyama T, Hasegawa K, Kobayashi Y, Takahashi O, Fukui T, Tsugawa Y. .. Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE)
Differential time trends of outcomes and costs of care for acute myocardial .. and the National Cardiovascular Data Registry Acute Coronary Treatment and
infarction hospitalizations by ST elevation and type of intervention in the .. Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION
United States, 2001-2011. J Am Heart Assoc 2015;4(3):e001445.
.. Registry-GWTG). Am Heart J 2010;160(1):80–87.e3.
16. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent .. 30. Kang SH, Suh JW, Yoon CH, Cho MC, Kim YJ, Chae SC, Yoon JH, Gwon HC,
trends in the incidence, treatment, and outcomes of patients with STEMI and .. Han KR, Kim JH, Ahn YK, Jeong MH, Kim HS, Choi DJ, KAMIR/KorMI Registry.
NSTEMI. Am J Med 2011;124(1):40–47. .. Sex differences in management and mortality of patients with ST-elevation
17. Jernberg T. Swedeheart Annual Report 2015. In: Karolinska University Hospital, .. myocardial infarction (from the Korean Acute Myocardial Infarction National
Huddinge, 14186 Stockholm; 2016. .. Registry). Am J Cardiol 2012;109(6):787–793.
18. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, Andrikopoulos G, .. 31. Kyto V, Sipila J, Rautava P. Gender and in-hospital mortality of ST-segment ele-
Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J, Huber
.. vation myocardial infarction (from a multihospital nationwide registry study of
K, Kala P, Klinceva M, Kristensen SD, Ludman P, Ferre JM, Merkely B, Milicic D, .. 31,689 patients). Am J Cardiol 2015;115(3):303–306.
Morais J, Noc M, Opolski G, Ostojic M, Radovanovic D, De Servi S, Stenestrand U, .. 32. Hvelplund A, Galatius S, Madsen M, Rasmussen JN, Rasmussen S, Madsen JK,
Studencan M, Tubaro M, Vasiljevic Z, Weidinger F, Witkowski A, Zeymer U, .. Sand NP, Tilsted HH, Thayssen P, Sindby E, Hojbjerg S, Abildstrom SZ.
European Association for Percutaneous Cardiovascular Interventions. Reperfusion .. Women with acute coronary syndrome are less invasively examined and subse-
therapy for ST elevation acute myocardial infarction in Europe: description of the .. quently less treated than men. Eur Heart J 2010;31(6):684–690.
current situation in 30 countries. Eur Heart J 2010;31(8):943–957. .. 33. Nguyen JT, Berger AK, Duval S, Luepker RV. Gender disparity in cardiac proce-
19. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de
.. dures and medication use for acute myocardial infarction. Am Heart J
Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela .. 2008;155(5):862–868.
BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, .. 34. de Torbal A, Boersma E, Kors JA, van Herpen G, Deckers JW, van der Kuip
McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, .. DA, Stricker BH, Hofman A, Witteman JC. Incidence of recognized and unrec-
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, .. ognized myocardial infarction in men and women aged 55 and older: the
Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh .. Rotterdam Study. Eur Heart J 2006;27(6):729–736.
RW, Turner MB, American Heart Association Statistics Committee and Stroke .. 35. Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, Friedlander T,
Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a .. Bushnell AC, Chandra-Strobos N. Chest pain relief by nitroglycerin does not
report from the American Heart Association. Circulation 2015;131(4):e29–322.
.. predict active coronary artery disease. Ann Intern Med 2003;139(12):979–986.
20. Khera S, Kolte D, Gupta T, Subramanian KS, Khanna N, Aronow WS, Ahn C, .. 36. Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV, Jr, Kirk JD, Smith
Timmermans RJ, Cooper HA, Fonarow GC, Frishman WH, Panza JA, Bhatt DL. .. SC, Jr, Gibler WB, Ohman EM, Blomkalns AL, Newby LK, Hochman JS,
Temporal trends and sex differences in revascularization and outcomes of .. Peterson ED, Roe MT. Frequency and consequences of recording an electro-
st-segment elevation myocardial infarction in younger adults in the United .. cardiogram >10 minutes after arrival in an emergency room in non-ST-segment
States. J Am Coll Cardiol 2015;66(18):1961–1972. .. elevation acute coronary syndromes (from the CRUSADE Initiative). Am J
21. Puymirat E, Simon T, Steg PG, Schiele F, Gueret P, Blanchard D, Khalife K, .. Cardiol 2006;97(4):437–442.
Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrieres J, Danchin N, USIK USIC
.. 37. Tubaro M, Danchin N, Goldstein P, Filippatos G, Hasin Y, Heras M, Jansky P,
2000 Investigators, FAST MI Investigators. Association of changes in clinical .. Norekval TM, Swahn E, Thygesen K, Vrints C, Zahger D, Arntz HR, Bellou A,
characteristics and management with improvement in survival among patients .. De La Coussaye JE, De Luca L, Huber K, Lambert Y, Lettino M, Lindahl B,
with ST-elevation myocardial infarction. JAMA 2012;308(10):998–1006. .. McLean S, Nibbe L, Peacock WF, Price S, Quinn T, Spaulding C, Tatu-Chitoiu
22. Gale CP, Allan V, Cattle BA, Hall AS, West RM, Timmis A, Gray HH, Deanfield .. G, Van De Werf F. Pre-hospital treatment of STEMI patients. A scientific state-
J, Fox KA, Feltbower R. Trends in hospital treatments, including revascularisa- .. ment of the Working Group Acute Cardiac Care of the European Society of
tion, following acute myocardial infarction, 2003-2010: a multilevel and relative .. Cardiology. Acute Card Care 2011;13(2):56–67.
survival analysis for the National Institute for Cardiovascular Outcomes
.. 38. Rokos IC, French WJ, Koenig WJ, Stratton SJ, Nighswonger B, Strunk B, Jewell
Research (NICOR). Heart 2014;100(7):582–589. .. J, Mahmud E, Dunford JV, Hokanson J, Smith SW, Baran KW, Swor R, Berman
23. Kristensen SD, Laut KG, Fajadet J, Kaifoszova Z, Kala P, Di Mario C, Wijns W, .. A, Wilson BH, Aluko AO, Gross BW, Rostykus PS, Salvucci A, Dev V, McNally
Clemmensen P, Agladze V, Antoniades L, Alhabib KF, De Boer MJ, Claeys MJ, .. B, Manoukian SV, King SB, 3rd. Integration of pre-hospital electrocardiograms
Deleanu D, Dudek D, Erglis A, Gilard M, Goktekin O, Guagliumi G, Gudnason .. and ST-elevation myocardial infarction receiving center (SRC) networks: impact
T, Hansen KW, Huber K, James S, Janota T, Jennings S, Kajander O, Kanakakis J, .. on door-to-balloon times across 10 independent regions. JACC Cardiovasc Interv
Karamfiloff KK, Kedev S, Kornowski R, Ludman PF, Merkely B, Milicic D, .. 2009;2(4):339–346.
Najafov R, Nicolini FA, Noc M, Ostojic M, Pereira H, Radovanovic D, Sabate M,
.. 39. Quinn T, Johnsen S, Gale CP, Snooks H, McLean S, Woollard M, Weston C.
Sobhy M, Sokolov M, Studencan M, Terzic I, Wahler S, Widimsky P, European .. Effects of prehospital 12-lead ECG on processes of care and mortality in acute
Association for Percutaneous Cardiovascular Interventions. Reperfusion ther- .. coronary syndrome: a linked cohort study from the Myocardial Ischaemia
apy for ST elevation acute myocardial infarction 2010/2011: current status in 37 .. National Audit Project. Heart 2014;100(12):944–950.
ESC countries. Eur Heart J 2014;35(29):1957–1970. .. 40. Sorensen JT, Terkelsen CJ, Norgaard BL, Trautner S, Hansen TM, Botker HE,
24. Pedersen F, Butrymovich V, Kelbaek H, Wachtell K, Helqvist S, Kastrup J, .. Lassen JF, Andersen HR. Urban and rural implementation of pre-hospital diag-
Holmvang L, Clemmensen P, Engstrom T, Grande P, Saunamaki K, Jorgensen E. .. nosis and direct referral for primary percutaneous coronary intervention in
Short- and long-term cause of death in patients treated with primary PCI for .. patients with acute ST-elevation myocardial infarction. Eur Heart J
STEMI. J Am Coll Cardiol 2014;64(20):2101–2108.
.. 2011;32(4):430–436.
25. Fokkema ML, James SK, Albertsson P, Akerblom A, Calais F, Eriksson P, Jensen .. 41. Chan AW, Kornder J, Elliott H, Brown RI, Dorval JF, Charania J, Zhang R, Ding
J, Nilsson T, de Smet BJ, Sjogren I, Thorvinger B, Lagerqvist B. Population trends .. L, Lalani A, Kuritzky RA, Simkus GJ. Improved survival associated with pre-
in percutaneous coronary intervention: 20-year results from the SCAAR .. hospital triage strategy in a large regional ST-segment elevation myocardial
(Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol .. infarction program. JACC Cardiovasc Interv 2012;5(12):1239–46.
2013;61(12):1222–1230. .. 42. Dhruva VN, Abdelhadi SI, Anis A, Gluckman W, Hom D, Dougan W, Kaluski E,
26. EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V, Oertelt- .. Haider B, Klapholz M. ST-Segment Analysis Using Wireless Technology in
Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A, Maas AH,
.. Acute Myocardial Infarction (STAT-MI) trial. J Am Coll Cardiol
Kautzky-Willer A, Knappe-Wegner D, Kintscher U, Ladwig KH, Schenck- .. 2007;50(6):509–513.
Gustafsson K, Stangl V. Gender in cardiovascular diseases: impact on clinical .. 43. Lopez-Sendon J, Coma-Canella I, Alcasena S, Seoane J, Gamallo C.
manifestations, management, and outcomes. Eur Heart J 2016;37(1):24–34. . Electrocardiographic findings in acute right ventricular infarction: sensitivity and
ESC Guidelines 53

specificity of electrocardiographic alterations in right precordial leads V4R, V3R,
.. 63. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska
V1, V2, and V3. J Am Coll Cardiol 1985;6(6):1273–1279. .. K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D,
44. O’Doherty M, Tayler DI, Quinn E, Vincent R, Chamberlain DA. Five hundred .. Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in
patients with myocardial infarction monitored within one hour of symptoms. .. patients with myocardial infarction: the randomized, double-blind, placebo-con-
BMJ (Clin Res Ed) 1983;286(6375):1405–1408. .. trolled IMPRESSION trial. Eur Heart J 2016;37(3):245–252.
45. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, .. 64. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, Cameron P,
Armstrong PW, Granger CB. Incidence of and outcomes associated with ven- .. Barger B, Ellims AH, Taylor AJ, Meredith IT, Kaye DM. Air versus oxygen in ST-
tricular tachycardia or fibrillation in patients undergoing primary percutaneous
.. segment-elevation myocardial infarction. Circulation 2015;131(24):2143–2150.
coronary intervention. JAMA 2009;301(17):1779–1789. .. 65. Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute
46. Rokos IC, Farkouh ME, Reiffel J, Dressler O, Mehran R, Stone GW. Correlation .. myocardial infarction. Cochrane Database Syst Rev 2013;8:CD007160.
between index electrocardiographic patterns and pre-intervention angiographic .. 66. Hofmann R, James SK, Svensson L, Witt N, Frick M, Lindahl B, Ostlund O,
findings: insights from the HORIZONS-AMI trial. Catheter Cardiovasc Interv .. Ekelund U, Erlinge D, Herlitz J, Jernberg T. Determination of the role of oxygen
2012;79(7):1092–1098. .. in suspected acute myocardial infarction trial. Am Heart J 2014;167(3):322–328.
47. Stribling WK, Kontos MC, Abbate A, Cooke R, Vetrovec GW, Dai D, .. 67. Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocar-
Honeycutt E, Wang TY, Lotun K. Left circumflex occlusion in acute myocardial
.. dial infarction. BMJ 1976;1(6018):1121–1123.
infarction (from the National Cardiovascular Data Registry). Am J Cardiol .. 68. Larsen JM, Ravkilde J. Acute coronary angiography in patients resuscitated from
2011;108(7):959–963. .. out-of-hospital cardiac arrest: a systematic review and meta-analysis.
48. Dixon WC, 4th, Wang TY, Dai D, Shunk KA, Peterson ED, Roe MT. Anatomic .. Resuscitation 2012;83(12):1427–1433.
distribution of the culprit lesion in patients with non-ST-segment elevation .. 69. Garot P, Lefevre T, Eltchaninoff H, Morice MC, Tamion F, Abry B, Lesault PF,
myocardial infarction undergoing percutaneous coronary intervention: findings .. Le Tarnec JY, Pouges C, Margenet A, Monchi M, Laurent I, Dumas P, Garot J,
from the National Cardiovascular Data Registry. J Am Coll Cardiol .. Louvard Y. Six-month outcome of emergency percutaneous coronary interven-
.. tion in resuscitated patients after cardiac arrest complicating ST-elevation myo-
49. Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, Gibson CM, Moliterno .. cardial infarction. Circulation 2007;115(11):1354–1362.
DJ, Van de Werf F, White HD, Harrington RA, Roe MT. Incidence, distribution, .. 70. Kern KB, Rahman O. Emergent percutaneous coronary intervention for resusci-
and prognostic impact of occluded culprit arteries among patients with non-ST- .. tated victims of out-of-hospital cardiac arrest. Catheter Cardiovasc Interv
elevation acute coronary syndromes undergoing diagnostic angiography. Am .. 2010;75(4):616–624.
Heart J 2009;157(4):716–723. .. 71. Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut JF, Carli
50. Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, .. P. Immediate coronary angiography in survivors of out-of-hospital cardiac
Califf RM, Wagner GS. Electrocardiographic diagnosis of evolving acute myocar-
.. arrest. N Engl J Med 1997;336(23):1629–1633.
dial infarction in the presence of left bundle-branch block. GUSTO-1 (Global .. 72. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J,
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded .. Empana JP, Carli P, Mira JP, Jouven X, Spaulding C. Immediate percutaneous
Coronary Arteries) Investigators. N Engl J Med 1996;334(8):481–487. .. coronary intervention is associated with better survival after out-of-hospital
51. Wong CK, French JK, Aylward PE, Stewart RA, Gao W, Armstrong PW, Van .. cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital
De Werf FJ, Simes RJ, Raffel OC, Granger CB, Califf RM, White HD. Patients .. Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3(3):200–207.
with prolonged ischemic chest pain and presumed-new left bundle branch block .. 73. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, Windecker S,
have heterogeneous outcomes depending on the presence of ST-segment .. Spaulding C, European Association for Percutaneous Cardiovascular
changes. J Am Coll Cardiol 2005;46(1):29–38.
.. Interventions, Stent for Life Group. Invasive coronary treatment strategies for
52. Shlipak MG, Lyons WL, Go AS, Chou TM, Evans GT, Browner WS. Should the .. out-of-hospital cardiac arrest: a consensus statement from the European
electrocardiogram be used to guide therapy for patients with left bundle- .. Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for
branch block and suspected myocardial infarction? JAMA 1999;281(8):714–719. .. LIfe (SFL) groups. EuroIntervention 2014;10(1):31–37.
53. Lopes RD, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, Granger CB. .. 74. Monsieurs KG, Nolan JP, Bossaert LL, Greif R, Maconochie IK, Nikolaou NI,
Diagnosing acute myocardial infarction in patients with left bundle branch block. .. Perkins GD, Soar J, Truhlar A, Wyllie J, Zideman DA. European Resuscitation
Am J Cardiol 2011;108(6):782–788. .. Council Guidelines for Resuscitation 2015: Section 1. Executive summary.
54. Chang AM, Shofer FS, Tabas JA, Magid DJ, McCusker CM, Hollander JE. Lack of
.. Resuscitation 2015;95:1–80.
association between left bundle-branch block and acute myocardial infarction in .. 75. Reynolds JC, Frisch A, Rittenberger JC, Callaway CW. Duration of resuscitation
symptomatic ED patients. Am J Emerg Med 2009;27(8):916–921. .. efforts and functional outcome after out-of-hospital cardiac arrest: when should
55. Widimsky P, Rohac F, Stasek J, Kala P, Rokyta R, Kuzmanov B, Jakl M, Poloczek M, .. we change to novel therapies? Circulation 2013;128(23):2488–2494.
Kanovsky J, Bernat I, Hlinomaz O, Belohlavek J, Kral A, Mrazek V, Grigorov V, .. 76. Moulaert VR, Verbunt JA, van Heugten CM, Wade DT. Cognitive impairments
Djambazov S, Petr R, Knot J, Bilkova D, Fischerova M, Vondrak K, Maly M, .. in survivors of out-of-hospital cardiac arrest: a systematic review. Resuscitation
Lorencova A. Primary angioplasty in acute myocardial infarction with right bundle .. 2009;80(3):297–305.
branch block: should new onset right bundle branch block be added to future
.. 77. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia
guidelines as an indication for reperfusion therapy? Eur Heart J 2012;33(1):86–95. .. to improve the neurologic outcome after cardiac arrest. N Engl J Med
56. Madias JE. The nonspecificity of ST-segment elevation > or = 5.0 mm in V1-V3 .. 2002;346(8):549–556.
in the diagnosis of acute myocardial infarction in the presence of ventricular .. 78. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith
paced rhythm. J Electrocardiol 2004;37(2):135–139. .. K. Treatment of comatose survivors of out-of-hospital cardiac arrest with
57. Sgarbossa EB, Pinski SL, Gates KB, Wagner GS. Early electrocardiographic diag- .. induced hypothermia. N Engl J Med 2002;346(8):557–563.
nosis of acute myocardial infarction in the presence of ventricular paced .. 79. Nikolaou NI, Welsford M, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H,
rhythm. GUSTO-I Investigators. Am J Cardiol 1996;77(5):423–424.
.. O’Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG. Part 5: Acute
58. Krishnaswamy A, Lincoff AM, Menon V. Magnitude and consequences of missing .. coronary syndromes: 2015 International Consensus on Cardiopulmonary
the acute infarct-related circumflex artery. Am Heart J 2009;158(5):706–712. .. Resuscitation and Emergency Cardiovascular Care Science with Treatment
59. From AM, Best PJ, Lennon RJ, Rihal CS, Prasad A. Acute myocardial infarction .. Recommendations. Resuscitation 2015;95:e121–e146.
due to left circumflex artery occlusion and significance of ST-segment elevation. .. 80. Belliard G, Catez E, Charron C, Caille V, Aegerter P, Dubourg O, Jardin F,
Am J Cardiol 2010;106(8):1081–1085. .. Vieillard-Baron A. Efficacy of therapeutic hypothermia after out-of-hospital car-
60. Yan AT, Yan RT, Kennelly BM, Anderson FA, Jr, Budaj A, Lopez-Sendon J, .. diac arrest due to ventricular fibrillation. Resuscitation 2007;75(2):252–259.
Brieger D, Allegrone J, Steg G, Goodman SG. Relationship of ST elevation in .. 81. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J,
lead aVR with angiographic findings and outcome in non-ST elevation acute cor-
.. Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP,
onary syndromes. Am Heart J 2007;154(1):71–78. .. Aneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF,
61. Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder- .. Hingston CD, Juffermans NP, Koopmans M, Kober L, Langorgen J, Lilja G, Moller
Plassmann R, Jilma-Stohlawetz P, Mannhalter C, Posch M, Jilma B. Morphine .. JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H, TTM Trial
decreases clopidogrel concentrations and effects: a randomized, double-blind, .. Investigators. Targeted temperature management at 33 degrees C versus 36
placebo-controlled trial. J Am Coll Cardiol 2014;63(7):630–635. .. degrees C after cardiac arrest. N Engl J Med 2013;369(23):2197–2206.
62. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, .. 82. Vaahersalo J, Hiltunen P, Tiainen M, Oksanen T, Kaukonen KM, Kurola J,
Stavrou K, Migliorini A, Antoniucci D, Tamburino C, Alexopoulos D. Morphine
.. Ruokonen E, Tenhunen J, Ala-Kokko T, Lund V, Reinikainen M, Kiviniemi O,
is associated with a delayed activity of oral antiplatelet agents in patients with .. Silfvast T, Kuisma M, Varpula T, Pettila V. Therapeutic hypothermia after out-
ST-elevation acute myocardial infarction undergoing primary percutaneous cor- .. of-hospital cardiac arrest in Finnish intensive care units: the FINNRESUSCI
onary intervention. Circ Cardiovasc Interv 2015;8(1):e001593. . study. Intensive Care Med 2013;39(5):826–837.
54 ESC Guidelines

83. Penela D, Magaldi M, Fontanals J, Martin V, Regueiro A, Ortiz JT, Bosch X,
.. 101. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, Lips DL,
Sabate M, Heras M. Hypothermia in acute coronary syndrome: brain salvage .. Madison JD, Menssen KM, Mooney MR, Newell MC, Pedersen WR, Poulose
versus stent thrombosis? J Am Coll Cardiol 2013;61(6):686–687. .. AK, Traverse JH, Unger BT, Wang YL, Larson DM. A regional system to pro-
84. Shah N, Chaudhary R, Mehta K, Agarwal V, Garg J, Freudenberger R, Jacobs L, .. vide timely access to percutaneous coronary intervention for ST-elevation
Cox D, Kern KB, Patel N. Therapeutic hypothermia and stent thrombosis: a .. myocardial infarction. Circulation 2007;116(7):721–728.
nationwide analysis. JACC Cardiovasc Interv 2016;9(17):1801–1811. .. 102. Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, Wells GA, Davies RF,
85. Garcia-Tejada J, Jurado-Roman A, Rodriguez J, Velazquez M, Hernandez F, .. Sherrard HL, Maloney J, Marquis JF, O’Brien ER, Trickett J, Poirier P, Ryan SC,
Albarran A, Martin-Asenjo R, Granda-Nistal C, Coma R, Tascon J. Post-resusci-
.. Ha A, Joseph PG, Labinaz M. A citywide protocol for primary PCI in ST-
tation electrocardiograms, acute coronary findings and in-hospital prognosis of .. segment elevation myocardial infarction. N Engl J Med 2008;358(3):231–240.
survivors of out-of-hospital cardiac arrest. Resuscitation 2014;85(9):1245–1250. .. 103. Knot J, Widimsky P, Wijns W, Stenestrand U, Kristensen SD, Van THA,
86. Kim F, Nichol G, Maynard C, Hallstrom A, Kudenchuk PJ, Rea T, Copass MK, .. Weidinger F, Janzon M, Norgaard BL, Soerensen JT, van de Wetering H,
Carlbom D, Deem S, Longstreth WT, Jr, Olsufka M, Cobb LA. Effect of preho- .. Thygesen K, Bergsten PA, Digerfeldt C, Potgieter A, Tomer N, Fajadet J. How
spital induction of mild hypothermia on survival and neurological status among .. to set up an effective national primary angioplasty network: lessons learned
adults with cardiac arrest: a randomized clinical trial. JAMA 2014;311(1):45–52. .. from five European countries. EuroIntervention 2009;5(3):299,301–309.
87. Terkelsen CJ, Sorensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, Vach
.. 104. Nallamothu BK, Krumholz HM, Ko DT, LaBresh KA, Rathore S, Roe MT,
W, Johnsen SP, Thuesen L, Lassen JF. System delay and mortality among .. Schwamm L. Development of systems of care for ST-elevation myocardial
patients with STEMI treated with primary percutaneous coronary intervention. .. infarction patients: gaps, barriers, and implications. Circulation
JAMA 2010;304(7):763–771. .. 2007;116(2):e68–e72.
88. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, Berger PB, .. 105. Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, Krumholz
Corbett CC, Dauerman HL, Fox K, Garvey JL, Henry TD, Rokos IC, Sherwood .. HM, National Cardiovascular Data Registry. Association of door-to-balloon
MW, Wilson BH, Granger CB, STEMI Systems Accelerator Project. Association .. time and mortality in patients admitted to hospital with ST elevation myocardial
of rapid care process implementation on reperfusion times across multiple ST-
.. infarction: national cohort study. BMJ 2009;338:b1807.
segment-elevation myocardial infarction networks. Circ Cardiovasc Interv .. 106. Nielsen PH, Terkelsen CJ, Nielsen TT, Thuesen L, Krusell LR, Thayssen P,
2017;10(1):e004061. .. Kelbaek H, Abildgaard U, Villadsen AB, Andersen HR, Maeng M. System delay
89. Stowens JC, Sonnad SS, Rosenbaum RA. Using EMS dispatch to trigger STEMI .. and timing of intervention in acute myocardial infarction (from the Danish
alerts decreases door-to-balloon times. West J Emerg Med 2015;16(3):472–480. .. Acute Myocardial Infarction-2 [DANAMI-2] trial). Am J Cardiol
90. Squire BT, Tamayo-Sarver JH, Rashi P, Koenig W, Niemann JT. Effect of preho- .. 2011;108(6):776–781.
spital cardiac catheterization lab activation on door-to-balloon time, mortality, .. 107. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip
and false-positive activation. Prehosp Emerg Care 2014;18(1):1–8.
.. DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP,
91. Nallamothu BK, Normand SL, Wang Y, Hofer TP, Brush JE, Jr, Messenger JC, .. Gibson CM. Hospital delays in reperfusion for ST-elevation myocardial infarc-
Bradley EH, Rumsfeld JS, Krumholz HM. Relation between door-to-balloon .. tion: implications when selecting a reperfusion strategy. Circulation
times and mortality after primary percutaneous coronary intervention over .. 2006;114(19):2019–2025.
time: a retrospective study. Lancet 2015;385(9973):1114–1122. .. 108. Widimsky P, Fajadet J, Danchin N, Wijns W. "Stent 4 Life" targeting PCI at all
92. Bagai A, Jollis JG, Dauerman HL, Peng SA, Rokos IC, Bates ER, French WJ, .. who will benefit the most. A joint project between EAPCI, Euro-PCR,
Granger CB, Roe MT. Emergency department bypass for ST-segment-elevation .. EUCOMED and the ESC Working Group on Acute Cardiac Care.
myocardial infarction patients identified with a prehospital electrocardiogram: a .. EuroIntervention 2009;4(5):555,557.
report from the American Heart Association Mission: Lifeline program.
.. 109. Steg PG, Cambou JP, Goldstein P, Durand E, Sauval P, Kadri Z, Blanchard D,
Circulation 2013;128(4):352–359. .. Lablanche JM, Gueret P, Cottin Y, Juliard JM, Hanania G, Vaur L, Danchin N,
93. Wang TY, Nallamothu BK, Krumholz HM, Li S, Roe MT, Jollis JG, Jacobs AK, .. USIC Investigators. Bypassing the emergency room reduces delays and mortal-
Holmes DR, Peterson ED, Ting HH. Association of door-in to door-out time .. ity in ST elevation myocardial infarction: the USIC 2000 registry. Heart
with reperfusion delays and outcomes among patients transferred for primary .. 2006;92(10):1378–1383.
percutaneous coronary intervention. JAMA 2011;305(24):2540–2547. .. 110. Baran KW, Kamrowski KA, Westwater JJ, Tschida VH, Alexander CF, Beahrs
94. Huber K, De Caterina R, Kristensen SD, Verheugt FW, Montalescot G, .. MM, Biggs TA, Koller PT, Mahoney BD, Murray ST, Raya TE, Rusterholz PK,
Maestro LB, Van de Werf F. Pre-hospital reperfusion therapy: a strategy to
.. Valeti US, Wiberg TA. Very rapid treatment of ST-segment-elevation myocar-
improve therapeutic outcome in patients with ST-elevation myocardial infarc- .. dial infarction: utilizing prehospital electrocardiograms to bypass the emergency
tion. Eur Heart J 2005;26(19):2063–2074. .. department. Circ Cardiovasc Qual Outcomes 2010;3(4):431–437.
95. Welsh RC, Chang W, Goldstein P, Adgey J, Granger CB, Verheugt FW, .. 111. Thiemann DR, Coresh J, Oetgen WJ, Powe NR. The association between hos-
Wallentin L, Van de Werf F, Armstrong PW. Time to treatment and the impact .. pital volume and survival after acute myocardial infarction in elderly patients. N
of a physician on prehospital management of acute ST elevation myocardial .. Engl J Med 1999;340(21):1640–1648.
infarction: insights from the ASSENT-3 PLUS trial. Heart .. 112. West RM, Cattle BA, Bouyssie M, Squire I, de Belder M, Fox KA, Boyle R,
.. McLenachan JM, Batin PD, Greenwood DC, Gale CP. Impact of hospital pro-
96. Bjorklund E, Stenestrand U, Lindback J, Svensson L, Wallentin L, Lindahl B. Pre- .. portion and volume on primary percutaneous coronary intervention perform-
hospital thrombolysis delivered by paramedics is associated with reduced time .. ance in England and Wales. Eur Heart J 2011;32(6):706–711.
delay and mortality in ambulance-transported real-life patients with ST- .. 113. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van
elevation myocardial infarction. Eur Heart J 2006;27(10):1146–1152. .. ’t Hof AW, Suryapranata H. Long-term benefit of primary angioplasty as com-
97. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, .. pared with thrombolytic therapy for acute myocardial infarction. N Engl J Med
Leizorovicz A, Touboul P, CAPTIM Investigators. Impact of time to treatment .. 1999;341(19):1413–1419.
on mortality after prehospital fibrinolysis or primary angioplasty: data from the
.. 114. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous throm-
CAPTIM randomized clinical trial. Circulation 2003;108(23):2851–2856. .. bolytic therapy for acute myocardial infarction: a quantitative review of 23 rand-
98. Bonnefoy E, Steg PG, Boutitie F, Dubien PY, Lapostolle F, Roncalli J, Dissait F, .. omised trials. Lancet 2003;361(9351):13–20.
Vanzetto G, Leizorowicz A, Kirkorian G, Mercier C, McFadden EP, Touboul P. .. 115. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M,
Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myo- .. Branny M, St’asek J, Formanek P, ‘PRAGUE’ Study Group Investigators. Long
cardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J .. distance transport for primary angioplasty vs immediate thrombolysis in acute
2009;30(13):1598–1606. .. myocardial infarction. Final results of the randomized national multicentre
99. Danchin N, Coste P, Ferrieres J, Steg PG, Cottin Y, Blanchard D, Belle L, Ritz B, .. trial—PRAGUE-2. Eur Heart J 2003;24(1):94–104.
Kirkorian G, Angioi M, Sans P, Charbonnier B, Eltchaninoff H, Gueret P, Khalife
.. 116. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P,
K, Asseman P, Puel J, Goldstein P, Cambou JP, Simon T, FAST-MI Investigators. .. Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR,
Comparison of thrombolysis followed by broad use of percutaneous coronary .. Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS,
intervention with primary percutaneous coronary intervention for ST-segment- .. DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrino-
elevation acute myocardial infarction: Data from the French registry on acute .. lytic therapy in acute myocardial infarction. N Engl J Med 2003;349(8):733–742.
ST-elevation myocardial infarction (FAST-MI). Circulation 2008;118(3):268–276. .. 117. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrino-
100. Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, Schreiber W, .. lytic therapy in acute myocardial infarction: is timing (almost) everything? Am J
Unger G, Glogar HD, Kaff A, Laggner AN, Maurer G, Mlczoch J, Slany J, Weber
.. Cardiol 2003;92(7):824–826.
HS, Huber K. Implementation of guidelines improves the standard of care: the .. 118. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarc-
Viennese registry on reperfusion strategies in ST-elevation myocardial infarction .. tion treated by percutaneous coronary intervention versus fibrinolysis. Am J
(Vienna STEMI registry). Circulation 2006;113(20):2398–2405. . Cardiol 2005;95(1):100–101.
ESC Guidelines 55

119. Boersma E, Primary Coronary Angioplasty vs Thrombolysis Group. Does time
.. 134. Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schomig A. Mechanical reper-
matter? A pooled analysis of randomized clinical trials comparing primary per- .. fusion and long-term mortality in patients with acute myocardial infarction pre-
cutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial .. senting 12 to 48 hours from onset of symptoms. JAMA 2009;301(5):487–488.
infarction patients. Eur Heart J 2006;27(7):779–788. .. 135. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ,
120. Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, Miller .. Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin
DP, Henry TD, Gibson CM, National Registry of Myocardial Infarction .. JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V,
Investigators. Benefit of transferring ST-segment-elevation myocardial infarction .. Mark DB, Knatterud GL, Occluded Artery Trial Investigators. Coronary inter-
patients for percutaneous coronary intervention compared with administration
.. vention for persistent occlusion after myocardial infarction. N Engl J Med
of onsite fibrinolytic declines as delays increase. Circulation .. 2006;355(23):2395–2407.
2011;124(23):2512–2521. .. 136. Menon V, Pearte CA, Buller CE, Steg PG, Forman SA, White HD, Marino PN,
121. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, .. Katritsis DG, Caramori P, Lasevitch R, Loboz-Grudzien K, Zurakowski A,
Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz .. Lamas GA, Hochman JS. Lack of benefit from percutaneous intervention of per-
HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, .. sistently occluded infarct arteries after the acute phase of myocardial infarction
Vandenberghe K, Bogaerts K, Van de Werf F, STREAM Investigative Team. .. is time independent: insights from Occluded Artery Trial. Eur Heart J
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N
.. 2009;30(2):183–191.
Engl J Med 2013;368(15):1379–1387. .. 137. Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfu-
122. Task Force on the management of ST-segment elevationsacute myocardial .. sion after myocardial infarction in stable patients. Am Heart J
infarction of the European Society of Cardiology (ESC), Steg PG, James SK, .. 2007;154(6):1065–1071.
Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein .. 138. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment
K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, .. in acute myocardial infarction: reappraisal of the golden hour. Lancet
Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van .. 1996;348(9030):771–775.
’t Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute
.. 139. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous
myocardial infarction in patients presenting with ST-segment elevation. Eur .. thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev
Heart J 2012;33(20):2569–2619. .. 2003;3:CD001560.
123. Morrison LJ, Verbeck PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and .. 140. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angio-
prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA .. plasty versus immediate thrombolysis in acute myocardial infarction: a meta-
2000;283(20):2686–2692. .. analysis. Circulation 2003;108(15):1809–1814.
124. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, .. 141. Gierlotka M, Gasior M, Wilczek K, Hawranek M, Szkodzinski J, Paczek P,
de Belder A, Davis J, Pitt M, Banning A, Baumbach A, Shiu MF, Schofield P,
.. Lekston A, Kalarus Z, Zembala M, Polonski L. Reperfusion by primary percuta-
Dawkins KD, Henderson RA, Oldroyd KG, Wilcox R, REACT Trial .. neous coronary intervention in patients with ST-segment elevation myocardial
Investigators. Rescue angioplasty after failed thrombolytic therapy for acute .. infarction within 12 to 24 hours of the onset of symptoms (from a prospective
myocardial infarction. N Engl J Med 2005;353(26):2758–2768. .. national observational study [PL-ACS]). Am J Cardiol 2011;107(4):501–508.
125. Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, Le .. 142. Busk M, Kaltoft A, Nielsen SS, Bottcher M, Rehling M, Thuesen L, Botker HE,
May MR, Borgia F, Piscione F, Scheller B, Armstrong PW, Fernandez-Aviles F, .. Lassen JF, Christiansen EH, Krusell LR, Andersen HR, Nielsen TT, Kristensen
Sanchez PL, Graham JJ, Yan AT, Goodman SG. Relationship between time to .. SD. Infarct size and myocardial salvage after primary angioplasty in patients pre-
invasive assessment and clinical outcomes of patients undergoing an early inva- .. senting with symptoms for <12 h vs. 12-72 h. Eur Heart J
sive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a
.. 2009;30(11):1322–1330.
patient-level analysis of the randomized early routine invasive clinical trials. JACC .. 143. Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P,
Cardiovasc Interv 2015;8(1 Pt B):166–174. .. Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A,
126. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, .. Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F,
Morrison LJ, Langer A, Dzavik V, Mehta SR, Lazzam C, Schwartz B, Casanova A, .. Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N,
Goodman SG, TRANSFER-AMI Trial Investigators. Routine early angioplasty .. Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M,
after fibrinolysis for acute myocardial infarction. N Engl J Med .. Vranckx P, Juni P, MATRIX Investigators. Radial versus femoral access in
.. patients with acute coronary syndromes undergoing invasive management: a
127. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, .. randomised multicentre trial. Lancet 2015;385(9986):2465–2476.
Dimopoulos K, Manari A, Gaspardone A, Ochala A, Zmudka K, Bolognese L, .. 144. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela
Steg PG, Flather M, CARESS AMI Investigators. Immediate angioplasty versus .. M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner
standard therapy with rescue 3 angioplasty after thrombolysis in the Combined .. CD, Chrolavicius S, Mehta SR, RIVAL Trial Group. Radial versus femoral access
Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in- .. for coronary angiography and intervention in patients with acute coronary syn-
AMI): an open, prospective, randomised, multicentre trial. Lancet .. dromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet
.. 2011;377(9775):1409–1420.
128. Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and .. 145. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G,
safety of immediate angioplasty versus ischemia-guided management after .. Summaria F, Patrizi R, Borghi A, Di Russo C, Moretti C, Agostoni P, Loschiavo
thrombolysis in acute myocardial infarction in areas with very long transfer dis- .. P, Lioy E, Sheiban I, Sangiorgi G. Radial versus femoral randomized investigation
tances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment .. in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial
of ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2010;55(2):102–110. .. Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary
129. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, .. Syndrome) study. J Am Coll Cardiol 2012;60(24):2481–2489.
Fernandez-Aviles F, Sanchez PL, Dimopoulos K, Scheller B, Armstrong PW, Di
.. 146. Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of
Mario C. Early routine percutaneous coronary intervention after fibrinolysis vs. .. primary stenting versus balloon angioplasty in patients with myocardial infarc-
standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. .. tion: a meta-analysis of randomized controlled trials. Am J Med
Eur Heart J 2010;31(17):2156–2169. .. 2004;116(4):253–262.
130. D’Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary .. 147. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G,
angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST- .. Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Controlled
elevation myocardial infarction: a meta-analysis. Eur Heart J 2011;32(8):972–982. .. Abciximab and Device Investigation to Lower Late Angioplasty Complications
131. Neeland IJ, Kontos MC, de Lemos JA. Evolving considerations in the manage- .. (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or
ment of patients with left bundle branch block and suspected myocardial infarc-
.. without abciximab, in acute myocardial infarction. N Engl J Med
tion. J Am Coll Cardiol 2012;60(2):96–105. .. 2002;346(13):957–966.
132. Liakopoulos V, Kellerth T, Christensen K. Left bundle branch block and sus- .. 148. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di
pected myocardial infarction: does chronicity of the branch block matter? Eur .. Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT,
Heart J Acute Cardiovasc Care 2013;2(2):182–189. .. Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A.
133. Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, .. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in
Nekolla SG, Schlotterbeck K, Schuhlen H, Pache J, Seyfarth M, Martinoff S, .. patients with acute myocardial infarction. Eur Heart J 2007;28(22):2706–2713.
Benzer W, Schmitt C, Dirschinger J, Schwaiger M, Kastrati A, Beyond 12 hours
.. 149. Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C,
Reperfusion Alternative Evaluation Trial Investigators. Mechanical reperfusion in .. Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G,
patients with acute myocardial infarction presenting more than 12 hours from .. Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B,
symptom onset: a randomized controlled trial. JAMA 2005;293(23):2865–2872. . Juni P, Windecker S, COMFORTABLE AMI Trial Investigators. Effect of
56 ESC Guidelines

biolimus-eluting stents with biodegradable polymer vs bare-metal stents on car-
.. Dzavik V, TOTAL Investigators. Stroke in the TOTAL trial: a randomized trial
diovascular events among patients with acute myocardial infarction: the .. of routine thrombectomy vs. percutaneous coronary intervention alone in ST
COMFORTABLE AMI randomized trial. JAMA 2012;308(8):777–787. .. elevation myocardial infarction. Eur Heart J 2015;36(35):2364–2372.
150. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, .. 162. Jolly SS, James S, Dzavik V, Cairns JA, Mahmoud KD, Zijlstra F, Yusuf S,
Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez- .. Olivecrona GK, Renlund H, Gao P, Lagerqvist B, Alazzoni A, Kedev S, Stankovic
Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi .. G, Meeks B, Frobert O. Thrombus aspiration in ST-segment-elevation myocar-
M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. .. dial infarction. An individual patient meta-analysis: Thrombectomy Trialists
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myo-
.. Collaboration. Circulation 2017;135(2):143–152.
cardial infarction (EXAMINATION): 1 year results of a randomised controlled .. 163. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C,
trial. Lancet 2012;380(9852):1482–1490. .. Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW. Impact of
151. Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Jimenez-Quevedo P, .. multivessel disease on reperfusion success and clinical outcomes in patients
Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, van Es .. undergoing primary percutaneous coronary intervention for acute myocardial
GA, Backx B, Valgimigli M, Serruys PW. Clinical outcomes in patients with ST- .. infarction. Eur Heart J 2007;28(14):1709–1716.
segment elevation myocardial infarction treated with everolimus-eluting stents .. 164. Dziewierz A, Siudak Z, Rakowski T, Zasada W, Dubiel JS, Dudek D. Impact of
versus bare-metal stents (EXAMINATION): 5-year results of a randomised
.. multivessel coronary artery disease and noninfarct-related artery revasculariza-
trial. Lancet 2016;387(10016):357–366. .. tion on outcome of patients with ST-elevation myocardial infarction transferred
152. Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, Nilsen .. for primary percutaneous coronary intervention (from the EUROTRANSFER
DW, Klow NE, Uchto M, Trovik T, Bendz B, Stavnes S, Bjornerheim R, Larsen .. Registry). Am J Cardiol 2010;106(3):342–347.
AI, Slette M, Steigen T, Jakobsen OJ, Bleie O, Fossum E, Hanssen TA, Dahl- .. 165. Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao
Eriksen O, Njolstad I, Rasmussen K, Wilsgaard T, Nordrehaug JE, NORSTENT .. SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery inter-
Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N .. vention during primary percutaneous coronary intervention for ST-segment
Engl J Med 2016;375(13):1242–1252.
.. elevation myocardial infarction (from the National Cardiovascular Data
153. Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, Hood S, .. Registry). Am J Cardiol 2009;104(4):507–513.
Owens C, Watkins S, Layland J, Lindsay M, Peat E, Rae A, Behan M, Sood A, .. 166. Hannan EL, Samadashvili Z, Walford G, Holmes DR, Jr, Jacobs AK, Stamato NJ,
Hillis WS, Mordi I, Mahrous A, Ahmed N, Wilson R, Lasalle L, Genereux P, .. Venditti FJ, Sharma S, King SB, 3rd. Culprit vessel percutaneous coronary inter-
Ford I, Berry C. A randomized trial of deferred stenting versus immediate stent- .. vention versus multivessel and staged percutaneous coronary intervention for
ing to prevent no- or slow-reflow in acute ST-segment elevation myocardial .. ST-segment elevation myocardial infarction patients with multivessel disease.
infarction (DEFER-STEMI). J Am Coll Cardiol 2014;63(20):2088–2098. .. JACC Cardiovasc Interv 2010;3(1):22–31.
154. Belle L, Motreff P, Mangin L, Range G, Marcaggi X, Marie A, Ferrier N, Dubreuil
.. 167. Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, Bursi F, Sangiorgi
O, Zemour G, Souteyrand G, Caussin C, Amabile N, Isaaz K, Dauphin R, .. GM, Modena MG. A randomised trial of target-vessel versus multi-vessel revas-
Koning R, Robin C, Faurie B, Bonello L, Champin S, Delhaye C, Cuilleret F, .. cularisation in ST-elevation myocardial infarction: major adverse cardiac events
Mewton N, Genty C, Viallon M, Bosson JL, Croisille P, MIMI Investigators. .. during long-term follow-up. Heart 2010;96(9):662–667.
Comparison of immediate with delayed stenting using the minimalist immediate .. 168. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C,
mechanical intervention approach in acute ST-segment-elevation myocardial .. Oldroyd KG, PRAMI Investigators. Randomized trial of preventive angioplasty
infarction: the MIMI Study. Circ Cardiovasc Interv 2016;9(3):e003388. .. in myocardial infarction. N Engl J Med 2013;369(12):1115–1123.
155. Kelbaek H, Hofsten DE, Kober L, Helqvist S, Klovgaard L, Holmvang L, .. 169. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N,
Jorgensen E, Pedersen F, Saunamaki K, De Backer O, Bang LE, Kofoed KF,
.. Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M,
Lonborg J, Ahtarovski K, Vejlstrup N, Botker HE, Terkelsen CJ, Christiansen .. Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann
EH, Ravkilde J, Tilsted HH, Villadsen AB, Aaroe J, Jensen SE, Raungaard B, .. GP. Randomized trial of complete versus lesion-only revascularization in patients
Jensen LO, Clemmensen P, Grande P, Madsen JK, Torp-Pedersen C, Engstrom .. undergoing primary percutaneous coronary intervention for STEMI and multives-
T. Deferred versus conventional stent implantation in patients with ST-segment .. sel disease: the CvLPRIT trial. J Am Coll Cardiol 2015;65(10):963–972.
elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised .. 170. Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L,
controlled trial. Lancet 2016;387(10034):2199–2206. .. Jorgensen E, Pedersen F, Saunamaki K, Clemmensen P, De Backer O, Ravkilde J,
156. Burzotta F, De Vita M, Gu YL, Isshiki T, Lefevre T, Kaltoft A, Dudek D, Sardella
.. Tilsted HH, Villadsen AB, Aaroe J, Jensen SE, Raungaard B, Kober L, DANAMI-
G, Orrego PS, Antoniucci D, De Luca L, Biondi-Zoccai GG, Crea F, Zijlstra F. .. PRIMULTI Investigators. Complete revascularisation versus treatment of the
Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an .. culprit lesion only in patients with ST-segment elevation myocardial infarction
individual patient-data pooled analysis of 11 trials. Eur Heart J .. and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised
2009;30(18):2193–2203. .. controlled trial. Lancet 2015;386(9994):665–671.
157. Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, .. 171. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K,
Aasa M, Angeras O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, .. Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R,
Johansson AC, Karegren A, Nilsson J, Robertson L, Sandhall L, Sjogren I,
.. Angeras O, Richardt G, Omerovic E, Compare-Acute Investigators. Fractional
Ostlund O, Harnek J, James SK, TASTE Trial. Thrombus aspiration during ST- .. flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J
segment elevation myocardial infarction. N Engl J Med .. Med 2017;376(13):1234–1244.
2013;369(17):1587–1597. .. 172. Moreno R, Mehta SR. Nonculprit vessel intervention: let’s COMPLETE the evi-
158. Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, .. dence. Rev Esp Cardiol (English Ed) 2017;70:418–420.
Andersson J, Calais F, Carlsson J, Collste O, Gotberg M, Hardhammar P, Ioanes .. 173. Bangalore S, Toklu B, Wetterslev J. Complete versus culprit-only revasculariza-
D, Kallryd A, Linder R, Lundin A, Odenstedt J, Omerovic E, Puskar V, Todt T, .. tion for ST-segment-elevation myocardial infarction and multivessel disease: a
Zelleroth E, Ostlund O, James SK. Outcomes 1 year after thrombus aspiration
.. meta-analysis and trial sequential analysis of randomized trials. Circ Cardiovasc
for myocardial infarction. N Engl J Med 2014;371(12):1111–1120. .. Interv 2015;8(4):e002142.
159. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, .. 174. Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or
Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Steg PG, .. culprit-only revascularization for patients with multivessel coronary artery dis-
Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, .. ease undergoing percutaneous coronary intervention: a pairwise and network
Bertrand OF, Avezum A, Bhindi R, Pancholy S, Rao SV, Natarajan MK, ten Berg .. meta-analysis of randomized trials. JACC Cardiovasc Interv 2017;10(4):315–324.
JM, Shestakovska O, Gao P, Widimsky P, Dzavik V, TOTAL Investigators. .. 175. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Chew D,
Randomized trial of primary PCI with or without routine manual thrombec- .. Cohen M, French J, Perera D, Ohman EM. Intra-aortic balloon counterpulsation
tomy. N Engl J Med 2015;372(15):1389–1398.
.. and infarct size in patients with acute anterior myocardial infarction without
160. Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, .. shock: the CRISP AMI randomized trial. JAMA 2011;306(12):1329–1337.
Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Bernat I, Cantor WJ, .. 176. Sjauw KD, Engstrom AE, Vis MM, van der Schaaf RJ, Baan J, Jr, Koch KT, de
Cheema AN, Steg PG, Welsh RC, Sheth T, Bertrand OF, Avezum A, Bhindi R, .. Winter RJ, Piek JJ, Tijssen JG, Henriques JP. A systematic review and meta-
Natarajan MK, Horak D, Leung RC, Kassam S, Rao SV, El-Omar M, Mehta SR, .. analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarc-
Velianou JL, Pancholy S, Dzavik V, TOTAL Investigators. Outcomes after .. tion: should we change the guidelines? Eur Heart J 2009;30(4):459–468.
thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of .. 177. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt
the prospective randomised TOTAL trial. Lancet 2016;387(10014):127–135.
.. G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R,
161. Jolly SS, Cairns JA, Yusuf S, Meeks B, Gao P, Hart RG, Kedev S, Stankovic G, .. Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K, IABP-
Moreno R, Horak D, Kassam S, Rokoss MJ, Leung RC, El-Omar M, Romppanen .. SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarc-
HO, Alazzoni A, Alak A, Fung A, Alexopoulos D, Schwalm JD, Valettas N, . tion with cardiogenic shock. N Engl J Med 2012;367(14):1287–1296.
ESC Guidelines 57

178. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P,
.. 192. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM,
Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents .. Pollack CV, Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG,
reduce the risk of stent thrombosis at 4 years in patients undergoing percutane- .. Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH,
ous coronary intervention: a pooled analysis of individual patient data from the .. Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing
ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J .. PCI. N Engl J Med 2009;361(24):2318–2329.
2012;33(10):1214–1222. .. 193. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price
179. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M, .. MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth
Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone
.. J, Spriggs D, McLaurin BT, Angiolillo DJ, Genereux P, Liu T, Prats J, Todd M,
GW. Clinical outcomes with drug-eluting and bare-metal stents in patients with .. Skerjanec S, White HD, Harrington RA, CHAMPION PHOENIX Investigators.
ST-segment elevation myocardial infarction: evidence from a comprehensive .. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N
network meta-analysis. J Am Coll Cardiol 2013;62(6):496–504. .. Engl J Med 2013;368(14):1303–1313.
180. Karrowni W, Vyas A, Giacomino B, Schweizer M, Blevins A, Girotra S, Horwitz .. 194. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW,
PA. Radial versus femoral access for primary percutaneous interventions in ST- .. Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS,
segment elevation myocardial infarction patients: a meta-analysis of randomized .. Gruberg L, French WJ, White HD, Harrington RA, CHAMPION Investigators.
controlled trials. JACC Cardiovasc Interv 2013;6(8):814–823.
.. Effect of cangrelor on periprocedural outcomes in percutaneous coronary
181. Zeymer U, Hohlfeld T, Vom Dahl J, Erbel R, Munzel T, Zahn R, Roitenberg A, .. interventions: a pooled analysis of patient-level data. Lancet
Breitenstein S, Pap AF, Trenk D. Prospective, randomised trial of the time .. 2013;382(9909):1981–1992.
dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and .. 195. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L,
300 mg p. o. in ACS (ACUTE). Thromb Haemost 2017;117(3):625–635. .. Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O,
182. Montalescot G, van ’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, .. Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR,
Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, .. Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ,
Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM,
.. FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial
Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, .. infarction. N Engl J Med 2008;358(21):2205–2217.
Hamm CW, ATLANTIC Investigators. Prehospital ticagrelor in ST-segment ele- .. 196. ten Berg JM, van ’t Hof AW, Dill T, Heestermans T, van Werkum JW, Mosterd
vation myocardial infarction. N Engl J Med 2014;371(11):1016–1027. .. A, van Houwelingen G, Koopmans PC, Stella PR, Boersma E, Hamm C. Effect of
183. Koul S, Smith JG, Schersten F, James S, Lagerqvist B, Erlinge D. Effect of .. early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-
upstream clopidogrel treatment in patients with ST-segment elevation myocar- .. segment elevation myocardial infarction on short- and long-term clinical out-
dial infarction undergoing primary percutaneous coronary intervention. Eur .. come. J Am Coll Cardiol 2010;55(22):2446–2455.
Heart J 2011;32(23):2989–2997.
.. 197. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,
184. Dorler J, Edlinger M, Alber HF, Altenberger J, Benzer W, Grimm G, Huber K, .. Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane
Pachinger O, Schuchlenz H, Siostrzonek P, Zenker G, Weidinger F, Austrian .. AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators. Bivalirudin during
Acute PCI Investigators. Clopidogrel pre-treatment is associated with reduced .. primary PCI in acute myocardial infarction. N Engl J Med
in-hospital mortality in primary percutaneous coronary intervention for acute .. 2008;358(21):2218–2230.
ST-elevation myocardial infarction. Eur Heart J 2011;32(23):2954–1961. .. 198. Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled
185. Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Scholler R, Zahn R, .. trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa
Diller F, Darius H, Dill T, Huber K. Efficacy and safety of a high loading dose of .. inhibitors during percutaneous coronary intervention for acute coronary syn-
clopidogrel administered prehospitally to improve primary percutaneous coro-
.. drome. Am J Cardiol 2011;108(9):1244–1251.
nary intervention in acute myocardial infarction: the randomized CIPAMI trial. .. 199. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A,
Clin Res Cardiol 2012;101(4):305–312. .. Peters RJG, Bassand JP, Wallentin L, Joyner C, Fox KAA, OASIS-6 Trial Group.
186. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, .. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, .. segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA
Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel .. 2006;295(13):1519–1530.
in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001–2015. .. 200. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P,
187. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow
.. Ecollan P, Combes X, Huber K, Pollack C, Jr, Benezet JF, Stibbe O, Filippi E,
J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, .. Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout
Storey RF, Harrington RA, PLATO Investigators Freij A, Thorsen M. Ticagrelor .. M, Collet JP, Vicaut E, ATOLL Investigators. Intravenous enoxaparin or unfrac-
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med .. tionated heparin in primary percutaneous coronary intervention for ST-
2009;361(11):1045–1057. .. elevation myocardial infarction: the international randomised open-label
188. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, .. ATOLL trial. Lancet 2011;378(9792):693–703.
Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden .. 201. Collet JP, Huber K, Cohen M, Zeymer U, Goldstein P, Pollack C, Jr, Silvain J,
WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko
.. Henry P, Varenne O, Carrie D, Coste P, Angioi M, Le Breton H, Cayla G,
A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, .. Elhadad S, Teiger E, Filippi E, Aout M, Vicaut E, Montalescot G, ATOLL
Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, .. Investigators. A direct comparison of intravenous enoxaparin with unfractio-
Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM, .. nated heparin in primary percutaneous coronary intervention (from the
TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syn- .. ATOLL trial). Am J Cardiol 2013;112(9):1367–1372.
dromes without revascularization. N Engl J Med 2012;367(14):1297–1309. .. 202. Silvain J, Beygui F, Barthelemy O, Pollack C, Jr, Cohen M, Zeymer U, Huber K,
189. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, .. Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. Efficacy and safety of
Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L.
.. enoxaparin versus unfractionated heparin during percutaneous coronary inter-
Characterization of dyspnoea in PLATO study patients treated with ticagrelor .. vention: systematic review and meta-analysis. BMJ 2012;344:e553.
or clopidogrel and its association with clinical outcomes. Eur Heart J .. 203. Steg PG, van ’t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten
2011;32(23):2945–2953. .. Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell’ Orto M,
190. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon .. Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D,
DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, .. Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, EUROMAX Investigators.
Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, .. Bivalirudin started during emergency transport for primary PCI. N Engl J Med
Chrolavicius S, Gao P, Fox KA, Yusuf S, CURRENT-OASIS Trial Investigators. .. 2013;369(23):2207–2217.
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose
.. 204. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P,
aspirin in individuals undergoing percutaneous coronary intervention for acute .. Mehran R, Gershlick AH, Tolg R, Anette Fiedler K, Abdel-Wahab M, Kufner S,
coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet .. Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A, Bavarian Reperfusion
2010;376(9748):1233–1243. .. Alternatives Evaluation Investigators. Prasugrel plus bivalirudin vs. clopidogrel
191. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, .. plus heparin in patients with ST-segment elevation myocardial infarction. Eur
Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Jr, .. Heart J 2014;35(34):2285–2294.
Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, .. 205. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M,
Arneja J, Skerjanec S, Harrington RA, CHAMPION PLATFORM Investigators.
.. Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL,
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med .. Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, HEAT-
2009;361(24):2330–2341. .. PPCI Trial Investigators. Unfractionated heparin versus bivalirudin in primary
58 ESC Guidelines

percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre,
.. Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis in acute
randomised controlled trial. Lancet 2014;384(9957):1849–1858. .. myocardial infarction: a randomised study. Lancet 2002;360(9336):825–829.
206. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, .. 223. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2)
Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW, BRIGHT .. Investigators, Van de Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P,
Investigators. Bivalirudin vs heparin with or without tirofiban during primary .. Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger
percutaneous coronary intervention in acute myocardial infarction: the .. C, Heikkila J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J,
BRIGHT randomized clinical trial. JAMA 2015;313(13):1336–1346. .. Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R,
207. Zeymer U, van ’t Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg
.. Soares-Piegas L, Sugrue D, Tendera M, Topol E, Toutouzas P, Vahanian A,
J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, .. Verheugt F, Wallentin L, White H. Single-bolus tenecteplase compared with
Steg PG. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibi- .. front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-
tors in patients with ST-segment elevation myocardial infarction transported .. blind randomised trial. Lancet 1999;354(9180):716–722.
emergently for primary percutaneous coronary intervention: a pre-specified .. 224. The GUSTO Investigators. An international randomized trial comparing four
analysis from the EUROMAX trial. Eur Heart J 2014;35(36):2460–2467. .. thrombolytic strategies for acute myocardial infarction. N Engl J Med
208. Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW. .. 1993;329(10):673–682.
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in
.. 225. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS,
patients with STEMI undergoing primary PCI: An updated meta-analysis of .. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial)
10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc .. Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with
Care 2016;5(3):253–262. .. acute myocardial infarction: randomised placebo-controlled trial. Lancet
209. Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, .. 2005;366(9497):1607–1621.
Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, .. 226. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G,
Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, .. Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E,
Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N,
.. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrino-
Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabate .. lytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med
M, Heg D, Juni P, Vranckx P, MATRIX Investigators. Bivalirudin or unfractio- .. 2005;352(12):1179–1189.
nated heparin in acute coronary syndromes. N Engl J Med .. 227. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen
2015;373(11):997–1009. .. (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination
210. Leonardi S, Frigoli E, Rothenbuhler M, Navarese E, Calabro P, Bellotti P, .. with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 rando-
Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, .. mised trial in acute myocardial infarction. Lancet 2001;358(9282):605–613.
Esposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F,
.. 228. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ, Arntz HR,
Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van .. Bogaerts K, Danays T, Lindahl B, Makijarvi M, Verheugt F, Van de Werf F.
Mieghem NM, Heg D, Juni P, Windecker S, Valgimigli M, Investigators M. .. Efficacy and safety of tenecteplase in combination with the low-molecular-
Bivalirudin or unfractionated heparin in patients with acute coronary syndromes .. weight heparin enoxaparin or unfractionated heparin in the prehospital setting -
managed invasively with and without ST elevation (MATRIX): randomised con- .. the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen
trolled trial. BMJ 2016;354:i4935. .. (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation
211. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, .. 2003;108(2):135–142.
Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, .. 229. Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J,
Dirschinger J, Richardt G, Berger PB, Schomig A, ISAR-REACT 3 Trial
.. Parkhomenko A, Molhoek P, Mohanavelu S, Morrow DA, Antman EM.
Investigators. Bivalirudin versus unfractionated heparin during percutaneous .. Enoxaparin is superior to unfractionated heparin in patients with ST elevation
coronary intervention. N Engl J Med 2008;359(7):688–696. .. myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an
212. Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, Laugwitz KL, .. ExTRACT-TIMI 25 analysis. Eur Heart J 2007;28(13):1566–1573.
Neumann FJ, Seyfarth M, Berger PB, Schomig A, Kastrati A. Bleeding after per- .. 230. White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L,
cutaneous coronary intervention with Bivalirudin or unfractionated Heparin .. Antman EM. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-
and one-year mortality. Am J Cardiol 2010;105(2):163–167. .. elevation myocardial infarction in elderly and younger patients: results from
213. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
.. ExTRACT-TIMI 25. Eur Heart J 2007;28(9):1066–1071.
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither .. 231. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, Le
among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet .. Louer V, Bigonzi F, Schwartz W, de Jong E, Coyne K. Randomized comparison
1988;2(8607):349–360. .. of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin
214. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De .. adjunctive to recombinant tissue plasminogen activator thrombolysis and
Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann FJ, .. aspirin: second trial of heparin and aspirin reperfusion therapy (HART II).
Rasmussen LH, Siegbahn A, Steg PG, Storey RF, Van de Werf F, Verheugt F. .. Circulation 2001;104(6):648–652.
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur
.. 232. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand
Heart J 2011;32(23):2922–2932. .. JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, Van de Werf
215. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for .. F. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial
percutaneous coronary intervention: a meta-analysis of randomised controlled .. infarction: results of the ENTIRE-thrombolysis in myocardial infarction (TIMI)
trials. Lancet 2014;384(9943):599–606. .. 23 trial. Circulation 2002;105(14):1642–1649.
216. Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, Maehara A, .. 233. Peters RJ, Joyner C, Bassand JP, Afzal R, Chrolavicius S, Mehta SR, Oldgren J,
Eitel I, Granger CB, Jenkins PL, Nichols M, Ben-Yehuda O. Relationship .. Wallentin L, Budaj A, Fox KA, Yusuf S, OASIS-6 Investigators. The role of fon-
between infarct size and outcomes following primary PCI: patient-level analysis
.. daparinux as an adjunct to thrombolytic therapy in acute myocardial infarction:
from 10 randomized trials. J Am Coll Cardiol 2016;67(14):1674–1683. .. a subgroup analysis of the OASIS-6 trial. Eur Heart J 2008;29(3):324–331.
217. Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial .. 234. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, Vazquez N, Blanco J, Alonso-
ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454–1471. .. Briales J, Lopez-Mesa J, Fernandez-Vazquez F, Calvo I, Martinez-Elbal L, San
218. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction .. Roman JA, Ramos B, GRACIA (Grupo de Analisis de la Cardiopatıa Isquémica
in acute myocardial infarction. Eur Heart J 2016;37(13):1024–1033. .. Aguda) Group. Routine invasive strategy within 24 hours of thrombolysis versus
219. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Kloner .. ischaemia-guided conservative approach for acute myocardial infarction with
RA, Ovize M, Yellon DM, Garcia-Dorado D. Targeting reperfusion injury in .. ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet
patients with ST-segment elevation myocardial infarction: trials and tribulations.
.. 2004;364(9439):1045–1053.
Eur Heart J 2017;38(13):935–941. .. 235. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG,
220. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibri- .. Steingart R, Picard MH, Menegus MA, Boland J, Sanborn T, Buller CE, Modur S,
nolytic therapy in suspected acute myocardial infarction: collaborative overview .. Forman R, Desvigne-Nickens P, Jacobs AK, Slater JN, LeJemtel TH, SHOCK
of early mortality and major morbidity results from all randomised trials of .. Investigators. One-year survival following early revascularization for cardiogenic
more than 1000 patients. Lancet 1994;343(8893):311–322. .. shock. JAMA 2001;285(2):190–192.
221. White HD. Thrombolytic therapy in the elderly. Lancet 2000;356(9247): .. 236. Ellis SG, da Silva ER, Heyndrickx G, Talley JD, Cernigliaro C, Steg G, Spaulding
.. C, Nobuyoshi M, Erbel R, Vassanelli C, Topol EJ, RESCUE Investigators.
222. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, .. Randomized comparison of rescue angioplasty with conservative management
Cattan S, Boullenger E, Machecourt J, Lacroute JM, Cassagnes J, Dissait F, Touboul .. of patients with early failure of thrombolysis for acute anterior myocardial
P, Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial . infarction. Circulation 1994;90(5):2280–2284.
ESC Guidelines 59

237. Assessment of the Safety and Efficacy of a New Treatment Strategy with
.. 254. Hasin Y, Danchin N, Filippatos GS, Heras M, Janssens U, Leor J, Nahir M,
Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary .. Parkhomenko A, Thygesen K, Tubaro M, Wallentin LC, Zakke I.
versus tenecteplase-facilitated percutaneous coronary intervention in patients .. Recommendations for the structure, organization, and operation of intensive
with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): rando- .. cardiac care units. Eur Heart J 2005;26(16):1676–1682.
mised trial. Lancet 2006;367(9510):569–578. .. 255. Spencer FA, Lessard D, Gore JM, Yarzebski J, Goldberg RJ. Declining length of
238. Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, .. hospital stay for acute myocardial infarction and postdischarge outcomes: a
Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki .. community-wide perspective. Arch Intern Med 2004;164(7):733–740.
E, Bogaerts K, Van de Werf F, STREAM Investigators. ST-segment-elevation
.. 256. Berger AK, Duval S, Jacobs DR, Jr, Barber C, Vazquez G, Lee S, Luepker RV.
myocardial infarction patients randomized to a pharmaco-invasive strategy or .. Relation of length of hospital stay in acute myocardial infarction to postdi-
primary percutaneous coronary intervention: Strategic Reperfusion Early After .. scharge mortality. Am J Cardiol 2008;101(4):428–434.
Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation .. 257. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR,
2014;130(14):1139–1145. .. Balestrini C, Stone G, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M,
239. Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, Winter H, .. Ayres M, Jones D, Mason D, Sachs D, Grines LL, O’Neill W. Safety and cost-
Nickenig G, Bohm M, SIAM III Study Group. Beneficial effects of immediate .. effectiveness of early discharge after primary angioplasty in low risk patients
stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol
.. with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in
2003;42(4):634–641. .. Myocardial Infarction. J Am Coll Cardiol 1998;31(5):967–972.
240. Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, Maloney J, .. 258. De Luca G, Suryapranata H, van ’t Hof AW, de Boer MJ, Hoorntje JC,
McKibbin T, Quinn B, Beanlands RS, Glover C, Marquis JF, O’Brien ER, Williams .. Dambrink JH, Gosselink AT, Ottervanger JP, Zijlstra F. Prognostic assessment
WL, Higginson LA. Combined angioplasty and pharmacological intervention .. of patients with acute myocardial infarction treated with primary angioplasty:
versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). .. implications for early discharge. Circulation 2004;109(22):2737–2743.
J Am Coll Cardiol 2005;46(3):417–424. .. 259. Azzalini L, Sole E, Sans J, Vila M, Duran A, Gil-Alonso D, Santalo M, Garcia-Moll
241. Abdel-Qadir H, Yan AT, Tan M, Borgia F, Piscione F, Di Mario C, Halvorsen S,
.. X, Sionis A. Feasibility and safety of an early discharge strategy after low-risk
Cantor WJ, Westerhout CM, Scheller B, Le May MR, Fernandez-Aviles F, Sanchez .. acute myocardial infarction treated with primary percutaneous coronary inter-
PL, Lee DS, Goodman SG. Consistency of benefit from an early invasive strategy .. vention: the EDAMI pilot trial. Cardiology 2015;130(2):120–129.
after fibrinolysis: a patient-level meta-analysis. Heart 2015;101(19):1554–1561. .. 260. Melberg T, Jorgensen M, Orn S, Solli T, Edland U, Dickstein K. Safety and health
242. Sanchez PL, Gimeno F, Ancillo P, Sanz JJ, Alonso-Briales JH, Bosa F, Santos I, .. status following early discharge in patients with acute myocardial infarction treated
Sanchis J, Bethencourt A, Lopez-Messa J, de Prado AP, Alonso JJ, San Roman JA, .. with primary PCI: a randomized trial. Eur J Prev Cardiol 2015;22(11):1427–1434.
Fernandez-Aviles F. Role of the paclitaxel-eluting stent and tirofiban in patients .. 261. Noman A, Zaman AG, Schechter C, Balasubramaniam K, Das R. Early discharge
with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the
.. after primary percutaneous coronary intervention for ST-elevation myocardial
GRACIA-3 randomized clinical trial. Circ Cardiovasc Interv 2010;3(4):297–307. .. infarction. Eur Heart J Acute Cardiovasc Care 2013;2(3):262–269.
243. White HD, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial .. 262. Jones DA, Rathod KS, Howard JP, Gallagher S, Antoniou S, De Palma R,
Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin .. Guttmann O, Cliffe S, Colley J, Butler J, Ferguson E, Mohiddin S, Kapur A,
in patients receiving fibrinolytic therapy for acute myocardial infarction: the .. Knight CJ, Jain AK, Rothman MT, Mathur A, Timmis AD, Smith EJ, Wragg A.
HERO-2 randomised trial. Lancet 2001;358(9296):1855–1863. .. Safety and feasibility of hospital discharge 2 days following primary percutane-
244. Fernandez-Aviles F, Alonso JJ, Pena G, Blanco J, Alonso-Briales J, Lopez-Mesa J, .. ous intervention for ST-segment elevation myocardial infarction. Heart
Fernandez-Vazquez F, Moreu J, Hernandez RA, Castro-Beiras A, Gabriel R, .. 2012;98(23):1722–1727.
Gibson CM, Sanchez PL, GRACIA-2 (Groupo de Analisis de Cardiopatıa
.. 263. Estevez-Loureiro R, Calvino-Santos R, Vazquez JM, Barge-Caballero E, Salgado-
Isquémica Aguda) Investigators. Primary angioplasty vs. early routine post- .. Fernandez J, Pineiro M, Freire-Tellado M, Varela-Portas J, Martinez L, Gomez S,
fibrinolysis angioplasty for acute myocardial infarction with ST-segment eleva- .. Rodriguez JA, Vazquez N, Castro-Beiras A. Safety and feasibility of returning
tion: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J .. patients early to their originating centers after transfer for primary percutane-
2007;28(8):949–960. .. ous coronary intervention. Rev Esp Cardiol 2009;62(12):1356–1364.
245. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, .. 264. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA,
Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL, ASSENT- .. Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myo-
2 Investigators, Assessment of the safety and efficacy of a new thrombolytic.
.. cardial infarction: A convenient, bedside, clinical score for risk assessment at
Incidence and predictors of bleeding events after fibrinolytic therapy with .. presentation: An intravenous nPA for treatment of infarcting myocardium early
fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J .. II trial substudy. Circulation 2000;102(17):2031–2037.
2001;22(24):2253–2261. .. 265. Newby LK, Hasselblad V, Armstrong PW, Van de Werf F, Mark DB, White HD,
246. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO .. Topol EJ, Califf RM. Time-based risk assessment after myocardial infarction.
III) Investigators. A comparison of reteplase with alteplase for acute myocardial .. Implications for timing of discharge and applications to medical decision-making.
infarction. N Engl J Med 1997;337(16):1118–1123. .. Eur Heart J 2003;24(2):182–189.
247. Bottiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T,
.. 266. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M,
Carli PA, Adgey JA, Bode C, Wenzel V, TROICA Trial Investigators, European .. Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of
Resuscitation Council Study Group. Thrombolysis during resuscitation for out- .. antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation
of-hospital cardiac arrest. N Engl J Med 2008;359(25):2651–2662. .. of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation
248. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller .. 2013;127(5):634–640.
CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revasculariza- .. 267. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen
tion in acute myocardial infarction complicated by cardiogenic shock. SHOCK .. C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of
Investigators. Should We Emergently Revascularize Occluded Coronaries for
.. bleeding in patients with acute myocardial infarction treated with different com-
Cardiogenic Shock. N Engl J Med 1999;341(9):625–634. .. binations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retro-
249. Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD. Optimal timing of .. spective analysis of nationwide registry data. Lancet
coronary artery bypass after acute myocardial infarction: a review of California .. 2009;374(9706):1967–1974.
discharge data. J Thorac Cardiovasc Surg 2008;135(3):503–511. .. 268. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N,
250. Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A, Ivert T, .. Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE,
Nozohoor S, Barbu M, Svedjeholm R, Jeppsson A. Coronary artery bypass .. Kober L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy
grafting-related bleeding complications in patients treated with ticagrelor or .. with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch
clopidogrel: a nationwide study. Eur Heart J 2016;37(2):189–197.
.. Intern Med 2010;170(16):1433–1441.
251. Deja MA, Kargul T, Domaradzki W, Stacel T, Mazur W, Wojakowski W, Gocol .. 269. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG,
R, Gaszewska-Zurek E, Zurek P, Pytel A, Wos S. Effects of preoperative aspirin .. Van de Werf F, Wallentin L, Investigators R-D. Dabigatran vs. placebo in
in coronary artery bypass grafting: a double-blind, placebo-controlled, random- .. patients with acute coronary syndromes on dual antiplatelet therapy: a random-
ized trial. J Thorac Cardiovasc Surg 2012;144(1):204–209. .. ized, double-blind, phase II trial. Eur Heart J 2011;32(22):2781–2789.
252. Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S. Indirect com- .. 270. Barnes GD, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D,
parison meta-analysis of aspirin therapy after coronary surgery. BMJ .. Krol GD, Froehlich JB, Kaatz S. The predictive ability of the CHADS2 and
.. CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2)
253. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves .. experience. Thromb Res 2014;134(2):294–299.
vein graft patency early and late after coronary artery bypass graft surgery. A .. 271. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M,
placebo-controlled, randomized study. Circulation 1991;83(5):1526–1533. . Vicente V, Lip GY. The HAS-BLED score has better prediction accuracy for
60 ESC Guidelines

major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated
.. 289. La Canna G, Rahimtoola SH, Visioli O, Giubbini R, Alfieri O, Zognio M, Milan E,
patients with atrial fibrillation. J Am Coll Cardiol 2013;62(23):2199–2204. .. Ceconi C, Gargano M, Lo Russo R, Ferrari R. Sensitivity, specificity, and predic-
272. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, .. tive accuracies of non-invasive tests, singly and in combination, for diagnosis of
Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, .. hibernating myocardium. Eur Heart J 2000;21(16):1358–1367.
Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients .. 290. Gerber BL, Rousseau MF, Ahn SA, le Polain de Waroux JB, Pouleur AC, Phlips
with atrial fibrillation undergoing PCI. N Engl J Med 2016;375(25):2423–2434. .. T, Vancraeynest D, Pasquet A, Vanoverschelde JL. Prognostic value of myocar-
273. Toleva O, Ibrahim Q, Brass N, Sookram S, Welsh R. Treatment choices in eld- .. dial viability by delayed-enhanced magnetic resonance in patients with coronary
erly patients with ST: elevation myocardial infarction-insights from the Vital
.. artery disease and low ejection fraction: impact of revascularization therapy. J
Heart Response registry. Open Heart 2015;2(1):e000235. .. Am Coll Cardiol 2012;59(9):825–835.
274. Malkin CJ, Prakash R, Chew DP. The impact of increased age on outcome from .. 291. Shah DJ, Kim HW, James O, Parker M, Wu E, Bonow RO, Judd RM, Kim RJ.
a strategy of early invasive management and revascularisation in patients with .. Prevalence of regional myocardial thinning and relationship with myocardial
acute coronary syndromes: retrospective analysis study from the ACACIA .. scarring in patients with coronary artery disease. JAMA 2013;309(9):909–918.
registry. BMJ Open 2012;2(1):e000540. .. 292. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn
275. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, .. KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko
Pollack C, Gibler WB, Ohman EM, Peterson ED, CRUSADE Investigators.
.. RM, PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomog-
Excess dosing of antiplatelet and antithrombin agents in the treatment of non- .. raphy imaging-assisted management of patients with severe left ventricular dys-
ST-segment elevation acute coronary syndromes. JAMA .. function and suspected coronary disease: a randomized, controlled trial (PARR-
2005;294(24):3108–3116. .. 2). J Am Coll Cardiol 2007;50(20):2002–2012.
276. Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, Garcia EJ, Lopez-Sendon JL, .. 293. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing
Macaya C, Hernandez-Antolin R, TRIANA Investigators. Primary angioplasty vs. .. and impact of revascularization on prognosis in patients with coronary artery
fibrinolysis in very old patients with acute myocardial infarction: TRIANA .. disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol
(TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial
.. 2002;39(7):1151–1158.
and pooled analysis with previous studies. Eur Heart J 2011;32(1):51–60. .. 294. Eitel I, de Waha S, Wohrle J, Fuernau G, Lurz P, Pauschinger M, Desch S,
277. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, .. Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imaging
Wallentin L, Jernberg T, SWEDEHEART. Relation between renal function, .. after ST-segment elevation myocardial infarction. J Am Coll Cardiol
presentation, use of therapies and in-hospital complications in acute coronary .. 2014;64(12):1217–1226.
syndrome: data from the SWEDEHEART register. J Intern Med 2010;268(1): .. 295. Neskovic AN, Hagendorff A, Lancellotti P, Guarracino F, Varga A, Cosyns B,
40–49. .. Flachskampf FA, Popescu BA, Gargani L, Zamorano JL, Badano LP, European
278. Timmer JR, Ottervanger JP, de Boer MJ, Boersma E, Grines CL, Westerhout
.. Association of Cardiovascular Imaging. Emergency echocardiography: the
CM, Simes RJ, Granger CB, Zijlstra F, Primary Coronary Angioplasty vs .. European Association of Cardiovascular Imaging recommendations. Eur Heart J
Thrombolysis-2 Trialists Collaborators Group. Primary percutaneous coronary .. Cardiovasc Imaging 2013;14(1):1–11.
intervention compared with fibrinolysis for myocardial infarction in diabetes .. 296. Soholm H, Lonborg J, Andersen MJ, Vejlstrup N, Engstrom T, Moller JE,
mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. .. Hassager C. Repeated echocardiography after first ever ST-segment elevation
Arch Intern Med 2007;167(13):1353–1359. .. myocardial infarction treated with primary percutaneous coronary intervention
279. Alderman EL, Kip KE, Whitlow PL, Bashore T, Fortin D, Bourassa MG, .. – is it necessary? Eur Heart J Acute Cardiovasc Care 2015;4(6):528–536.
Lesperance J, Schwartz L, Stadius M, Bypass Angioplasty Revascularization .. 297. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR,
Investigation. Native coronary disease progression exceeds failed revasculariza-
.. Lamas GA, Klein M, Sussex B, Goldman S, Menapace FJ, Jr, Parker JO, Lewis S,
tion as cause of angina after five years in the Bypass Angioplasty .. Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E, SAVE
Revascularization Investigation (BARI). J Am Coll Cardiol 2004;44(4):766–774. .. Investigators. Quantitative two-dimensional echocardiographic measurements
280. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, .. are major predictors of adverse cardiovascular events after acute myocardial
Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L, PLATO Study Group. .. infarction. The protective effects of captopril. Circulation 1994;89(1):68–75.
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabe- .. 298. Carlos ME, Smart SC, Wynsen JC, Sagar KB. Dobutamine stress echocardiography
tes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) .. for risk stratification after myocardial infarction. Circulation 1997;95(6):1402–1410.
trial. Eur Heart J 2010;31(24):3006–3016.
.. 299. Brown KA, Heller GV, Landin RS, Shaw LJ, Beller GA, Pasquale MJ, Haber SB.
281. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster .. Early dipyridamole (99m)Tc-sestamibi single photon emission computed tomo-
D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, .. graphic imaging 2 to 4 days after acute myocardial infarction predicts in-hospital
Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, .. and postdischarge cardiac events: comparison with submaximal exercise imag-
Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glu- .. ing. Circulation 1999;100(20):2060–2066.
cose control in critically ill patients. N Engl J Med 2009;360(13):1283–1297. .. 300. Bulluck H, White SK, Frohlich GM, Casson SG, O’Meara C, Newton A,
282. Senthinathan A, Kelly V, Dzingina M, Jones D, Baker M, Longson D, Guideline .. Nicholas J, Weale P, Wan SM, Sirker A, Moon JC, Yellon DM, Groves A,
Development Group. Hyperglycaemia in acute coronary syndromes: summary
.. Menezes L, Hausenloy DJ. Quantifying the area at risk in reperfused ST-
of NICE guidance. BMJ 2011;343:d6646. .. segment-elevation myocardial infarction patients using hybrid cardiac positron
283. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, .. emission tomography-magnetic resonance imaging. Circ Cardiovasc Imaging
Avezum A, Goodman SG, Flather MD, Anderson FA, Jr, Granger CB. .. 2016;9(3):e003900.
Prediction of risk of death and myocardial infarction in the six months after pre- .. 301. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of
sentation with acute coronary syndrome: prospective multinational observatio- .. diet, exercise, and smoking modification with risk of early cardiovascular events
nal study (GRACE). BMJ 2006;333(7578):1091. .. after acute coronary syndromes. Circulation 2010;121(6):750–758.
284. Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, Coste P,
.. 302. Thomson CC, Rigotti NA. Hospital- and clinic-based smoking cessation inter-
Monsegu J, Gabriel Steg P, Danchin N, Anderson F. Should patients with acute .. ventions for smokers with cardiovascular disease. Prog Cardiovasc Dis
coronary disease be stratified for management according to their risk? .. 2003;45(6):459–479.
Derivation, external validation and outcomes using the updated GRACE risk .. 303. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation
score. BMJ Open 2014;4(2):e004425. .. in hospitalised patients. Cochrane Database Syst Rev 2012;5:CD001837.
285. van Loon RB, Veen G, Baur LH, Kamp O, Bronzwaer JG, Twisk JW, Verheugt .. 304. Critchley JA, Capewell S. Mortality risk reduction associated with smoking ces-
FW, van Rossum AC. Improved clinical outcome after invasive management of .. sation in patients with coronary heart disease: a systematic review. JAMA
patients with recent myocardial infarction and proven myocardial viability: pri- .. 2003;290(1):86–97.
mary results of a randomized controlled trial (VIAMI-trial). Trials 2012;13:1.
.. 305. Rallidis LS, Pavlakis G. The fundamental importance of smoking cessation in
286. van Loon RB, Veen G, Baur LH, Twisk JW, van Rossum AC. Long-term follow- .. those with premature ST-segment elevation acute myocardial infarction. Curr
up of the viability guided angioplasty after acute myocardial infarction (VIAMI) .. Opin Cardiol 2016;31(5):531–536.
trial. Int J Cardiol 2015;186:111–116. .. 306. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy
287. Neskovic AN, Bojic M, Popovic AD. Detection of significant residual stenosis of .. and behavioural interventions for smoking cessation. Cochrane Database Syst Rev
the infarct-related artery after thrombolysis by high-dose dipyridamole echo- .. 2016;3:CD008286.
cardiography test: is it detected often enough? Clin Cardiol 1997;20(6):569–572. .. 307. McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for
288. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow
.. smoking cessation and reduction. Cochrane Database Syst Rev
RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to .. 2014;12:CD010216.
identify reversible myocardial dysfunction. N Engl J Med 2000;343(20): .. 308. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N,
1445–1453. . Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R,
ESC Guidelines 61

Jackson Ch L, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, .. Jedraszewski D, Cotoi C, Haynes RB. Interventions for enhancing medication
Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR,
.. adherence. Cochrane Database Syst Rev 2014;11:CD000011.
Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda .. 325. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for
RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK, .. smoking cessation: an overview and network meta-analysis. Cochrane Database
Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima .. Syst Rev 2013;5:CD009329.
H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Z, Gapstur SM, Gunter .. 326. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation.
MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, .. Cochrane Database Syst Rev 2007;1:CD000031.
Danesh J, Hu FB. Body-mass index and all-cause mortality: individual- .. 327. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking
participant-data meta-analysis of 239 prospective studies in four continents. .. cessation. Cochrane Database Syst Rev 2012;4:CD006103.
Lancet 2016;388(10046):776–786.
.. 328. Anderson L, Taylor RS. Cardiac rehabilitation for people with heart disease: an
309. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, Taylor .. overview of Cochrane systematic reviews. Cochrane Database Syst Rev
RS. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane .. 2014;12:CD011273.
systematic review and meta-analysis. J Am Coll Cardiol 2016;67(1):1–12. .. 329. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, Collins R,
310. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone .. Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T,
JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with .. Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and
coronary heart disease: systematic review and meta-analysis of randomized .. secondary prevention of vascular disease: collaborative meta-analysis of
controlled trials. Am J Med 2004;116(10):682–692.
.. individual participant data from randomised trials. Lancet 2009;373(9678):
311. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre .. 1849–1860.
based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ .. 330. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R,
2010;340:b5631. .. Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ,
312. European Association of Cardiovascular Prevention and Rehabilitation .. Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and
Committee for Science Guidelines, EACPR, Corra U, Piepoli MF, Carre F, .. aspirin in acute coronary syndromes. N Engl J Med 2010;363(10):930–942.
Heuschmann P, Hoffmann U, Verschuren M, Halcox J, Document R, Giannuzzi .. 331. Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-
P, Saner H, Wood D, Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B,
.. eluting stent implantation: will we ever reach a consensus? Eur Heart J
Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AD, Schmid JP. .. 2015;36(20):1219–1222.
Secondary prevention through cardiac rehabilitation: physical activity counsel- .. 332. Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E, Guastaroba P, De Palma R,
ling and exercise training: key components of the position paper from the .. Ando G, Oreto G, Zijlstra F, Valgimigli M. Incremental value of the CRUSADE,
Cardiac Rehabilitation Section of the European Association of Cardiovascular .. ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events
Prevention and Rehabilitation. Eur Heart J 2010;31(16):1967–1974. .. after coronary stent implantation in patients undergoing long or short duration
313. Dreyer RP, Xu X, Zhang W, Du X, Strait KM, Bierlein M, Bucholz EM, Geda M, .. of dual antiplatelet therapy. J Am Heart Assoc 2015;4(12):e002524.
Fox J, D’Onofrio G, Lichtman JH, Bueno H, Spertus JA, Krumholz HM. Return
.. 333. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G,
to work after acute myocardial infarction: comparison between young women .. Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P,
and men. Circ Cardiovasc Qual Outcomes 2016;9(2 Suppl 1):S45–S52. .. Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott
314. Smith D, Toff W, Joy M, Dowdall N, Johnston R, Clark L, Gibbs S, Boon N, .. SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI 54 Steering Committee
Hackett D, Aps C, Anderson M, Cleland J. Fitness to fly for passengers with car- .. and Investigators. Long-term use of ticagrelor in patients with prior myocardial
diovascular disease. Heart 2010;96(Suppl 2):ii1–ii16. .. infarction. N Engl J Med 2015;372(19):1791–1800.
315. SPRINT Research Group, Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, .. 334. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel
.. Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr, Krucoff
PL, Johnson KC, Goff DC, Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK,
.. MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP,
Ambrosius WT. A randomized trial of intensive versus standard blood-pressure .. Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve
control. N Engl J Med 2015;373(22):2103–2116. .. or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med
316. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, .. 2014;371(23):2155–2166.
Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, .. 335. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K,
Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid .. Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A,
CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, .. Kjeldsen K, Storey RF, ESC Working Group on Cardiovascular Pharmacology
Dagenais G, Yusuf S, HOPE-3 Investigators. Blood-pressure lowering in
.. and Drug Therapy and ESC Working Group on Thrombosis. Expert position
intermediate-risk persons without cardiovascular disease. N Engl J Med .. paper on the use of proton pump inhibitors in patients with cardiovascular dis-
2016;374(21):2009–2020. .. ease and antithrombotic therapy. Eur Heart J 2013;34(23):1708–1713,
317. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, .. 1713a–1713b.
Johnson JA. A meta-analysis of the association between adherence to drug ther- .. 336. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL,
apy and mortality. BMJ 2006;333(7557):15. .. Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP,
318. Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of .. COGENT Investigators. Clopidogrel with or without omeprazole in coronary
first postdischarge follow-up and medication adherence after acute myocardial
.. artery disease. N Engl J Med 2010;363(20):1909–1917.
infarction. JAMA Cardiol 2016;1(2):147–155. .. 337. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S,
319. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovas- .. Vranckx P, Windecker S, Valgimigli M. Impact of proton pump inhibitors on
cular disease: meta-analysis on 376,162 patients. Am J Med .. clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet
2012;125(9):882–887 e1. .. therapy duration: Insights from the PROlonging Dual-antiplatelet treatment
320. Marcum ZA, Sevick MA, Handler SM. Medication nonadherence: a diagnosable .. after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J
and treatable medical condition. JAMA 2013;309(20):2105–2106. .. 2016;174:95–102.
321. Castellano JM, Sanz G, Fernandez Ortiz A, Garrido E, Bansilal S, Fuster V. A
.. 338. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,
polypill strategy to improve global secondary cardiovascular prevention: from .. Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,
concept to reality. J Am Coll Cardiol 2014;64(6):613–621. .. Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2–TIMI 51
322. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, .. Investigators. Rivaroxaban in patients with a recent acute coronary syndrome.
Bots ML, Reddy KS, Cidambi R, Bompoint S, Billot L, Rodgers A, UMPIRE .. N Engl J Med 2012;366(1):9–19.
Collaborative Group. Effects of a fixed-dose combination strategy on adher- .. 339. Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid A,
ence and risk factors in patients with or at high risk of CVD: the UMPIRE .. Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Mariani A, Della Riva
randomized clinical trial. JAMA 2013;310(9):918–929.
.. D, Genereux P, Leon MB, Bhatt DL, Bendetto U, Rapezzi C, Stone GW. Short-
323. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L,
.. versus long-term dual antiplatelet therapy after drug-eluting stent implantation:
Guzman L, Linares JC, Garcia F, D’Aniello F, Arnaiz JA, Varea S, Martinez F, .. an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol
Lorenzatti A, Imaz I, Sanchez-Gomez LM, Roncaglioni MC, Baviera M, Smith SC, .. 2015;65(11):1092–1102.
Jr, Taubert K, Pocock S, Brotons C, Farkouh ME, Fuster V. A polypill strategy to .. 340. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A,
improve adherence: results from the FOCUS project. J Am Coll Cardiol .. Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park
2014;64(20):2071–2082. .. KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Genereux P,
324. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, .. Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve
Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA,
.. months of dual antiplatelet therapy after DES implantation in patients with or
62 ESC Guidelines

without acute coronary syndromes: an individual patient data pairwise and net-
.. 355. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd
work meta-analysis of six randomized trials and 11 473 patients. Eur Heart J .. DB, Hlatky MA. Beta-blocker therapy and cardiac events among patients with
2017;38(14):1034–1043. .. newly diagnosed coronary heart disease. J Am Coll Cardiol 2014;64(3):247–252.
341. Reeder GS, Lengyel M, Tajik AJ, Seward JB, Smith HC, Danielson GK. Mural .. 356. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM,
thrombus in left ventricular aneurysm: incidence, role of angiography, and rela- .. Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL, REACH
tion between anticoagulation and embolization. Mayo Clin Proc .. Registry Investigators. Beta-blocker use and clinical outcomes in stable outpatients
1981;56(2):77–81. .. with and without coronary artery disease. JAMA 2012;308(13):1340–1349.
342. Keeley EC, Hillis LD. Left ventricular mural thrombus after acute myocardial
.. 357. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in
infarction. Clinical Cardiology 1996;19(2):83–86. .. patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
343. Turpie AG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, .. Lancet 2001;357(9266):1385–1390.
Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutane- .. 358. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
ous heparin to prevent left ventricular mural thrombosis in patients with acute .. Lancet 1999;353(9146):9–13.
transmural anterior myocardial infarction. N Engl J Med 1989;320(6):352–357. .. 359. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL,
344. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS, .. Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol
COMMIT Collaborative Group. Early intravenous then oral metoprolol in
.. Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol
45,852 patients with acute myocardial infarction: randomised placebo- .. on survival in severe chronic heart failure. N Engl J Med
controlled trial. Lancet 2005;366(9497):1622–1632. .. 2001;344(22):1651–1658.
345. Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, van de Werf .. 360. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
F, Stebbins AL, Lee KL, Topol EJ, Armstrong PW. Atenolol use and clinical out- .. Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet
comes after thrombolysis for acute myocardial infarction: the GUSTO-I experi- .. 1999;353(9169):2001–2007.
ence. Global Utilization of Streptokinase and TPA (alteplase) for Occluded .. 361. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A,
Coronary Arteries. J Am Coll Cardiol 1998;32(3):634–640.
.. Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J,
346. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, .. Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-
Mukherjee D. Early intravenous beta-blockers in patients with acute coronary .. Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of
syndrome—a meta-analysis of randomized trials. Int J Cardiol .. nebivolol on mortality and cardiovascular hospital admission in elderly patients
2013;168(2):915–921. .. with heart failure (SENIORS). Eur Heart J 2005;26(3):215–225.
347. Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, .. 362. Bugiardini R, Cenko E, Ricci B, Vasiljevic Z, Dorobantu M, Kedev S, Vavlukis M,
Fernandez-Ortiz A, Garcia-Ruiz JM, Garcia-Alvarez A, Iniguez A, Jimenez- .. Kalpak O, Puddu PE, Gustiene O, Trninic D, Knezevic B, Milicic D, Gale CP,
Borreguero J, Lopez-Romero P, Fernandez-Jimenez R, Goicolea J, Ruiz-Mateos B,
.. Manfrini O, Koller A, Badimon L. Comparison of early versus delayed oral beta
Bastante T, Arias M, Iglesias-Vazquez JA, Rodriguez MD, Escalera N, Acebal C, .. blockers in acute coronary syndromes and effect on outcomes. Am J Cardiol
Cabrera JA, Valenciano J, Perez de Prado A, Fernandez-Campos MJ, Casado I, .. 2016;117(5):760–767.
Garcia-Rubira JC, Garcia-Prieto J, Sanz-Rosa D, Cuellas C, Hernandez-Antolin R, .. 363. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A,
Albarran A, Fernandez-Vazquez F, de la Torre-Hernandez JM, Pocock S, Sanz G, .. Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists
Fuster V. Effect of early metoprolol on infarct size in ST-segment-elevation myo- .. Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospec-
cardial infarction patients undergoing primary percutaneous coronary interven- .. tive meta-analysis of data from 90,056 participants in 14 randomised trials of
tion: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial .. statins. Lancet 2005;366(9493):1267–1278.
Infarction (METOCARD-CNIC) trial. Circulation 2013;128(14):1495–1503.
.. 364. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal
348. Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz JM, .. SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and
Garcia-Alvarez A, Mateos A, Barreiro MV, Escalera N, Rodriguez MD, de .. Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.
Miguel A, Garcia-Lunar I, Parra-Fuertes JJ, Sanchez-Gonzalez J, Pardillos L, .. Intensive versus moderate lipid lowering with statins after acute coronary syn-
Nieto B, Jimenez A, Abejon R, Bastante T, Martinez de Vega V, Cabrera JA, .. dromes. N Engl J Med 2004;350(15):1495–1504.
Lopez-Melgar B, Guzman G, Garcia-Prieto J, Mirelis JG, Zamorano JL, Albarran .. 365. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D,
A, Goicolea J, Escaned J, Pocock S, Iniguez A, Fernandez-Ortiz A, Sanchez- .. Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with
Brunete V, Macaya C, Ibanez B. Long-term benefit of early pre-reperfusion
.. Aggressive Cholesterol Lowering Study Investigators. Effects of atorvastatin on
metoprolol administration in patients with acute myocardial infarction: results .. early recurrent ischemic events in acute coronary syndromes: the MIRACL
from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection .. study: a randomized controlled trial. JAMA 2001;285(13):1711–1718.
During an Acute Myocardial Infarction). J Am Coll Cardiol 2014;63(22): .. 366. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L,
2356–2362. .. Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J,
349. Garcia-Prieto J, Villena-Gutierrez R, Gomez M, Bernardo E, Pun-Garcia A, .. Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a
Garcia-Lunar I, Crainiciuc G, Fernandez-Jimenez R, Sreeramkumar V, Bourio- .. meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet
Martinez R, Garcia-Ruiz JM, Del Valle AS, Sanz-Rosa D, Pizarro G, Fernandez-
.. 2010;376(9753):1670–1681.
Ortiz A, Hidalgo A, Fuster V, Ibanez B. Neutrophil stunning by metoprolol .. 367. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR,
reduces infarct size. Nat Commun 2017;8:14780. .. LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D,
350. Roolvink V, Ibanez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, .. Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM,
Dambrink JH, Escalera N, Lipsic E, Albarran A, Fernandez-Ortiz A, Fernandez- .. Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipopro-
Aviles F, Goicolea J, Botas J, Remkes W, Hernandez-Jaras V, Kedhi E, Zamorano .. teins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am
JL, Navarro F, Alfonso F, Garcia-Lledo A, Alonso J, van Leeuwen M, Nijveldt R, .. Coll Cardiol 2014;64(5):485–494.
Postma S, Kolkman E, Gosselink M, de Smet B, Rasoul S, Piek JJ, Fuster V, van ’t
.. 368. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM,
Hof AW, EARLY-BAMI Investigators. Early intravenous beta-blockers in .. Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets
patients with ST-segment elevation myocardial infarction before primary percu- .. Investigators. Intensive lipid lowering with atorvastatin in patients with stable
taneous coronary intervention. J Am Coll Cardiol 2016;67(23):2705–2715. .. coronary disease. N Engl J Med 2005;352(14):1425–1435.
351. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, .. 369. Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, Voysey M,
Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone .. Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H,
GW. Impact of intravenous beta-blockade before primary angioplasty on sur- .. Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi
vival in patients undergoing mechanical reperfusion therapy for acute myocar- .. MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among
dial infarction. J Am Coll Cardiol 2004;43(10):1780–1787.
.. men and women: meta-analysis of individual data from 174,000 participants in
352. Harjai KJ, Stone GW, Boura J, Grines L, Garcia E, Brodie B, Cox D, O’Neill .. 27 randomised trials. Lancet 2015;385(9976):1397–1405.
WW, Grines C. Effects of prior beta-blocker therapy on clinical outcomes after .. 370. Shrivastava AK, Singh HV, Raizada A, Singh SK. Serial measurement of lipid pro-
primary coronary angioplasty for acute myocardial infarction. Am J Cardiol .. file and inflammatory markers in patients with acute myocardial infarction.
2003;91(6):655–660. .. EXCLI J 2015;14:517–526.
353. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myo- .. 371. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syn-
cardial infarction: systematic review and meta regression analysis. BMJ .. dromes. J Am Coll Cardiol 2008;51(15):1440–1445.
.. 372. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based popula-
354. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, Smith SC, Jr, .. tion: a cross-sectional study. Arch Intern Med 2012;172(22):1707–1710.
Subacius H, OBTAIN Investigators. Effect of beta-blocker dose on survival after .. 373. Food and Drug Administration. FDA Drug Safety Communication: New
acute myocardial infarction. J Am Coll Cardiol 2015;66(13):1431–1441. . restrictions, contraindications, and dose limitations for Zocor (simvastatin) to
ESC Guidelines 63

reduce the risk of muscle injury.
.. 391. Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and myocardial
256581.htm, accessed July 26, 2017. .. infarction—the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.
374. Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, .. Eur Heart J 1994;15(Suppl B):20–5; discussion 26–30.
Holme I, Larsen ML, Lindahl C, Szarek M. Comparison of atorvastatin 80 mg/ .. 392. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR,
day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events .. Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J,
late (five years) after acute myocardial infarction (from the Incremental .. Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, SAVE Investigators.
Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J .. Effect of captopril on mortality and morbidity in patients with left ventricular
Cardiol 2010;106(3):354–359.
.. dysfunction after myocardial infarction. Results of the survival and ventricular
375. Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein .. enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669–677.
JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR, IDEAL Investigators. Total .. 393. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE
cardiovascular disease burden: comparing intensive with moderate statin ther- .. inhibitors in the early treatment of acute myocardial infarction: systematic over-
apy insights from the IDEAL (Incremental Decrease in End Points Through .. view of individual data from 100,000 patients in randomized trials. Circulation
Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009;54(25):2353–2357. .. 1998;97(22):2202–2212.
376. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius .. 394. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in sta-
H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im
.. ble coronary Artery disease Investigators. Efficacy of perindopril in reduction of
K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, .. cardiovascular events among patients with stable coronary artery disease: rand-
Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after .. omised, double-blind, placebo-controlled, multicentre trial (the EUROPA
acute coronary syndromes. N Engl J Med 2015;372(25):2387–2397. .. study). Lancet 2003;362(9386):782–788.
377. Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, Luo H, Cai Y, Zeng C. .. 395. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an
Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal .. angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled .. high-risk patients. The Heart Outcomes Prevention Evaluation Study
trials. J Am Heart Assoc 2015;4(6):e001937.
.. Investigators. N Engl J Med 2000;342(3):145–153.
378. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, Xie J, Kang LN, Xu B. .. 396. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP,
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, .. Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M,
controlled trials. BMC Med 2015;13:123. .. Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial
379. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne .. Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarc-
CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open- .. tion complicated by heart failure, left ventricular dysfunction, or both. N Engl J
Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) .. Med 2003;349(20):1893–1906.
Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovas-
.. 397. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R,
cular events. N Engl J Med 2015;372(16):1500–1509. .. Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction
380. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, .. Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective
Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, .. aldosterone blocker, in patients with left ventricular dysfunction after myocar-
Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and .. dial infarction. N Engl J Med 2003;348(14):1309–1321.
safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med .. 398. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes
2015;372(16):1489–1499. .. J. The effect of spironolactone on morbidity and mortality in patients with
381. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, .. severe heart failure. Randomized Aldactone Evaluation Study Investigators. N
Brockmeyer M, Kandzari DE, Kubica JM, D’Agostino RB, Sr., Kubica J, Volpe M,
.. Engl J Med 1999;341(10):709–717.
Agewall S, Kereiakes DJ, Kelm M. Effects of proprotein convertase subtilisin/ .. 399. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent
kexin type 9 antibodies in adults with hypercholesterolemia: a systematic .. J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with
review and meta-analysis. Ann Intern Med 2015;163(1):40–51. .. systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11–21.
382. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, .. 400. Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van
Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER .. Veldhuisen DJ, Vincent J, Pitt B, Zannad F. Clinical benefits of eplerenone in
Steering Committee and Investigators. Evolocumab and clinical outcomes in .. patients with systolic heart failure and mild symptoms when initiated shortly
patients with cardiovascular disease. N Engl J Med 2017;376(18):1713–1722.
.. after hospital discharge: analysis from the EMPHASIS-HF trial. Eur Heart J
383. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS- .. 2015;36(34):2310–2317.
4: a randomised factorial trial assessing early oral captopril, oral mononitrate, .. 401. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H,
and intravenous magnesium sulphate in 58,050 patients with suspected acute .. Turgonyi E, Orri M, Vincent J, Zannad F, REMINDER Investigators. Early eplere-
myocardial infarction. Lancet 1995;345(8951):669–685. .. none treatment in patients with acute ST-elevation myocardial infarction with-
384. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocar- .. out heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J
dial infarction or angina in light of the second Danish Verapamil Infarction Trial .. 2014;35(34):2295–2302.
(DAVIT-II) and other recent studies. Am J Cardiol 1991;67(15):1295–1297.
.. 402. Beygui F, Cayla G, Roule V, Roubille F, Delarche N, Silvain J, Van Belle E, Belle
385. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial .. L, Galinier M, Motreff P, Cornillet L, Collet JP, Furber A, Goldstein P, Ecollan P,
infarction and unstable angina: an overview. BMJ 1989;299(6709):1187–1192. .. Legallois D, Lebon A, Rousseau H, Machecourt J, Zannad F, Vicaut E,
386. Effect of verapamil on mortality and major events after acute myocardial infarc- .. Montalescot G, ALBATROSS Investigators. Early aldosterone blockade in acute
tion (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol .. myocardial infarction: the ALBATROSS Randomized Clinical Trial. J Am Coll
1990;66(10):779–785. .. Cardiol 2016;67(16):1917–1927.
387. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality .. 403. Garcia-Ruiz JM, Fernandez-Jimenez R, Garcia-Alvarez A, Pizarro G, Galan-
in patients with coronary heart disease. Circulation 1995;92(5):1326–1331.
.. Arriola C, Fernandez-Friera L, Mateos A, Nuno-Ayala M, Aguero J, Sanchez-
388. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, .. Gonzalez J, Garcia-Prieto J, Lopez-Melgar B, Martinez-Tenorio P, Lopez-Martin
Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, .. GJ, Macias A, Perez-Asenjo B, Cabrera JA, Fernandez-Ortiz A, Fuster V, Ibanez
Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, .. B. Impact of the timing of metoprolol administration during STEMI on infarct
Seabra-Gomes R, Soler-Soler J, Weber S, Coronary Disease Trial Investigating .. size and ventricular function. J Am Coll Cardiol 2016;67(18):2093–2104.
Outcome with Nifedipine Gastrointestinal Therapeutic System Investigators. .. 404. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in .. JJ, Devereaux PJ, Alexander KP, Wetterslev J, Messerli FH. Clinical outcomes
patients with stable angina requiring treatment (ACTION trial): randomised .. with beta-blockers for myocardial infarction: a meta-analysis of randomized tri-
controlled trial. Lancet 2004;364(9437):849–857.
.. als. Am J Med 2014;127(10):939–53.
389. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace .. 405. Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, Gui YY, Xia TL, Xin
FJ, Jr, Rapaport E, Ridker PM, Rouleau JL, Solomon SD, Hennekens CH. Early .. ZM, Liu W, Zhang C, Chen SJ, Pu XB, Chen M, Huang DJ. Meta-analysis of rela-
versus delayed angiotensin-converting enzyme inhibition therapy in acute myo- .. tion between oral beta-blocker therapy and outcomes in patients with acute
cardial infarction. The healing and early afterload reducing therapy trial. .. myocardial infarction who underwent percutaneous coronary intervention. Am
Circulation 1997;95(12):2643–2651. .. J Cardiol 2015;115(11):1529–1538.
390. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, .. 406. Authors/Task Force Members, Catapano AL, Graham I, De Backer G, Wiklund
Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-
.. O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen
converting-enzyme inhibitor trandolapril in patients with left ventricular dys- .. TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM,
function after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) .. Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the
Study Group. N Engl J Med 1995;333(25):1670–1676. . Management of Dyslipidaemias: The Task Force for the Management of
64 ESC Guidelines

Dyslipidaemias of the European Society of Cardiology (ESC) and European
.. 423. Engstrom AE, Vis MM, Bouma BJ, van den Brink RBA, Baan J, Claessen B,
Atherosclerosis Society (EAS) Developed with the special contribution of the .. Kikkert WJ, Sjauw KD, Meuwissen M, Koch KT, de Winter RJ, Tijssen JGP, Piek
European Assocciation for Cardiovascular Prevention & Rehabilitation .. JJ, Henriques JPS. Right ventricular dysfunction is an independent predictor for
(EACPR). Atherosclerosis 2016;253:281–344. .. mortality in ST-elevation myocardial infarction patients presenting with cardio-
407. Dickstein K, Kjekshus J, Optimaal Steering Committee of the OPTIMAAL Study .. genic shock on admission. Eur J Heart Fail 2010;12(3):276–282.
Group. Effects of losartan and captopril on mortality and morbidity in high-risk .. 424. Jeger RV, Lowe AM, Buller CE, Pfisterer ME, Dzavik V, Webb JG, Hochman JS,
patients after acute myocardial infarction: the OPTIMAAL randomised trial. .. Jorde UP, SHOCK Investigators. Hemodynamic parameters are prognostically
Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
.. important in cardiogenic shock but similar following early revascularization or
Lancet 2002;360(9335):752–760. .. initial medical stabilization: a report from the SHOCK trial. Chest
408. Iakobishvili Z, Cohen E, Garty M, Behar S, Shotan A, Sandach A, Gottlieb S, .. 2007;132(6):1794–1803.
Mager A, Battler A, Hasdai D, Heart Failure Survey in Isarel Investigators. Use .. 425. Hochman JS, Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington
of intravenous morphine for acute decompensated heart failure in patients with .. RA, de Werf FV, TRIUMPH Investigators. Effect of tilarginine acetate in patients
and without acute coronary syndromes. Acute Card Care 2011;13(2):76–80. .. with acute myocardial infarction and cardiogenic shock: the TRIUMPH random-
409. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. .. ized controlled trial. JAMA 2007;297(15):1657–1666.
Morphine and outcomes in acute decompensated heart failure: an ADHERE
.. 426. Lancellotti P, Price S, Edvardsen T, Cosyns B, Neskovic AN, Dulgheru R,
analysis. Emerg Med J 2008;25(4):205–209. .. Flachskampf FA, Hassager C, Pasquet A, Gargani L, Galderisi M, Cardim N,
410. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, Chen YW, He QY. Meta- .. Haugaa KH, Ancion A, Zamorano JL, Donal E, Bueno H, Habib G. The use of
analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann .. echocardiography in acute cardiovascular care: Recommendations of the
Intern Med 2010;152(9):590–600. .. European Association of Cardiovascular Imaging and the Acute Cardiovascular
411. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation .. Care Association. Eur Heart J Acute Cardiovasc Care 2015;4(1):3–5.
(CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database .. 427. Hussain F, Philipp RK, Ducas RA, Elliott J, Dzavik V, Jassal DS, Tam JW, Roberts
Syst Rev 2013;5:CD005351.
.. D, Garber PJ, Ducas J. The ability to achieve complete revascularization is asso-
412. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for .. ciated with improved in-hospital survival in cardiogenic shock due to myocardial
the management of heart failure patients at high risk for admission: a systematic .. infarction: Manitoba cardiogenic SHOCK Registry investigators. Catheter
review of randomized trials. J Am Coll Cardiol 2004;44(4):810–819. .. Cardiovasc Interv 2011;78(4):540–548.
413. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of rami- .. 428. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur
pril on mortality and morbidity of survivors of acute myocardial infarction with .. A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators. Comparison of
clinical evidence of heart failure. Lancet 1993;342(8875):821–828. .. dopamine and norepinephrine in the treatment of shock. N Engl J Med
414. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J,
.. 2010;362(9):779–789.
Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus .. 429. Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, Vis
KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, .. MM, Wykrzykowska JJ, Koch KT, Baan J, de Winter RJ, Piek JJ, Lagrand WK, de
Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release .. Mol BA, Tijssen JG, Henriques JP. Percutaneous mechanical circulatory support
metoprolol on total mortality, hospitalizations, and well-being in patients with .. versus intra-aortic balloon pump in cardiogenic shock after acute myocardial
heart failure: the Metoprolol CR/XL Randomized Intervention Trial in conges- .. infarction. J Am Coll Cardiol 2017;69(3):278–287.
tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA .. 430. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT,
2000;283(10):1295–1302. .. Serruys PW. Percutaneous left ventricular assist devices vs. intra-aortic balloon
415. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,
.. pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of
Shusterman NH. The effect of carvedilol on morbidity and mortality in patients .. controlled trials. Eur Heart J 2009;30(17):2102–2108.
with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J .. 431. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell
Med 1996;334(21):1349–1355. .. SD, Conte JV, Aaronson KD, McGee EC, Cotts WG, DeNofrio D, Duc TP,
416. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, .. Farrar DJ, Pagani FD. Results of the post-US Food and Drug Administration-
Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, .. approval study with a continuous flow left ventricular assist device as a bridge
Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of .. to heart transplantation. A prospective study using the INTERMACS
carvedilol on the morbidity of patients with severe chronic heart failure: results
.. (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll
of the carvedilol prospective randomized cumulative survival (COPERNICUS) .. Cardiol 2011;57(19):1890–1898.
study. Circulation 2002;106(17):2194–2199. .. 432. Sheu JJ, Tsai TH, Lee FY, Fang HY, Sun CK, Leu S, Yang CH, Chen SM, Hang
417. Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon S, Crane S, .. CL, Hsieh YK, Chen CJ, Wu CJ, Yip HK. Early extracorporeal membrane
Elliott M, Nicholl J, 3CPO Study Investigators. A multicentre randomised con- .. oxygenator-assisted primary percutaneous coronary intervention improved 30-
trolled trial of the use of continuous positive airway pressure and non-invasive .. day clinical outcomes in patients with ST-segment elevation myocardial infarc-
positive pressure ventilation in the early treatment of patients presenting to the .. tion complicated with profound cardiogenic shock. Crit Care Med
emergency department with severe acute cardiogenic pulmonary oedema: the
.. 2010;38(9):1810–1817.
3CPO trial. Health Technol Assess 2009;13(33):1–106. .. 433. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G,
418. Park M, Sangean MC, Volpe Mde S, Feltrim MI, Nozawa E, Leite PF, Passos .. Califf RM. Impact of the pulmonary artery catheter in critically ill patients:
Amato MB, Lorenzi-Filho G. Randomized, prospective trial of oxygen, continu- .. meta-analysis of randomized clinical trials. JAMA 2005;294(13):1664–1670.
ous positive airway pressure, and bilevel positive airway pressure by face mask .. 434. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield
in acute cardiogenic pulmonary edema. Crit Care Med 2004;32(12):2407–2415. .. MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran
419. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, 3CPO .. MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez
Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl
.. EJ, Ibarra JC, Mascette AM, Braunwald E, Heart Failure Clinical Research
J Med 2008;359(2):142–51. .. Network. Ultrafiltration in decompensated heart failure with cardiorenal syn-
420. Harjola VP, Mebazaa A, Celutkiene J, Bettex D, Bueno H, Chioncel O, Crespo- .. drome. N Engl J Med 2012;367(24):2296–2304.
Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J, .. 435. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski
Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, .. BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA,
Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A, .. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for
Yilmaz MB, Konstantinides S. Contemporary management of acute right ventric- .. patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol
ular failure: a statement from the Heart Failure Association and the Working .. 2007;49(6):675–683.
Group on Pulmonary Circulation and Right Ventricular Function of the
.. 436. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA, Ultrafiltration
European Society of Cardiology. Eur J Heart Fail 2016;18(3):226–241. .. Versus Intravenous Diuretics for Patients Hospitalized for Acute
421. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends .. Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is asso-
(1975 to 2005) in the magnitude of, management of, and hospital death rates .. ciated with fewer rehospitalizations than continuous diuretic infusion in patients
associated with cardiogenic shock in patients with acute myocardial infarction a .. with decompensated heart failure: results from UNLOAD. J Card Fail
population-based perspective. Circulation 2009;119(9):1211–1219. .. 2010;16(4):277–284.
422. Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V, .. 437. Buerke M, Prondzinsky R, Lemm H, Dietz S, Buerke U, Ebelt H, Bushnaq H,
Steingart R, Gin K, White HD, Hochman JS, SHOCK Trial. Echocardiographic
.. Silber RE, Werdan K. Intra-aortic balloon counterpulsation in the treatment of
predictors of survival and response to early revascularization in cardiogenic .. infarction-related cardiogenic shock—review of the current evidence. Artif
shock. Circulation 2003;107(2):279–284. .. Organs 2012;36(6):505–511.
ESC Guidelines 65

438. Gorenek B, Blomstrom Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks
.. 456. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous
G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, .. ventricular tachycardia associated with acute myocardial infarction. Circulation
Tilz RR, Valgimigli M, Vos MA, Vrints C, Zeymer U, Lip GY, Potpara T, Fauchier .. 1991;84(4):1543–1551.
L, Sticherling C, Roffi M, Widimsky P, Mehilli J, Lettino M, Schiele F, Sinnaeve P, .. 457. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, Fahy M, Mehran R,
Boriani G, Lane D, Savelieva I, European Heart Rhythm Association, Acute .. Stone GW. Prognostic significance of postprocedural sustained ventricular
Cardiovascular Care Association, European Association of Percutaneous .. tachycardia or fibrillation in patients undergoing primary percutaneous coro-
Cardiovascular Interventions. Cardiac arrhythmias in acute coronary syn- .. nary intervention (from the HORIZONS-AMI Trial). Am J Cardiol
dromes: position paper from the joint EHRA, ACCA, and EAPCI task force.
.. 2012;109(6):805–812.
Europace 2014;16(11):1655–1673. .. 458. Masuda M, Nakatani D, Hikoso S, Suna S, Usami M, Matsumoto S, Kitamura T,
439. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, .. Minamiguchi H, Okuyama Y, Uematsu M, Yamada T, Iwakura K, Hamasaki T,
Ardissino D, Califf RM, Granger CB, Ohman EM, Alexander JH. Antiarrhythmic .. Sakata Y, Sato H, Nanto S, Hori M, Komuro I, Sakata Y, OACIS investigators.
drug therapy for sustained ventricular arrhythmias complicating acute myocar- .. Clinical impact of ventricular tachycardia and/or fibrillation during the acute
dial infarction. Crit Care Med 2011;39(1):78–83. .. phase of acute myocardial infarction on in-hospital and 5-year mortality rates in
440. Piers SR, Wijnmaalen AP, Borleffs CJ, van Huls van Taxis CF, Thijssen J, van .. the percutaneous coronary intervention era. Circ J 2016;80(7):1539–1547.
Rees JB, Cannegieter SC, Bax JJ, Schalij MJ, Zeppenfeld K. Early reperfusion
.. 459. Haissaguerre M, Vigmond E, Stuyvers B, Hocini M, Bernus O. Ventricular
therapy affects inducibility, cycle length, and occurrence of ventricular tachycar- .. arrhythmias and the His-Purkinje system. Nat Rev Cardiol 2016;13(3):155–166.
dia late after myocardial infarction. Circ Arrhythm Electrophysiol .. 460. Enjoji Y, Mizobuchi M, Muranishi H, Miyamoto C, Utsunomiya M, Funatsu A,
2011;4(2):195–201. .. Kobayashi T, Nakamura S. Catheter ablation of fatal ventricular tachyarrhyth-
441. Nalliah CJ, Zaman S, Narayan A, Sullivan J, Kovoor P. Coronary artery reperfu- .. mias storm in acute coronary syndrome—role of Purkinje fiber network. J
sion for ST elevation myocardial infarction is associated with shorter cycle .. Interv Card Electrophysiol 2009;26(3):207–215.
length ventricular tachycardia and fewer spontaneous arrhythmias. Europace .. 461. Peichl P, Cihak R, Kozeluhova M, Wichterle D, Vancura V, Kautzner J. Catheter
.. ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients
442. Liang JJ, Fender EA, Cha YM, Lennon RJ, Prasad A, Barsness GW. Long-term .. with coronary artery disease. J Interv Card Electrophysiol 2010;27(1):51–59.
outcomes in survivors of early ventricular arrhythmias after acute ST-elevation .. 462. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical
and non-ST-elevation myocardial infarction treated with percutaneous coro- .. storm : sympathetic blockade versus advanced cardiac life support-guided ther-
nary intervention. Am J Cardiol 2016;117(5):709–713. .. apy. Circulation 2000;102(7):742–747.
443. Danchin N, Fauchier L, Marijon E, Barnay C, Furber A, Mabo P, Bernard P, .. 463. Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshida K, Yanagisawa R, Ishiguro H,
Blanc JJ, Jouven X, Le Heuzey JY, Charbonnier B, Ferrieres J, Simon T, French .. Tsukada T, Abe A, Yusu S, Yoshino H. Effects of landiolol, an ultra-short-acting
registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction
.. beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic
(FAST-MI) Investigators. Impact of early statin therapy on development of atrial .. drugs. Circ J 2010;74(5):856–863.
fibrillation at the acute stage of myocardial infarction: data from the FAST-MI .. 464. Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against pro-
register. Heart 2010;96(22):1809–1814. .. phylactic use of lidocaine in acute myocardial infarction. Arch Intern Med
444. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocar- .. 1989;149(12):2694–2698.
dial infarction: a systematic review of the incidence, clinical features and prog- .. 465. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhyth-
nostic implications. Eur Heart J 2009;30(9):1038–1045. .. mias. N Engl J Med 2001;345(20):1473–1482.
445. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, Oldgren J. .. 466. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP,
All types of atrial fibrillation in the setting of myocardial infarction are associ-
.. Higgins SL, Brown MW, Andrews ML, Multicenter Automatic Defibrillator
ated with impaired outcome. Heart 2016;102(12):926–933. .. Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in
446. Nilsson KR, Jr, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober .. patients with myocardial infarction and reduced ejection fraction. N Engl J Med
L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation .. 2002;346(12):877–883.
management strategies and early mortality after myocardial infarction: results .. 467. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M,
from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart .. Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-
2010;96(11):838–842. .. Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart
447. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Roger VL. Atrial
.. Failure Trial Investigators. Amiodarone or an implantable cardioverter-defibrillator
fibrillation and death after myocardial infarction: a community study. Circulation .. for congestive heart failure. N Engl J Med 2005;352(3):225–237.
2011;123(19):2094–100. .. 468. Chen A, Ashburn MA. Cardiac effects of opioid therapy. Pain Med
448. Siu CW, Jim MH, Ho HH, Miu R, Lee SW, Lau CP, Tse HF. Transient atrial .. 2015;16(Suppl 1):S27–31.
fibrillation complicating acute inferior myocardial infarction: implications for .. 469. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt
future risk of ischemic stroke. Chest 2007;132(1):44–49. .. OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW,
449. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson .. Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC
K, Yu D, Bass EB. The evidence regarding the drugs used for ventricular rate
.. Guidelines on cardiac pacing and cardiac resynchronization therapy. The Task
control. J Fam Pract 2000;49(1):47–59. .. Force on cardiac pacing and resynchronization therapy of the European Society
450. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute .. of Cardiology (ESC). Developed in collaboration with the European Heart
treatment of recent-onset atrial fibrillation and flutter with a tailored dosing .. Rhythm Association (EHRA). Eur Heart J 2013;34(29):2281–2329.
regimen of intravenous amiodarone. A randomized, digoxin-controlled study. .. 470. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M,
Eur Heart J 1995;16(4):521–528. .. Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W,
451. Metawee M, Charnigo R, Morales G, Darrat Y, Sorrell V, Di Biase L, Natale A, .. Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene
Delisle B, Elayi CS; Magic Investigators. Digoxin and short term mortality after
.. G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working
acute STEMI: results from the MAGIC trial. Int J Cardiol 2016;218:176–180. .. Group on Myocardial and Pericardial Diseases. Current state of knowledge on
452. Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen P, Bergez .. aetiology, diagnosis, management, and therapy of myocarditis: a position state-
B, Vandekerckhove Y. Conversion of atrial fibrillation to sinus rhythm and rate .. ment of the European Society of Cardiology Working Group on Myocardial
control by digoxin in comparison to placebo. Eur Heart J 1997;18(4):643–648. .. and Pericardial Diseases. Eur Heart J 2013;34(33):2636–48, 2648a–2648d.
453. Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, .. 471. Emrich T, Emrich K, Abegunewardene N, Oberholzer K, Dueber C, Muenzel T,
Cooper MJ. Rapid loading of sotalol or amiodarone for management of recent .. Kreitner KF. Cardiac MR enables diagnosis in 90% of patients with acute chest
onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am .. pain, elevated biomarkers and unobstructed coronary arteries. Br J Radiol
Heart J 2004;147(1):E3.
.. 2015;88(1049):20150025.
454. Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de .. 472. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan
Werf F, Solomon SD, Califf RM, Velazquez EJ. Relation of mortality to failure to .. AD, Grover S, Smith E, Mazhar J, Bridgman C, Ganesan AN, Selvanayagam JB.
prescribe beta blockers acutely in patients with sustained ventricular tachycar- .. Troponin-positive chest pain with unobstructed coronary arteries: incremental
dia and ventricular fibrillation following acute myocardial infarction (from the .. diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J
VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J .. Cardiovasc Imaging 2016;17(10):1146–1152.
Cardiol 2008;102(11):1427–1432. .. 473. Dastidar AG, Rodrigues JC, Johnson TW, De Garate E, Singhal P, Baritussio A,
455. Zafari AM, Zarter SK, Heggen V, Wilson P, Taylor RA, Reddy K, Backscheider
.. Scatteia A, Strange J, Nightingale AK, Angelini GD, Baumbach A, Delgado V,
AG, Dudley SC, Jr. A program encouraging early defibrillation results in .. Bucciarelli-Ducci C. Myocardial Infarction with nonobstructed coronary
improved in-hospital resuscitation efficacy. J Am Coll Cardiol .. arteries: impact of CMR early after presentation. JACC Cardiovasc Imaging;doi:
2004;44(4):846–852. . 10.1016/j.jcmg.2016.11.010. Published online ahead of print 18 January 2017.
66 ESC Guidelines

474. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. .. 476. Schiele F, Gale CP, Bonnefoy E, Capuano F, Claeys MJ, Danchin N, Fox KA, Huber
Management of acute coronary syndromes. Variations in practice and outcome; .. K, Iakobishvili Z, Lettino M, Quinn T, Rubini Gimenez M, Botker HE, Swahn E,
findings from the Global Registry of Acute Coronary Events (GRACE). Eur
.. Timmis A, Tubaro M, Vrints C, Walker D, Zahger D, Zeymer U, Bueno H. Quality
Heart J 2002;23(15):1177–1189. .. indicators for acute myocardial infarction: A position paper of the Acute
475. Lenfant C. Shattuck lecture - clinical research to clinical practice - lost in trans- .. Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 2017;6(1):34–59.
lation? N Engl J Med 2003;349(9):868–874. .. 477. Ford I, Norrie J. Pragmatic trials. N Engl J Med 2016;375(5):454–463.